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Abstract 
Kidney disease is a common and serious problem affecting approximately 1.7 million 
Australians over the age of 25. The proximal tubular epithelial cells (PTEC) of the kidney are 
known to respond to and mediate the pathological processes of a range of kidney diseases. When 
these cells become perturbed during the disease state they secrete a range of pro-inflammatory 
cytokines which attract monocytes/macrophages, dendritic cells (DC) and lymphocytes into the 
kidney tissue. These in turn produce a secondary wave of cytokines which continue the 
inflammatory cycle and up-regulate molecules on the surface of PTEC. This enables them to 
behave as non-professional antigen presenting cells (AgPC) and modulate immune responses in 
the context of disease and allograft rejection. In this project we demonstrate that PTEC regulate 
DC, T cell and B cell responses in the context of the autologous human setting. When preformed 
blood CD1c
+
 DC or monocyte derived DC (MoDC) were co-cultured with interferon-γ (IFN-γ) 
activated PTEC, the CD1c
+
 DC and MoDC were immature and less effective in stimulating 
allogeneic T cell responses. The IFN-γ activated PTEC also down-regulated autologous CD4+ T 
cell responses and significantly compromised the antibody producing function of autologous B 
cells. To identify the mechanisms responsible for these immune modulations, we investigated 
molecules produced by PTEC within an IFN-γ induced inflammatory micro-environment. These 
activated PTEC expressed elevated levels immuno-regulatory of soluble human leukocyte 
antigen –G (sHLA-G), programmed cell death ligand-1 (PD-L1) and indoleamine-2,3-
dioxygenase (IDO) which may enable then to interact with immune cells in the context of non-
professional AgPC. Blocking experiments for each of these molecules have identified 
mechanisms of autologous PTEC regulating immune cell phenotype and function. The sHLA-G 
secreted by PTEC was partially responsible for the down-regulation of MHC-II on autologous 
MoDC. The expression of IDO and PD-L1 by PTEC were partly responsible for the elevated 
levels of PD-L1 expression on MoDC and down-regulated the allogeneic CD4
+
 T cell response 
inducing function of these cells. The IDO and sHLA-G expressed by PTEC also had an autocrine 
effect on the up-regulation of molecules which then induced autologous MoDC to secrete 
elevated levels of anti-inflammatory cytokine IL-10. IDO and sHLA-G expressed on PTEC were 
V 
 
partially responsible for down-modulating the number of autologous B cells capable of secreting 
IgM antibody, whilst PD-L1 expression on PTEC played a partial role in the regulation of both 
IgM and IgG antibody levels from autologous B cells. Collectively, all these results suggest that 
autologous PTEC down-regulate DC, T cell and B cell responses, which may then control on-
going inflammation and prevent the progression of kidney disease. 
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Chapter 1: Literature Review 
1.1. Introduction 
Kidney disease is one of the major health problems in Australia affecting 1 in 3 Australians 
over the age group of 25 and contributing to approximately 15% of all hospitalisations [1-3]. It is 
often called as a silent problem because of its lack of warning signs before 90% loss of kidney 
function. A report published by Kidney Health Australia estimates that patients receiving 
treatment for end stage kidney disease (ESKD) could increase more than 54% from 2008-2020 
[3]. The National Mortality Database in 2012 attributed 13.8% of all Australian deaths to Kidney 
Disease [3]. Financially, the total cost estimated for the Australian health system to treat ESKD 
between 2009 and 2020 is approximately $12 billion [3]. Currently, the more common treatment 
against ESKD is dialysis or transplantation. However, the limitations associated with these 
treatments are high cost and availability of donor match respectively. Therefore, understanding 
the physiological events underlying 
kidney disease may enable the 
development of novel therapies for 
improved treatment outcomes. 
1.2. Kidney parenchyma 
The kidneys are vital organs 
which filter blood and excrete waste 
in the form of urine, regulate blood 
pressure, maintain acid-base balance 
and secrete a range of chemokines, 
cytokines and other active 
biomolecules essential to normal 
homeostasis [4]. Structurally, the 
kidney possesses a bean shape with 
Figure 1.1. Cross-section of a kidney. 
Macroscopic cross-section of a kidney (A) showing the 
functional unit nephron (B) stained for glomerulus and 
proximal tubule epithelial cells (PTEC) (C) (adapted from 
R.Wilkinson et al, Frontiers in Immunological Research 
presentation, Salzburg 2012). 
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an external and internal layer called the renal cortex and renal medulla respectively. The nephron 
is the functional unit of the kidney and comprises a network of capillary loops called the 
glomerulus which is embedded within the fluid filled Bowman’s capsule (Figure 1.1). This 
Bowman’s capsule extends as the proximal convoluted tubule, followed by the loop of Henle and 
the distal convoluted tubule which finally ends into a collecting duct. All of these tubules are 
lined with specialised epithelia that perform different functions and display differing morphology 
as the distance from the glomerulus increases. The nephrons are structurally supported within the 
interstitial space by a range of endothelial cells, fibroblasts and glial cells and this interstitial 
space also contains numerous small blood vessels and a network of surveillance cells derived 
from macrophage and dendritic cell lineages [5, 6]. Due to the abundance and importance of the 
glomeruli, it is customary for nephrologists and pathologists to describe the kidney in terms of 
the glomerular compartment and the tubulointerstitium, which is the combined tubular and 
interstitial space. 
Both the glomeruli and the tubulointerstitium are important components in chronic kidney 
disease (CKD). Over the last four decades the importance of glomerular versus tubulointerstitial 
damage for the progression of kidney disease has oscillated in the literature. Until the late 
1960’s, the prevailing dogma for the progression of kidney disease was largely glomerulocentric. 
Then, in 1968, Risdon et al [7] analysed the pathological changes in renal biopsy specimens 
from patients with persistent glomerular nephritis. A significant correlation was found between 
the degree of tubular damage and creatinine levels in blood plasma and urine, a key biomarker of 
kidney failure. In contrast, a very low correlation was observed between structural changes in the 
glomeruli and creatinine levels in blood plasma and urine. These observations led them to 
speculate that tubulointerstitial injury was the main mechanism behind the progression of CKD. 
This observation was supported by Cameron et al, [8], who illustrated high correlations between 
ammonia concentration in urine and the degree of tubular atrophy and interstitial fibrosis, which 
led to a tubulointerstitial model of kidney disease progression taking centre stage. Then, in 1980, 
Hostetter et al [9] revitalised the glomerulocentric dogma by demonstrating that alterations in 
glomerular pressure contributed to its structural and functional injury in rat models. However, 
the focus skewed back onto the tubulointerstitium in 1986 when Remuzzi et al published a series 
of research findings from mouse and human models demonstrating tubular interstitial lesions as 
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the important determinant for progression of renal damage [10, 11]. Today, it is generally 
accepted that whatever the original disease etiology affecting the kidney, corresponding damage 
within the tubulointerstitium contributes significantly towards disease progression [12].  
This chapter will present a thorough overview of proximal tubule epithelial cells (PTEC) 
located in the tubulointerstitium and immuno-regulatory molecules expressed by PTEC. It will 
then explore existing literature of PTEC, under inflammatory conditions, behaving as non-
professional antigen presenting cells (AgPC) in the context of PTEC cross-talk with B-, T- cells 
and dendritic cells (DC) and highlighting the limitations of these experimental models.  
1.3. Age associated dysregulation of the innate immune response 
Existing literature demonstrates an age-dependent change in the human innate immune 
system which when activated results in dysregulated function causing inflammation. For 
instance, Pang et al have shown that hematopoietic stem cells (HSC) from elderly human 
individuals (age >65) have significantly diminished capacity to give rise to the lymphoid B cell 
lineage and are skewed towards differentiating into the myeloid lineage [13]. Monocyte numbers 
are similar between aged and young humans [14] but, an increase in non-classical CD14
+
 CD16
+
 
monocytes in elderly donors (age >66) has been reported [15]. Increased numbers of non-
classical monocytes in aged donors does not necessarily mean improved availability and 
functionality. Seidler et al have reported that monocytes obtained from aged human donors 
express low level of fractalkine receptor (CX3CR1), which aids in monocyte migration into 
inflammatory sites [16]. Hearps et al have also shown that monocytes obtained from elderly 
donors are less phagocytic when compared to young individuals [17]. Decreases in the number 
of DC and impairment in their function has also been reported [18]. Sridharan et al identified 
lower levels of interferon (IFN) secretion by plasmacytoid DC obtained from aged individuals 
(age 65-90) in response to influenza virus stimulation [19]. In addition, Panda et al have reported 
that DC from aged individuals (≥ 65 years), in response to toll-like receptor (TLR) stimulation, 
secrete lower levels of tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6 and IL-12 
cytokines - thereby suggesting that the impaired TLR function supports immunosenescence in 
DC [20]. Taken together, the above mentioned studies indicate that elderly participants in this 
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study may affect the research outcome, and therefore, the age of the participants is restricted to 
65 years and below. 
1.4. Proximal tubule epithelial cells 
PTEC line the proximal tubule downstream of the glomerulus and play a major role in 
protein absorption from the urine. In the proteinuric driven disease state, high levels of proteins 
and other molecules secreted into the proximal tubule from damaged glomeruli can compromise 
the function of PTEC [21, 22] and cause them to secrete a range of pro-inflammatory cytokines. 
Numerous in vitro studies have demonstrated PTEC, in response to pro-inflammatory stimuli, 
secrete monocyte chemotactic protein-1 (MCP-1) [23, 24], regulated upon activation normal T-
cell expressed and secreted (RANTES) (CCL5) [23, 25], IL-6 [23], and IL-8 [26] via the 
basolateral side.  MCP-1 as its name suggests is instrumental in attracting monocytes and 
macrophages to the inflamed tissue whilst the chemotactic nature of RANTES plays a major role 
in recruiting T cells [26], eosinophils [27, 28] and basophils [29]. These extravasated 
lymphocytes, monocytes and macrophages in the renal interstitium further secrete a secondary 
wave of inflammatory cytokines including interferon-gamma (IFN-γ), TNF-α and IFN-α, which 
amplify the inflammatory cycle. PTEC, as a response to these inflammatory cytokines and 
infiltrating leukocytes, upregulate a range of surface markers like major histocompatibility 
complex class-II (MHC-II), human leukocyte antigen G (HLA-G), indoleamine-2,3-dioxygenase 
(IDO) and programmed cell death 1 ligand (PD-L1 or B7-H1), which may enable them to 
interact with immune cells in the context of non-professional AgPC. Thus they may be able to 
present antigen to T cells, become targets of cytotoxic T cells or modulate immune responses. 
Inflammation within the tubulointerstitium is intimately linked with disease progression and our 
own observations from 75 human kidney disease biopsies positive for fibrosis, a marker for 
CKD, demonstrate 96% also have a corresponding interstitial mononuclear inflammatory 
infiltrate [30]. Therefore, understanding the physiological events taking place in the kidney 
interstitium between PTEC and inflammatory cells may enable us to identify specific pathways 
to target for early intervention in response to deteriorating kidney function.  
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1.5. Immuno-regulatory molecules expressed on PTEC 
In a range of disease settings the perturbed PTEC are known to express immuno-regulatory 
molecules which may enable them to modulate B/T cell and DC responses. However, there are 
conflicting data within the literature regarding the expression of some of these molecules, both in 
steady-state versus the disease state. 
1.5.1. Major Histocompatibility Complex class I and II 
There are two main types of MHC molecules, Class I (MHC-I), expressed on all nucleated 
cells and Class II (MHC-II), expressed primarily on AgPC such as DC, macrophages and B cells. 
Their primary function is to bind endogenous and exogenous derived peptide and present these to 
T cells via the T cell receptor (TCR) to initiate immune responses. [31]. Structurally, MHC-I 
consists of two polypeptide chains α and β2-microglobulin (β2m). The α–chain has three 
domains α1, α2 and α3. The α3 domain is a transmembrane domain non-covalently attached to 
β2m, while the α1 and α2 form the platform for peptide binding [32]. MHC-II also consists of 
two polypeptide chains α and β but each chain is further divided into two domains, α1, α2 and 
β1, β2 respectively. The α2 and β2 form the transmembrane domain while the α1 and β1 form 
the peptide binding site [33].   
MHC-I molecules mainly bind to peptides derived from the cytoplasm such as self proteins 
or proteins released from viral infected cells [34]. These proteins are degraded by the proteasome 
and transported to the endoplasmic reticulum (ER) by the aid of transporter molecules where 
they bind to the MHC-I and are eventually transported to the cell surface to present antigens to 
CD8
+
 T cells [34]. MHC-II molecules predominantly bind to peptides derived from proteins 
phagocytosed by the cell. The MHC-II molecule is assembled in the ER and transported through 
the golgi apparatus into the endosomal or lysosomal compartments [35]. In these compartments 
they are complexed with the peptide and transported to the cell surface to present antigens to 
CD4
+
 T cells [35, 36]. The binding of the MHC-peptide complex to the TCR is regarded as the 
first step (signal 1) in the initiation of immune responses. For a full T cell response, stimulation 
through co-stimulatory molecules such as CD80 and CD86 are required (signal 2) and responses 
to cytokines produced by AgPC, such as IL-12, IL-4, IL-17 and TGF-  direct and complete this 
response [37, 38] (signal 3).   
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MHC-II expression on PTEC was first demonstrated by Hart and Faber in 1980 on 
convoluted tubules of rat kidneys [39]. Subsequent studies have shown MHC expression on 
PTEC of other species including mice and human and that this expression can be up-regulated in 
pathological conditions or following allograft rejection [40-43].  In vitro studies in mouse models 
have illustrated constitutive low level MHC-II expression on kidney epithelial cells [44]. Our 
earlier findings in human studies have demonstrated constitutive low levels of MHC-II 
expression on primary PTEC [45]. However, contrary to these findings, others such as  Starke et 
al, have reported no expression of MHC-II on primary PTEC until stimulation with IFN-γ [46].   
1.5.2. Co-stimulatory molecules CD80 and CD86 
The co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) are membrane bound 
proteins expressed on activated cells including DC, Langerhans cells, activated monocytes, B 
cells and tumour cells. Freshly isolated murine and human T cells express low level of CD86 
alone [47]. The overall structure of CD80 and CD86 was found to be similar to each other with 
two extracellular Ig-like domains, a transmembrane domain and a cytoplasmic tail. The 
cytoplasmic tail comprises of three protein kinase C phosphorylation sites [48, 49]. The 
expression of CD80 and CD86 is controlled by the influence of various regulatory cytokines. 
Th2 cytokine IL-4 is shown to induce CD86 but not CD80 on B cells [50]. IFN-γ induces the 
expression of CD80 and CD86 on monocytes but decreases the expression of CD80 on 
macrophages [47, 51]. IL-10 blocks the up-regulation of CD80 and CD86 on monocytes and DC 
[52, 53]. Functionally, CD80 and CD86 binds with their receptor CD28 and enhances the TCR 
mediated proliferation of T cells [54]. One of the mechanisms of enhancing T cell proliferation 
involves creating a micro-environment suitable for the proliferation of T cells. Logue et al [55] 
have demonstrated in vitro that binding of CD80 and CD86 on mouse DC with CD28-
immunoglobulin (CD28-Ig) fusion protein results in IL-6 secretion by DC mediated by 
intracellular activation of p38 MAPK and NF-κβ. The IL-6 further acts in an autocrine manner to 
down-regulate IDO expression which inhibits the activity of T cells (discussed in section 1.5.5).  
Apart from CD28 binding, CD80 and CD86 binds with high affinity and avidity to 
cytotoxic T lymphocyte antigen-4 (CTLA-4) [56-58] and down-regulates the proliferation of T 
cells [59, 60]. Though the pathway of CTLA-4-mediated suppression of T cell proliferation is 
not well established, one mechanism could be via the up-regulation of IDO. Finger et al [61] 
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have demonstrated that engagement of CTLA-4-immunoglobulin fusion protein with CD80 and 
CD86 stimulates mouse DC to secrete IFN-γ mediated by intracellular activation of STAT1, p38 
MAPK and NF-κβ. The IFN-γ further acts in an autocrine manner to up-regulate IDO which 
leads to inhibition of T cell responses.  
 There are conflicting reports in the literature regarding the expression of CD80 and CD86 
on PTEC. Niemann-Masanek et al have observed in vivo expression of CD80 and CD86 on 
PTEC in renal biopsy specimens from patients with lupus nephritis, interstitial nephritis, 
glomerulonephritis (GN) and acute and chronic allograft rejection [62]. They have further 
demonstrated in vitro up-regulation of CD80 and CD86 on human PTEC when stimulated with 
the combination of IFN-γ, IL-1α, IL-4, anti-CD40 and IFN-γ, IL-1α, IL-13, anti-CD40 
respectively.  However, numerous in vitro studies involving murine and human models have 
shown that these molecules are not expressed on PTEC [63-66].  
1.5.3. Programmed cell death ligand-1  
Immuno-regulatory molecule PD-L1 is a 40kDa type 1 transmembrane protein that plays 
an important role in down-regulating immune responses [67] by interacting with its receptor PD-
1, a type 1 transmembrane protein transcriptionally induced on T cells, B cells and myeloid cells. 
Latchman et al [68] have reported PD-L2 as a second ligand for PD-1. The characterisation of 
the inhibitory pathway of PD-1 was hampered due to lack of knowledge regarding its functional 
binding unit, until Freeman et al [69] identified PD-L1 and demonstrated that this ligand–
receptor interaction leads to inhibition of lymphocyte proliferation. Later, Okazaki et al [70] 
demonstrated that PD-1 belongs to the Ig superfamily which has an immuno-receptor tyrosine 
based inhibitory motif (ITIM) in the cytoplasmic region. Ligation of PD-1 with its ligand PD-L1 
induces inhibition signals by phosphorylation of tyrosine residues on PD-1. This activates an 
enzyme Src homology region 2 domain containing phosphatase-2 (SHP-2) which in turn 
deactivates positive signal transducers such as phosphatidyl-inositol 3-kinase (PI3K), 
phospholipase C-γ2 (PLCγ2) and extracellular signal regulated kinases-1 and 2 (ERK1/2). 
Various studies have shown that the interaction of PD-1/PD-L1 [69] exerts an inhibitory effect 
on lymphocyte activation and proliferation [71]. Contrary to these findings, Dong et al [72] and 
Tamura et al [73] have demonstrated a co-stimulatory effect of PD-L1 on T cell proliferation. In 
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addition Tamura et al speculate that this mechanism could occur by an unidentified PD-L1 
receptor [73].  
Chen et al [74] reported that PD-L1 is not expressed on human PTEC under normal 
conditions but is up-regulated in a number of kidney diseases. Ding et al [75] illustrated in vivo 
expression of PD-L1 in renal biopsies from patients with type IV lupus nephritis (LN) on 
proximal tubules in areas of mononuclear cell infiltration, suggesting that the cytokines secreted 
from infiltrating cells induced PD-L1 expression on PTEC. To gain more insight into PD-L1 
expression on primary human PTEC, Ding et al analysed renal samples of normal human kidney 
and by utilising in situ hybridisation and immunohistochemistry staining techniques, they 
demonstrated moderate level of PD-L1 mRNA and protein expression respectively in normal 
kidneys. A number of other researchers, including ourselves [45], have reported low levels of 
PD-L1 on healthy human PTEC [65, 75, 76].  
The expression of PD-L2 on normal human PTEC is uncertain. Some studies have reported 
its expression on normal human PTEC using Western blot, immunohistochemistry and flow 
cytometry [76, 77], whilst others, using Northern analysis, have been unable to demonstrate its 
presence in human kidney [68]. 
In this project, we consider PD-L1 as one of the immuno-regulatory mechanisms of human 
PTEC and by blocking PD-L1, we evaluate the effect on monocyte-derived DC (MoDC) 
differentiation, B cell antibody production and T cell proliferation. 
1.5.4. Human leukocyte antigen-G  
HLA-G is a non-classical MHC class I antigen encoded by a gene on chromosome 6p21. It 
can be expressed as seven different isoforms, four (HLA-G1 to -G4) of which are membrane 
bound and three (HLA-G5 to -G7) are soluble (sHLA-G) due to alternate splicing and 
differential association of the HLA-G primary transcript with β2m (Figure 1.2) [78]. The 
structure of HLA-G1 and HLA-G5 is similar to the classical HLA class I molecule – the heavy 
chain consisting of three globular domains (α1, α2 and α3) non-covalently attached to β2m. The 
α1 and α2 complex forms the antigen binding groove. The membrane bound HLA-G isoforms 
have transmembrane domains and a cytoplasmic tail [78, 79]. 
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Functionally an immunosuppressive role for HLA-G was first identified at the foetal-
maternal interface where its expression was linked to foetal protection from the maternal 
immune system [80]. Certain tissues such as thymus, trophoblasts, cornea, pancreas and 
erythroid precursors are also known to express low levels of HLA-G under normal homeostasis 
[78]. However, the expression on these cells can be up regulated following transplantation, viral 
infection, inflammation and autoimmune disease, suggesting that the micro-environmental 
factors of a tissue plays a regulatory role in its expression [78]. In addition, other physiological 
conditions such as heat shock and hypoxia are shown to induce HLA-G expression [81, 82]. The 
activity of intracellular enzyme IDO is also shown to induce HLA-G expression on monocyte-
derived macrophages and DC [83, 84]. The pro-inflammatory cytokine IFN-γ also induces 
surface expression of HLA-G on monocytes [85]. 
Functionally, HLA-G down-regulates the activity of natural killer (NK) cells, T cells and 
Figure 1.2. Seven isoforms of non-classical HLA-G molecule.  
Four membrane bound (HLA-G1 – G4) and three soluble (HLA-G5 – G6) isoforms of human 
leukocyte antigen-G (HLA-G) (adapted from Clark et al 2012). 
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DC by binding to the inhibitory receptors ILT-2 (LILRB1/CD85j) [86, 87], ILT-4 
(LILRB2/CD85d) [88] and KIR2DL4 (CD158d) [89-91]. The interaction of HLA-G with these 
inhibitory receptors works in a feedback mechanism to up-regulate the expression of the 
receptors [92].  
The biological significance of HLA-G in kidney is shown to be beneficial during 
transplantation [93, 94]. Various studies have demonstrated a positive correlation between the 
expression of surface and soluble isoforms of HLA-G on PTEC and better graft acceptance 
following transplantation [95-97]. The mechanisms by which HLA-G affects the transplantation 
outcome are not completely identified [98]. However, studies have shown that the expression of 
HLA-G may aid in allo-transplantation acceptance by down-regulating the activity of cells that 
are mainly involved in rejection such as natural killer cells [99] and CD4 T cells [100, 101]. In 
addition, sHLA-G molecules can also bind to CD8 receptors expressed on NK cells or cytotoxic 
T cells causing them to undergo natural cell death [99, 102]. 
In this project, we consider the expression of HLA-G as one of the immuno-regulatory 
mechanism of human autologous PTEC and by blocking HLA-G1 and sHLA-G, we evaluate the 
effect on MoDC differentiation, B cell antibody production and T cell proliferation. 
1.5.5. Indoleamine-2,3-dioxygenase  
Intracellular enzyme IDO was initially identified in rabbit intestine and catalyses the 
breakdown of essential amino acid tryptophan into kynurenine [103, 104] (Figure 1.3) to create a 
micro-environment devoid of tryptophan. It is expressed in many  tissues and cell types such as 
liver [105], spleen [106], intestine [107], brain [108], placenta [109], myeloid cell lineage (DC, 
monocytes, and macrophages) [110, 111], epithelial cells [112], fibroblasts [113], endothelial 
cells [114], stem cells [115] and certain tumour cells [116]. In humans, IDO is encoded by the 
IDO1 gene on chromosome 8p12 [117] and its cDNA encodes a protein of 403 amino acids with 
a molecular weight of about 45 kDa [118, 119]. The expression of IDO is regulated by 
inflammatory stimuli, with IFN-γ being one of the principle stimulators [112, 120]. The IDO 
promoter contains multiple promoter sequence elements such as IFN-stimulated response 
element (ISRE) and IFN-γ-activated sequence (GAS). In response to IFN-γ stimulation, 
transcription factors such as signal transducer and activator of transcription 1 (STAT1) and IFN-
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regulatory factor 1 (IRF1) are activated and bind to GAS and ISRE respectively to enhance IDO 
expression [121]. Other studies have shown that lipopolysaccharide (LPS) [122] or other 
inflammatory cytokines such as IFN-α or IFN-β), IL-1 [123] and TNF-α [121, 122] act 
synergistically with IFN-γ to enhance in vitro IDO expression. However, Fujigaki et al have 
demonstrated in vivo that LPS and TNF-α function co-operatively and autonomously of IFN-γ to 
induce IDO expression, suggesting the existence of a IFN-γ independent pathway [124]. 
The function of IDO was initially thought to be antimicrobial by reducing the availability 
of tryptophan in the inflammatory environment [125, 126]. However, Munn et al, for the first 
time, identified the immunosuppressive capacity of IDO during pregnancy [127]. They mated 
genetically identical mice, except the males carried a transgene which drives the expression of 
H-2k
b
 in trophoblast (outer layer 
cells of the embryo). The mated 
females induced a strong T cell 
response against the H-2k
b
 antigen 
when treated with IDO inhibitor 1-
methyl-tryptophan (1-MT [128]), 
resulting in a miscarriage [127]. In 
addition, when immunodeficient 
pregnant mice were reconstituted 
with T cells specific for H-2k
b
 
antigen and treated with 1-MT, the animals also miscarried. From these two observations, Munn 
et al concluded that placental cells produce IDO which catalyses the essential amino acid 
tryptophan, preventing T cell proliferation that would otherwise destroy the foetus [127]. 
Although, tryptophan depletion through IDO activity is the principle mechanism of immune-
regulation [127, 129], other studies have demonstrated the role of kynurenine or its catabolic 
pathway by-products such as 3-hydroxykyrunine, 3-hydroxyanthranilate, quinolinate or picolinic 
acid in regulating immune cell responses [130-133].  
The role of IDO expression in PTEC under clinical settings is not fully defined. However, 
data from various studies have shown a connection between IDO and CKD, suggesting that its 
activity significantly increases with the severity of CKD [134, 135]. In addition, Schefold et al 
Figure 1.3. Indoleamine-2,3-dioxygenase (IDO) activity. 
Initial step of tryptophan metabolism catalysed by 
intracellular enzyme IDO. 
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have shown a correlation between IDO activity and key inflammatory markers hs-CRP and 
sTNFR-1, indicating the regulatory role of IDO under inflammatory settings [135]. 
The expression of IDO in kidney PTEC could be a defensive mechanism under various 
kidney pathological conditions. Hou et al showed that IDO is significantly upregulated in 
glomeruli and PTEC of a nephrotoxic serum nephritis (NTN) mouse model and stated that its 
expression negatively regulates the development of NTN. This was supported by experimental 
evidence that inhibition of IDO with 1-MT in NTN mice leads to an elevated level of crescent 
formation and renal injury, accumulation of CD4
+
 T cells and macrophages in glomeruli and the 
tubulointerstitium and enhanced Th1 responses [136]. Likewise, IDO expression in kidney cells 
could be beneficial in controlling graft damage following transplantation. Vavrincova-yaghi et al 
demonstrated that IDO expression in a kidney transplanted mouse model significantly decreased 
plasma creatinine, tubular injury bio-marker KIM-1 mRNA and increased expression of 
regulatory T cell (Treg) transcription factor foxp3 mRNA, indicating better survival and function 
of the graft [137]. However, damaging effects of IDO in certain disease models have also been 
reported. Mohib et al showed that IDO expression could promote renal injury in mice following 
ischemia-reperfusion (IR) operation. They demonstrated IR operated mice upregulated IDO 
expression in renal epithelial cells and increased serum creatinine levels when compared with 
control groups. Treating IR operated mice with IDO inhibitor 1-MT prevented the increase of 
serum creatinine, implying that IDO expression is harmful to kidney function in this model. This 
prompted them to suggest that inhibiting IDO activity may represent a novel strategy in 
improving kidney graft function and survival. This finding was supported in IDO knockout mice 
studies which showed normal levels of serum creatinine following IR operation when compared 
with wild type mice [138]. 
Various other studies have indicated that IDO expression in kidney PTEC could be utilised 
as a target molecule to diagnose or treat various kidney pathological conditions. For instance, 
Yuan et al compared the levels of IDO mRNA expression in renal cell carcinoma (RCC) kidney 
tissue and control samples and showed significantly higher levels of IDO mRNA expression in 
RCC tissue, suggesting that IDO may be a prognostic marker for patients with RCC [139]. In 
another study, Arioka et al demonstrated a time dependent increase in IDO expression in mice 
kidney tubule epithelial cells following Adriamycin induced kidney failure. In addition, they also 
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showed that administration of tryptophan was effective in suppressing the kidney failure, 
suggesting tryptophan infusion as a possible treatment for renal failure patients [140]. 
In this project, we consider IDO activity as one of the immuno-regulatory mechanism of 
human PTEC and by utilising its inhibitor 1-MT, we evaluate the effect on MoDC differentiation, 
B cell antibody production and T cell proliferation. 
1.6. DC subsets 
DC are bone marrow derived, highly migratory, professional AgPC that regulate innate and 
adaptive immune responses. Human DC are a heterogeneous population that can be classified 
into: (i) inflammatory MoDC and (ii) lineage negative (i.e. not T cells (CD3), B cells (CD19, 
CD20), monocytes (CD14), eosinophils and neutrophils (CD15), haematopoietic progenitors 
(CD34), or NK cells (CD56)), MHC class II (HLA-DR) positive blood DC (BDC) [141]. MoDC 
differentiate from peripheral blood monocytes under inflammatory conditions and this process 
can be mimicked in vitro by culturing monocytes in the presence of stimulators such as 
granulocyte/macrophage-colony stimulating factor (GM-CSF) and IL-4. BDC can be divided 
into CD11c
+
 conventional or myeloid DC (mDC) and CD11c
-
 CD123
high
 plasmacytoid DC 
(pDC). pDC are also identified by surface markers such as CD303 (blood DC antigen (BDCA)-
2) and CD304 (BDCA-4). Myeloid DC are further delineated into three phenotypically distinct 
subtypes CD16
+
 DC, CD1c
+
 (BDCA-1
+
) and CD141
+
 (BDCA-3
+
).  
1.6.1. Human DC and kidney disease 
In kidney, DC are distributed throughout the tubulointerstitium ensuring complete 
surveillance of the organ [142]. In the steady-state, various subsets of DC exist and different 
nomenclature have been proposed to study them [143]. According to Steinman et al, most of the 
DC are positive for CD11c, otherwise referred to as myeloid DC [144]. In kidney tissue, such 
DC also express fractalkine (CX3CL1) receptor CX3CR1, CD11b, MHC-II [145] and DC-SIGN 
[146]. Hart et al were the first to show the existence of DC shaped cells in the human kidney 
tubulointerstitium which stained positive for HLA-DR [147]. Later on, Markovic-Lipkovski et 
al, in a study involving 69 patients with various forms of GN, showed elevated levels of HLA-
DQ (MHC-II) positive cells when compared with the total number of CD14
+
 and CD20
+
 cells in 
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the interstitium, and therefore, concluded that human DC accumulated in tubulointerstitium 
during GN [148]. It is now well established in the literature that DC reside in various tissues 
along with kidney and during homeostatic settings they tolerise infiltrating T cells, thereby 
maintaining peripheral immune tolerance against auto-antigens [149]. However, during a 
pathological situation DC affect organ homeostasis and induce innate immunity [150].  
During early pathological conditions, DC are generally considered to be beneficial, as 
demonstrated in acute kidney disease (AKD) models [151]. In the NTN mouse model, DC are 
demonstrated to be protective in 
function via an IL-10 dependent 
mechanism [152]. In this model, 
when the CD11c
+
 DC were 
depleted at early stages, the mice 
developed severe 
tubulointerstitial inflammation 
and glomerular damage, 
indicating that DC negatively 
regulated the development of 
NTN. In the same study, in vitro 
experiments showed that DC 
induced elevated levels of IL-10 
when co-cultured with antigen 
specific CD4
+
 T cells [152]. In 
various other studies it is well 
established that IL-10 reduces the development of NTN [153, 154]. Similarly, in the cisplatin 
induced nephrotoxic mouse model, using cell ablation techniques, Tadagavadi et al demonstrated 
that IL-10 secreted by DC was partly responsible for reducing nephrotoxicity as measured by 
serum creatinine levels [155]. 
DC also play a role in kidney ischemia-reperfusion injury (IRI), which is a major problem 
following transplantation. CD11c
+
 DC isolated from kidneys of IRI mice during the recovery 
phase showed elevated levels of IL-10 when compared with the DC isolated during the injury 
Figure 1.4. Human DC subsets. 
Hierarchy of the heterogeneous human DC population 
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phase, suggesting that DC have an anti-inflammatory effect during recovery from IRI [156]. This 
was supported by in vivo experiments showing that infusion of CD11c
+
 splenic DC into IRI mice 
following DC depletion significantly decreased tissue injury [156]. In another study, also 
involving the IRI model, it was shown that DC were beneficial by suppressing proinflammatory 
cytokines, particularly TNF-α and IL-6. This was partly mediated by the self expression of 
interferon regulator-4 [157]. 
Interestingly, studies have also shown that DC function may become harmful as the disease 
progresses to the chronic stage [151]. For instance, in the NTN model mentioned earlier, the DC 
depleted during the later stage of the disease expressed high levels of co-stimulatory molecules 
CD80 and CD86 and induced elevated levels of pro-inflammatory cytokines IL-12 and TNF-α. 
In addition, depletion of DC during later stages of NTN decreased the severity of the disease in 
contrast to depleting at an early stage which increased the severity of disease [158]. Furthermore, 
kidney DC captured more filterable antigen or self-antigens in proteinuric mice at later time 
points of NTN [158] or in a five-sixths nephrectomy [159] model and presented the antigens to 
cytotoxic CD8
+
 T cells, which responded by producing pro-inflammatory cytokines. Likewise, in 
an experimental model of glomerular injury, the kidney DC activated CD4
+
 T cells and skewed 
them towards a Th1 response, eventually causing progressive kidney damage [160].  In a chronic 
LN mouse model, DC were also shown to play a prominent role in expansion of T and B cells, 
contributing to the progression of the disease [161]. 
Almost all studies examining the location of DC within the kidney report them exclusively 
within the interstitium where they would be ideally located to interact with, and receive signals 
from, PTEC. Such interaction is discussed later in this chapter (refer 1.9.1).   
1.7. B cell subsets 
B cells are a population of cells that play the major role in humoral immune responses via 
the production and secretion of antigen specific antibodies and defend the host against 
extracellular bacteria and viruses. B cells recognise their specific antigen via the B cell receptor 
(BCR), a membrane bound immunoglobulin (Ig), usually of the IgM subclass, in close 
association with CD79, a transmembrane activation motif. This BCR provides the specificity of 
the B cell and it has been estimated that there are around 10
9
 possible variant specificities [162].  
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Upon interaction of the BCR with its specific antigen, B cells become activated and differentiate 
into either antibody secreting plasma cells or memory B cells. 
B cells can be broadly classified into: 
(i)  Non-classical B-1 B cells that generally show innate responses to T cell independent 
antigen [163] by producing antibody in response to non-protein antigen such as polysaccharides, 
lipids and nucleic acids. They are characterised by the expression of high levels of surface IgM 
(sIgM), CD11b and low levels of surface IgD (sIgD), CD21 and CD23. They are further 
delineated into B1a B cells (CD5
+
) and B1b B cells (CD5
-
) [164]. 
(ii) Classical B-2 B cells that generally produce antibody to foreign protein-based antigen 
under T cell dependant conditions. When a T cell dependent antigen is recognised and bound to 
the BCR, the B cell internalises it, digests it and presents it on MHC-II to responding CD4
+
 T 
helper cells which induce B cell maturation by secreting cytokines and stimulating through 
CD40 [165]. The matured B cell undergoes isotype switching to produce high affinity IgG 
antibody and differentiates into a plasma B cell or a memory B cell. 
Plasma B cells have an intermediate life span ranging from a few days to several months 
and secrete high levels of antibody [166, 167]. At this mature stage, plasma B cells lose the 
expression of surface BCR and can no longer act as antigen-presenting cells. Phenotypically, 
human plasma B cells are identified by the expression of activation markers CD38
++
, CD138
+
 
and CD27
++
 [168]. Memory B cells are long-lived and express high affinity Ig receptor, CD38
+
, 
CD138
-
, CD27
+
 and exhibit rapid responses to a repeated exposure of the primary antigen [168].   
1.7.1. B cells in kidney disease 
Although B cells were reported in kidney tissue more than half a century ago, for many 
years their presence appears to have gone almost un-noticed as T cells took centre stage in the 
kidney disease process. Only in the last decade or so research has emerged reporting on the 
presence of these cells in many kidney diseases and, indeed, suggesting that B cells play multiple 
roles in both the acute and CKD process apart from that of antibody  production and its 
subsequent role in kidney transplantation rejection. Numerous groups have suggested a 
pathological role for intra-renal B cells in LN[169, 170]. Jang et al used knock-out mouse 
models to demonstrate that B cells limit tissue repair following IRI [171]. Segerer’s group has 
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reported on the presence of B cells in acute human kidney disease biopsies, with six out of ten 
primary interstitial nephritis cases positive for B cells, and in chronic human kidney disease 
biopsies, with fourteen out of twenty nine chronic interstitial nephritis cases and seven out of 
eighteen IgA nephropathy cases demonstrating B cell infiltrates [172]. B cells have also been 
described in biopsies from patients with LN, anti-neutrophil cytoplasmic antibody (ANCA)-
associated nephritis and membranous nephropathy [173, 174]. Many groups have also reported 
that B cells within the kidney can form an integral component of tertiary lymphoid organs and 
these structures have been associated with renal interstitial fibrosis and both positive and 
negative outcomes in kidney transplantation [175-178]. In all of these studies, B cells were found 
almost exclusively within the interstitium of the kidney, where they would be ideally located to 
interact with the basolateral surface of PTEC.  
1.8. T cell subsets 
T cells are a population of immune cells that defend the host body against foreign antigens 
via cell mediated immunity. They can be broadly classified into two main sub-types; (i) CD4
+
 T 
cells (T helper cell) that are referred to as “Class II restricted” in that they recognise and respond 
to peptides presented in the context of MHC Class II antigen only and (ii) CD8
+
 T cells 
(cytotoxic T cell) that are referred to as “Class I restricted” in that they recognise and respond to 
peptides presented in the context of MHC Class I antigens only. Naive T cells generally require 3 
signals for full activation [179]. The first signal  is provided by binding of the MHC-peptide to 
its TCR complex, signal 2 is the interaction of co-stimulatory ligand CD80 and CD86 on AgPC 
with their receptor CD28 on T cells [54] and signal 3 is given by cytokines secreted by AgPC, 
which drive the T cell subset pathway [37, 38]. 
 A number of CD4
+
 T cell subsets have now been identified with the Th1, Th2 and Th17 
subsets being the best characterised. Differentiation of naive CD4
+
 T cells towards a Th1 subset 
phenotype is induced by secretion of IL-12 by the AgPC [180]. The Th1 subset is characterised 
by expression of the Th1 transcription factor T-bet [181] and secretion of its signature cytokine 
IFN-γ which is fundamental in activating macrophages and NK cells. Th1 immune responses are 
important for eliminating pathogen and viruses but these cells have also been implicated in organ 
specific autoimmune diseases [182]. 
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 The Th2 subset is induced by DC derived IL-4 which down regulates the expression of 
IL-12 surface receptors on naive CD4
+
 T cells thereby facilitating their commitment to the Th2 
subtype. IL-4 is also the signature cytokine of Th2 T cells, along with IL-5 and IL-13. The Th2 
subset is distinguished by the expression of its transcription factor GATA binding protein-3 
(GATA-3) [183]. Th2 responses are critical in activating mast cells and eosinophils, and 
eradicating helminths and other extracellular parasites. 
  
Differentiation of naive CD4
+
 T cells into the Th17 subset is stimulated by DC cytokines 
TGF-β [184], IL-1β [185] and IL-23 [186] and is characterised by expression of Stat3 protein 
and transcription factor retinoic acid receptor related orphan receptor-γt (RORγt) [187]. IL-6 and 
TGF-β seem to synergistically induce RORγt – the master transcription factor of the Th17 subset 
and expression of IL-23 receptor maintains Th17 cells [184, 187]. The effector cytokines 
secreted by this cell type are IL-17, IL-21 and IL-22. The Th17 subset has a defensive role 
against extracellular bacteria and plays a key role in various autoimmune diseases [186]. 
 It is important to note however that commitment to these subsets is not “absolute” and 
depending upon a range of factors including interaction with co-stimulatory/inhibitory 
Table 1.1. Category, differentiation and function of effector CD4+ Th cells 
T cell 
Subset 
Inducing 
cytokines 
Signature 
cytokines 
Lineage 
Transcription 
Factors 
Function 
Protection Pathology 
Th1 IL-12, IFN-γ IFN-γ T-bet Eliminates intracellular 
bacteria and viruses 
Inflammation 
Th2 IL-4 IL-4, IL-5, IL-
13 
GATA-3 Humoral immunity Allergy and 
asthma 
Th17 TGF-β, IL-1β, 
IL-23, IL-6 
IL-17, IL-21, 
IL-22 
RORγt Defence vs. extracellular 
bacteria 
Autoimmune 
diseases 
Treg TGF-β, IL-10, 
IL-2 
 
TGF-β, IL-10 
 
FoxP3 
 
Downregulate Tcell 
responses and maintain 
immune tolerance 
 
CD8
+
 T 
cell 
IFN-γ IFN-γ,   perforin 
and granzymes 
T-bet and Eomes Eliminating tumour cells 
and virus infected cells 
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molecules, regulatory proteins and changing cytokine milieu, apparently “committed” T cells 
may undergo phenotypic shifts [188, 189] 
Treg or suppressor T cells are a subpopulation of T cells that downregulate T cell 
responses and maintain immune tolerance. These cells are characterised by the expression of 
surface markers CD4
+
, CD127
low
, activation marker CD25
+ 
[190], transcription factor fork head 
box P3 (Foxp3) [191] and expression of TGF-β and IL-10 as their signature cytokines [192].  
CD8
+
 T cells (cytotoxic T cells) are another group of T cells that are critical in eliminating 
tumour cells and somatic cells infected with viruses. The effector products of CD8
+
 T cells are 
IFN-γ and cytotoxic granules including perforin and granzymes. The induction signals of 
cytotoxic T cells are similar to CD4
+
 Th1 cells with T-bet [193] being expressed in both cell 
types. However, eomesodermin (Eomes), another transcription factor highly homologous to T-
bet, is shown to be expressed along with T-bet in antigen specific CD8
+
 T cells [194].  
1.8.1. T cells in kidney disease 
T cells are well described effector cells in immunologic renal diseases, including LN [195], 
IgA nephropathy [196], GN [197] and graft rejection. T cells infiltrating the kidney are activated 
mainly through antigen-independent or antigen-dependent mechanisms. The antigen-independent 
mechanism includes activation through cytokines like IFN-γ and reactive oxygen species. The 
antigen-dependent mechanism is mediated by specific antigens presented by kidney resident DC 
[198]. Dong et al demonstrated that renal DC migrate to kidney lymph node and activate antigen 
specific CD4
+
 T cells, thereby contributing to the progression of disease [199]. Generally, T cells 
within the inflamed kidney interstitium are demonstrated to be directly pathophysiological and 
associated with poor prognosis. Biopsies of human kidney with acute tubular necrosis have 
demonstrated the accumulation of T cells in the kidney interstitium [200]. Rabb et al showed 
significant decreases in tubular necrosis and increases in kidney function in CD4/CD8 knockout 
mice following IRI [201]. In another study, depletion of CD4
+
 T cells from mice which 
underwent IRI resulted in significant protection of renal structure and function [202]. Direct 
evidence for the role of T cells in mediating the IRI injury was given by Ascon et al. In their 
study, elevated numbers of CD4
+
 and CD8
+
 T cells were observed in mouse kidney following 
IRI. Furthermore, these cells expressed high levels of activation and effector cell markers CD69 
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and CD44 respectively. Depletion of these cells prior to IRI caused less kidney damage when 
compared to depletion after IRI which had no effect on the histology of kidney damage [203].  
The role of T cells in causing glomerular damage is widely studied in animal models of 
NTN which display an immunopathology very similar to human crescentic GN [204]. Depletion 
of CD4
+
 T cells but not CD8
+
 T cells was shown to attenuate NTN in these mice [205] whereas, 
depletion of both CD4
+
 and CD8
+
 T cells was shown to be protective in a rat model of NTN 
[206, 207]. Recently identified effector T cell subset Th17 has also shown to be harmful during 
GN. In Th17 cells and IL-17 knockout mouse models, induction of NTN injury resulted in less 
severe kidney inflammation and improved renal function when compared with wild type mice. 
The authors therefore suggested that IL-17/Th17 may provide a therapeutic target for the 
treatment of crescentic GN [208].  
The role of T cells is also demonstrated in other kidney disease. Adrouge et al showed 
elevated level of Th2 cells in peripheral blood mononuclear cells obtained from patients with 
minimal change disease (kidney disease that causes nephritic syndrome). These T cells expressed 
high levels of activation marker CD69 and Th2 cytokine IL-4 mRNA as determined by flow 
cytometry and RT-PCR respectively. The authors therefore demonstrated a correlation between 
minimal change disease and activated Th2 cells [209].    
In a few disease models, T cell presence has been reported as beneficial, presumably 
reflecting the development or presence of Treg. For example, as discussed above in an IRI 
model, following injury there are elevated levels of effector T cells infiltrating the kidney 
causing inflammation [203]. Infusion of Treg cells 24 h after IRI negatively regulates the 
production of pro-inflammatory cytokines by CD4
+
 or CD8
+
 T cells and improves kidney 
function as indicated by reduced serum creatinine levels, thereby, suggesting that Treg play a 
beneficial role following kidney injury [210]. Similarly, Treg have also been demonstrated to be 
beneficial in various other kidney diseases such as organ transplantation [211], autoimmune 
kidney disease [212] and chronic proteinuria associated kidney injury [213].   
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1.9. The role of PTEC as immune modulating cells 
1.9.1. PTEC and DC interaction 
 Recent studies indicate that DC in kidney tissue are critical to maintain health-disease 
homeostasis of the kidney. A cross-section analysis of DC in biopsy of diseased kidney has 
demonstrated that DC localise primarily in the interstitium, with minimal or no evidence for their 
localisation in the glomerular compartment [214]. Similarly, Segerer et al observed a localisation 
of mDC (CD11c
+
) within the tubulointerstitium in patients with proliferative GN [215]. Fiore et 
al also showed a significant reduction in circulating CD1c
+
 BDC in patients with active LN 
compared to those in remission, with a corresponding tubulointerstitial accumulation of CD1c
+
 
BDC in patients with active disease [216]. Monocytes, capable of differentiation into 
inflammatory MoDC have also been reported in the tubulointerstitium of patients with GN [146, 
217]. All of these studies indicate that DC within the kidney are ideally positioned to receive 
signals from the perturbed PTEC in the tubulointerstitium. However, very little is known about 
the mechanisms by which resident kidney cells regulate DC function during various pathological 
conditions. An early paper by Frank et al indicated that PTEC secrete granulocyte-macrophage 
colony stimulating factor (GM-CSF) [218] which contributes to the differentiation of monocytes 
into MoDC and may be responsible for the progression of the disease in cases of GN [146]. In 
vitro, Kronsteiner et al have shown that in contact independent co-cultures of monocytes and 
PTEC, the PTEC inhibited the maturation of MoDC. These MoDC expressed low levels of 
maturation marker CD1a and demonstrated elevated levels of antigen-uptake, which is a 
functional characteristic of immature DC [219]. They proposed a mechanism of PTEC-induced 
sHLA-G production from the developing MoDC to account for these observations.  
One of the aims in this project is to understand and deduce the immuno-regulatory 
mechanisms of PTEC on DC activation and maturation in the context of the autologous human 
system.       
1.9.2. PTEC-B cell interactions 
No literature exists investigating the interaction of PTEC and B cells except for our 
previously published data where we have demonstrated that PTEC down-regulate B cell 
proliferation [45]. This project is the first study to demonstrate the in vitro immuno-regulatory 
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mechanisms of PTEC on B cell activation and antibody production in the context of an 
autologous human setting.      
1.9.3. PTEC and T cell interaction 
PTEC express MHC II (refer to section 1.5.1) which may enable them to initiate T cell 
responses and act as non-professional AgPC. Wuthrich et al have demonstrated that PTEC under 
Figure 1.5. Perturbed PTEC cross-talk with infiltrating DC and Lymphocytes.  
 (1) PTEC being activated in response to injurious stimuli. (2) The activated PTEC secrete pro-
inflammatory cytokines in the tubulointerstitium. (3) The pro-inflammatory cytokines mediate 
the extravasation of lymphocytes, monocytes and DC into the tubulointerstitium. (4) The 
extravasating lymphocytes secrete a secondary wave of cytokines which act on PTEC modulating 
the upregulation of MHC-II, PD-L1, IDO and sHLA-G. These molecules facilitate the interaction of 
PTEC with extravasating lymphocytes and regulate immune responses. (5) The activated PTEC 
influences the maturation of BDC and/or differentiation of monocytes into MoDC which in turn 
regulates the proliferation of extravasating lymphocytes.  
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inflammatory situations can regulate T cell responses. They demonstrated that murine PTEC cell 
lines up-regulated MHC-II in response to stimulation with pro-inflammatory cytokine IFN-γ. 
Furthermore, these PTEC could up-take foreign antigen such as hen’s egg lysozyme (HEL) and 
activate HEL restricted T cell hybridomas. The control (not treated with IFN-γ) PTEC did not 
express MHC-II, and therefore, failed to stimulate T cell hybridomas even in the presence of 
high concentrations of HEL antigen [220]. This suggests that during an inflammatory situation, 
PTEC acquire an immuno regulatory phenotype and modulate the disease process. In another 
study, Hagerty et al demonstrated the in vivo self and foreign antigen presentation ability of 
primary PTEC during a perturbed situation. IFN-γ was injected into the tail veins of mice for 3 
days to initiate an inflammatory microenvironment. This was followed by injecting HEL on day 
4 so that PTEC would up-take exogenous antigens. PTEC isolated two hours later from these 
mice were able to stimulate HEL specific T cell hybridomas in the co-cultures, illustrating their 
ability to process and present foreign antigen [44]. 
The presentation of self-antigens by professional AgPC can induce tolerance. However, 
during pathological conditions the presentation of self-antigens by PTEC can initiate T cell 
responses, and contribute to the progression of autoimmune disease. The self-antigen presenting 
ability of PTEC was analysed using transgenic mice for the human α1-antitrypsin (hAAt) gene. 
hAAT specific T cell hybridomas were generated in non-transgenic mice and used as a probe to 
detect endogenously formed hAAT/MHC complexes on various AgPC populations in the 
transgenic mice, demonstrating the capability of PTEC to process and present self antigen [44].  
The responding cells discussed are all T cell hybridomas. Unlike naive T cells, T cell 
hybridomas are activated by the engagement of TCR with a MHC-peptide complex without 
further need of CD80 and CD86 co-stimulatory signal. If a similar type of activation is induced 
on a naive T cell, it results in T cell un-responsiveness or anergy. As discussed in section 1.5.2, 
various studies demonstrate that PTEC do not express costimulatory molecules CD80 and CD86. 
Singer et al have demonstrated the ability of PTEC to induce anergy in naive T cells [63]. The 
authors compared the antigen presenting ability of IFN-γ treated primary PTEC to naive T cells 
or T cell hybridomas. The PTEC were able to activate T cell hybridomas but failed to activate 
naive T cells and in fact induced only anergy in these cells. As the authors were unable to detect 
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the expression of CD80/86 on the IFN-γ treated PTEC they speculated that this lack of co-
stimulatory signals was responsible for the observed T cell anergy [63].   
Using mouse models, a number of other researchers (discussed below) have investigated 
the role of PD-L1, an immuno-regulatory molecule expressed (refer section 1.5.3) on PTEC, in 
the context of non-professional antigen presentation and regulation of T cell responses. Schoop 
et al demonstrated that in response to IFN-γ, PTEC can up-regulate MHC-II and PD-L1, act as 
non-professional AgPC and suppress CD4
+
 Th1 and Th2 responses [221]. In addition, when the 
PD-L1 was blocked, the activation of CD4
+
 T cells was restored as indicated by expression of 
activation marker CD69 and elevated levels of the Th1 cytokines IFN-γ and IL-2 [74]. Others 
have also demonstrated that the expression of PD-L1 on murine PTEC also down-regulates 
CD8
+
 T cells, thereby protecting them from cytotoxic activity [222]. Starke et al demonstrated 
that the inflammatory mediator TGF-β plays a role in enhancing such cytotoxic affects by down 
modulating IFN-γ induced PD-L1 and CD40 expression. TGF-β is detected in many renal 
diseases and plays a critical role in renal diseases such as IgA nephropathy, tubulointerstial 
injury and acute and chronic renal failure [46]. In an another study, Waeckerle-Men et al 
compared the antigen presenting ability of primary PTEC and bone marrow derived DC and 
reported that PTEC were poor AgPC. The authors further demonstrated that this antigen 
presenting ability of PTEC could be up-regulated by blocking PD-L1 on PTEC, speculating that 
PTEC may use PD-L1 to suppress T cell activity [223]. In a similar study performed on T cell 
hybridomas, blocking PD-L1 on PTEC considerably elevated the level of IL-2 cytokine in the 
co-culture system suggesting the inhibitory role of PD-L1 on T cell hybridoma activation [74].    
As mouse models do not always mimic the human response, initial work to translate this 
research into the human biological system was done by Van Kooten et al at the Leiden 
University Medical Centre, Netherlands. They demonstrated that primary PTEC or the PTEC cell 
line from normal adult human kidney (HK-2) induced IL-10 production from allogeneic anti-
CD3 stimulated T cells [65]. Furthermore, by blocking PD-L1 expressed on HK-2 cells they 
demonstrated, in this culture system, the altered cytokine profile of low IFN-γ secretion and high 
IL-10 production was independent of PD-L1 expression  [65]. In a similar study on HK-2 cell 
lines, Ding et al demonstrated elevated levels of PD-L1 expression in response to IFN-γ and that 
when this PD-L1 was blocked, these cells were able to induce significantly increased levels of 
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IL-2 production from PHA stimulated peripheral blood T cells [75]. Furthermore, Starke et al 
showed that renal expression of PD-L1 on human PTEC exerts an inhibitory effect on 
alloreactive CD4
+
 and CD8
+
 T cell responses. They further suggested that upregulation of PD-L1 
in patients with allograft rejection may reduce T cell mediated injury [76].  
The mechanisms of PTEC immune modulation observed in human studies have all been 
undertaken using transformed cell lines such as HK-2 cells or primary PTEC from one donor and 
assayed against immune competent cells from a different donor, that is, in an allogeneic system. 
This mechanism confounds interpretation of what may be occurring in the autologous immune 
pathway. To overcome this limitation, our Lab has undertaken experiments to define whether 
human PTEC can modulate autologous immune responses [45]. This is achieved by utilizing 
PTEC and peripheral blood mononuclear cells from the same donor (autologous). We have 
demonstrated that primary human PTEC down-regulate autologous T cell and B cell responses 
[45] and that this down-regulation is: (a) partly mediated by PD-L1 and (b) accompanied by 
strong skewing of cytokine profiles from T and B cells, significantly decreasing IFN-γ, IL-2, 
TNF-α and increasing IL-4 production, indicating a shift from a Th1 type profile towards a Th2 
type profile [45]. This data from the autologous human system partially support some findings 
and refute others from previous mouse and allogeneic human studies. It now remains imperative 
to fully define the cellular and molecular mechanisms by which human PTEC modulate 
autologous immune responses.  
One of the aims in this project is to understand and deduce the immuno-regulatory 
mechanisms of PTEC on CD4
+
 T cell activation and proliferation in the context of autologous 
human conditions.       
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1.10. Hypotheses 
For the present study we hypothesize that, within the inflammatory renal disease setting, 
PTEC down-regulate autologous local immune responses in order to protect themselves from 
direct and bystander damage. 
1.11. Aims 
 To define whether PTEC affect immune responses via modulation of DC 
maturation/function. 
 To define whether PTEC immune modulation is contact dependant. 
 To define the mechanism of autologous PTEC regulating CD4
+
 T cell responses. 
 To identify whether activated PTEC interact with autologous B cells to inhibit the 
production of antibodies. 
 To define the roles of sHLA-G, PD-L1 and IDO in autologous PTEC immune 
modulation.  
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Chapter 2: Materials and methods 
2.1. PTEC culture methods 
2.1.1. Participants 
Kidney tissue from the healthy portion of malignant and non-malignant nephrectomies was 
obtained with informed consent. Peripheral blood was obtained from these same donors three to 
six months post-nephrectomy. A total number of 29 donors were used in this study with an age 
variation of minimum 18 years to maximum 65 years. Of these, male donors (n=14) with mean 
age 50 ± 9 years and female donors (n=15) with mean age 51 ± 13 years were used. 
2.1.2. Ethics approval 
This project has ethics approval from the Queensland University of Technology (reference 
number: 1400000867), QIMR Berghofer Medical Research Institute - Human Research Ethics 
Committee (QIMR Berghofer-HREC reference number: P293), The Royal Brisbane and 
Women’s Hospital - Human Research Ethics Committee (RBWH-HREC reference number: 
2002/011), Queensland Health-Pathology (reference number: P293RB) and the Wesley Research 
Hospital Tissue Bank.  
2.1.3. PTEC culture media 
PTEC were cultured in defined media (DM) comprising of a 1:1 mixture of Dulbecco’s 
modified Eagles medium and Ham’s F12 (DMEM/F12) containing 15mM HEPES buffer, L-
glutamine and pyridoxine hydrochloride (Life Technologies), epidermal growth factor (10 
ng/mL) (Sigma-Aldrich), insulin (10 μg/mL) (Roche), transferrin (5 μg/mL) (Roche), selenium 
(5 ng/mL) (Roche), hydrocortisone (36 ng/mL) (Sigma-Aldrich), tri-iodothyronine (4 pg/mL) 
(Sigma-Aldrich), penicillin (100 U/mL) (Life Technologies) and streptomycin (100 µg/mL) (Life 
Technologies). 
2.1.4. PTEC isolation from donor tissue 
Healthy portion of the kidney cortex was dissected from macroscopically/microscopically 
normal portions of nephrectomies and used as the source to isolate PTEC. The cortex was 
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separated from the outer capsule, washed thoroughly using DMEM media supplemented with 
fungizone, dissected into small pieces (approximately 1 mm
2
) using a sterile scalpel (Labtech) 
and subjected to collagenase (Sigma-Aldrich) digestion (1mg/mL) for 1 hr at 37°C with 
vortexing every 10 min. The digest was passed through a 100 μM nylon cell strainer (BD 
Biosciences) followed by a 40 μM nylon cell strainer (BD Biosciences). The flow through was 
centrifuged at 300xg for 5 min. The supernatant was discarded and the pellet was resuspended in 
DM. Cell stocks were frozen at passage 1 (P1) and all PTEC were used in experiments between 
passage 2 (P2) and passage 4 (P4). PTEC were characterised on the basis of: (i) strong staining 
for cytoketatin-18 (ii) strong staining for alkaline phosphatase activity using the napthal AS-MX 
method and (iii) characteristic cobblestone morphology. 
2.1.5. PTEC cryopreservation 
For PTEC cryopreservation, the cells were centrifuged and resuspended in a final 
concentration of 1x10
6
-2x10
6
 cells/mL in serum free cryopreservation media comprising of 10% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and ice cold 90% DM media. 1 mL aliquots were 
then distributed into thermo scientific cryotube vials, placed into a Mr. Frosty Cryo 1C freezing 
container (Nalgene) and stored at -80°C for 24-48 h before being transferred to liquid nitrogen 
storage (-196°C) until further use. 
2.1.6. PTEC cell culture 
P1 PTEC were removed from liquid nitrogen , thawed in a 37°C water bath and diluted 
1:10 with pre-warmed sterile phosphate buffered saline (PBS). The diluted PTEC were 
centrifuged at 300xg for 5 min, supernatant was discarded and the pellet was resuspended in DM 
media and expanded in a tissue culture flask as passage 2 (P2) until 90% confluency. PTEC were 
detached from the tissue culture flask using recombinant enzyme TrypLE and its inhibitor (both 
from Life Technologies). Cells were then used in further experiments or passaged for future use.  
2.1.7. PTEC irradiation 
Where required the PTEC were exposed to γ-irradiation at 3000 cGY in the Gamma-cell 
irradiator to prevent further proliferation. 
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2.2. Peripheral blood mononuclear cells (PBMC) isolation and 
preservation 
2.2.1. Isolation of PBMC from whole blood 
PBMC were isolated from a unit of whole blood donated by PTEC donors using a density 
gradient centrifugation technique. 20 mL aliquots of whole blood were distributed into 50 mL 
falcon tubes and diluted 1:2 with sterile PBS. Gently, 10 mL Ficoll-Paque
TM
 Plus (GE 
Healthcare) was under-laid in each tube using a sterile syringe and cannula. The tubes were 
centrifuged in a Thermo Scientific Multifuge 1S-R centrifuge at 521xg for 20 min at room 
temperature, with the brake set to zero. PBMC were harvested from the ficoll interface using a 
pasteur pipette and washed three times with ice cold sterile PBS. After the final wash, PBMC 
were cryopreserved (refer 2.2.3) until further use.  
2.2.2. Cell Counting 
Cell concentrations were calculated using a haemocytometer (Boeco). In brief, the sample 
was diluted 1:2 with trypan blue (Sigma-Aldrich) and 10μL was transferred on to the 
haemocytometer counting chamber. Live cells, marked by trypan blue exclusion, were counted 
from one or more corner squares of the haemocytometer counting area using an Olympus CX40 
phase contrast microscope (Olympus Corporation). Cell concentration was calculated using the 
formula:  
Cell concentration/mL = (Average number of live cells counted from one or more corner squares 
of the haemocytometer) X (dilution factor) X 10000 
Percentage of viable cells in a given sample was calculated as: 
Viability percentage = (Average number of live cells counted from one or more corner squares of 
the haemocytometer / Average number of all cells counted from one or more corner squares of 
the haemocytometer) X 100 
2.2.3. PBMC cryopreservation 
For cryopreservation, the PBMC were resuspended in a final concentration of 25x10
6
-
30x10
6
 cells/mL by slowly adding appropriate volumes of ice cold cryopreservation media which 
consists of 10% DMSO, 50% heat inactivated fetal calf serum (FCS) and 40% RPMI media. 1 
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mL aliquots were then distributed into thermo scientific cryotube vials, placed into a Mr. Frosty 
Cryo 1C freezing container  and stored at -80°C for 24-48 h before being transferred to liquid 
nitrogen storage (-196°C) until further use. 
2.3. Autologous PTEC-B cell immune modulation methods 
2.3.1. B cell culture media 
All B cell cultures were performed in Complete Medium (CM-FCS) consisting of 
Rosewell Park Memorial Institute (RPMI) 1640 supplemented with 10% heat-inactivated foetal 
calf serum, 100U/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine, 1mM sodium 
pyruvate, 0.1mM non-essential amino acids, 10mM HEPES buffer solution (all from Life 
Technologies), and 50 M 2-mercaptoethanol (Sigma-Aldrich). 
2.3.2. Isolation of CD19+ B cells and purity staining 
CD19
+
 B cells were isolated from PBMC based on the cell surface expression of CD19 
antigen. PBMC were treated with CD19 micro-beads (Miltenyi Biotech) and CD19
+
 B cells were 
positively selected based on manufacturer’s instructions. Briefly, 107 PBMC were treated with 
20 μL CD19 micro-beads and incubated for 15 min at 4°C with mixing every 5 min. Excess 
micro-beads were removed by diluting PBMC 1:50 with MACS buffer and centrifuging at 400xg 
for 5 min. The supernatant was discarded and the PBMC was passed through a LS column 
(Miltenyi Biotech) fitted to a magnet. The CD19 positive cells bind to the column, while all the 
CD19 negative cells flow out through the column. The column was then separated from the 
magnet and CD19
+ 
B cells were eluted out of the column. The cellular flow-through from the 
column was subsequently used for the purification of CD14
+
 monocytes (refer 2.5.3) and CD4
+
 T 
cells (refer 2.4.2).  
The purity of B cells eluted from the column was analysed by staining with fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), and Pac-orange (PO) 
conjugated monoclonal antibodies against CD4, CD14, CD20 and CD3. Conjugated mouse IgG1 
and IgG2a served as isotype controls. The concentrations of these antibodies were pre-optimised 
in our Lab and previously published [45]. Briefly, 2.5x10
4
 cells were resuspended in 30 μL 
FACS buffer (PBS + 0.5% bovine serum albumin (BSA) + 0.02% Sodium Azide) supplemented 
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with 1 μL of each antibody and incubated at 4°C in the dark for 30 min. The cells were then 
washed and fixed in 200 μL of 1% paraformaldehyde (PFA). Samples were stored at 4°C 
(protected from light) for up to 72 h until measured on a FACS canto using BD FACS-Diva 
software. The purity of B cells was reported as percentage of cells positive for CD20 and 
negative for CD14, CD4 and CD3.  
Prior to co-culture, the autologous PTEC were seeded at a concentration of 1-1.5x10
5
 cells 
per mL with 1000 µL being added to the wells of a polystyrene 24 well plate (BD Biosciences) 
and bottom chamber of 0.4µM pore size polystyrene transwell-24 well plate (Corning) to 
establish contact dependent and independent co-culture systems respectively. Following 8 h of 
seeding, the PTEC were activated with 100 ng/mL IFN-γ (R&D systems) with continued 
incubation for another 16-18 h. PTEC proliferation was then stopped by exposing them to γ-
irradiation at 3000 cGY.  
2.3.3. PTEC- B cell co-culture 
Two different methods were followed to set-up autologous PTEC and B cell co-cultures – 
contact dependent and contact independent. For the contact dependent co-culture method, B cells 
(refer 2.3.1) were resuspended in CM at a concentration of 1x10
6
 per mL. 1 mL aliquots were 
then added to the wells of a polystyrene 24 well plate previously seeded with activated and 
irradiated PTEC (PTEC-B cells). 1 mL was also added to the empty wells of the plate as control 
(Ctrl-B cells).  
To set-up contact-independent co-cultures, B cells (refer 2.3.1) were made up to a final 
concentration of 5x10
6
 per mL and 200 μL aliquots were added on top of a 0.4µM pore size 
polystyrene membrane of a transwell-24 well plate. The DM media covering the PTEC in the 
bottom chamber was replaced with 800 µL CM-FCS. For a control, the top chamber had 200 μL 
aliquots of B cell solution and the bottom chamber had only 800 µL of CM-FCS. 
2.3.4. Activation of B cells 
B cells cultures were activated with 50µg/mL pokeweed mitogen (PWM) (Sigma-Aldrich) 
and 1µg/mL non-specific activation molecule-R848 (Mabtech). Following 48 h of culture, the 
effects of autologous PTEC on B cells were studied by analysing the total number of B cells 
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secreting IgG and IgM antibody, quantity of IgG and IgM secreted, expression of B cell 
inflammatory cytokines, B cell surface antigen expression and B cell proliferation.  
2.3.5. PTEC-B cell blocking studies 
To identify the mechanism behind the immuno-regulatory effect of autologous PTEC, 
surface molecule PD-L1, intracellular IDO and soluble HLA-g were neutralised within the 
PTEC-B cell co-culture. 
For PD-L1 blocking, 10 μg/mL of anti-human PD-L1 (Biolegend) blocking antibody was 
added to the surface of PTEC and incubated for 2 h. Following incubation, the PTEC wells were 
washed to remove excess antibody and the co-culture was established.  
To neutralise sHLA-G and IDO, 10 μg/mL of anti human sHLA-G (Biolegend) blocking 
antibody and 1500 μM/mL IDO inhibitor 1-MT (Life Technologies, California) respectively was 
added into the PTEC or control wells following the set-up of co-culture.  
The concentrations of anti-human PD-L1 and anti-human sHLA-G were pre-optimised in 
our Lab for other studies. To obtain the optimal concentration of IDO inhibitor 1-MT, varying 
concentrations of 1-MT, such as 500 μM/mL, 1000 μM/mL, 1500 μM/mL and 2000 μM/mL, 
were added into the autologous PTEC culture for 5 days. The supernatants were then harvested 
and based on the kynurenine:tryptophan ratio levels, the optimal concentration of 1-MT was 
finalised as 1500 μM/mL. Furthermore, the use of 1-MT at 1500 μM/mL was demonstrated to be 
non-toxic to the cells.         
2.3.6. B cells activation markers 
PTEC-B cells and Ctrl-B cells harvested after 48 h of co-culture were treated with FITC, 
PE and APC-conjugated monoclonal antibodies against CD38, CD138 and CD27. Conjugated 
mouse IgG1 served as an isotype control. The concentrations of these antibodies were pre-
optimised in our Lab and previously published [45]. For brief protocol refer to section 2.3.2. 
Expression of surface markers was reported as a percentage of cells expressing selected surface 
markers. 
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2.3.7. IgG/IgM ELISPOT 
After 48 h of co-culture, the B cells were harvested from the PTEC-B cell and Ctrl-B cell 
wells and their ability to produce antibody was monitored using a human IgG and IgM ELISPOT 
(Mabtech) assay, performed according to the manufacturer’s instructions. Briefly, the ELISPOT 
plate was coated with 10 μg/mL capture anti-IgM or 15 μg/mL capture anti-IgG and incubated 
overnight at 4°C. Following incubation, the plate was washed and blocked with 200 μL per well 
CM for 30 min at room temperature. The B cells were seeded into the plate as triplicates and at 
three different cell concentrations. The top concentration had 5000 cells per well and subsequent 
serial dilutions of 1:2 and 1:4 were performed. The plate was then incubated for 18-24 h in a 
37°C/5% CO2 incubator. To develop IgG or IgM spots, the plate was treated with 100 μL per 
well of 1 μg/mL biotin labelled anti-IgM or anti-IgG and incubated at room temperature for 2 h. 
The biotin-labelled antibody wells were then treated with a 1:1000 dilution of Streptavidin-HRP 
and further incubated for 1 h. 100 μL per well of TMB substrate was added and developed until 
distinct spots emerged. The reaction was stopped by washing the plate extensively under tap 
water. The spots developed were visualised using autoimmune diagnostika (AID) Gmbh Elispot 
reader classic and analysed using AID Elispot software version 4.0. 
2.3.8.  B cell cytokine expression 
Cell free supernatants of PTEC-B cell and Ctrl-B cells from individual experiments were 
harvested on day 2 and stored at -80°C until analysis. IL-1β, IL-6, IL-8, IL-10, IL-12p70 and 
TNF were analysed using a multiplex cytometric bead array (CBA) (BD Biosciences) according 
to manufacturer’s instructions. The CBA technology provided a method of capturing soluble 
cytokines with beads of known size and fluorescence, making it possible to detect cytokines 
using flow cytometry. Briefly, 50 µL of capture bead mixture (10 µL of each capture bead X 
number of wells (96 v-bottom plate)) was added to all wells containing 50 µL of diluted 
standards (refer Table 2.1) or unknown samples. To this, 50 µL of human cytokine PE detection 
reagent was added, with the plate then incubated for 3 h at room temperature protected from 
light. The wells were then topped up with 150 µL wash buffer and centrifuged at 200xg for 5 
min. The supernatant was discarded and the pellet was resuspended in 100 µL wash buffer. 
Samples and standards were acquired using a FACS array (BD Biosciences). Data analysis was 
done using FCAP array v3 software. 
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Table 2.1: Standard concentrations of cytokine multiplex set CBA assay 
Concentration (pg/mL) in each dilution 
Top 
Standard 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 
5000 2500 1250 625 312.5 156 80 40 20 
 
2.3.9. IgG/IgM Quantitation assay (CBA) 
The total amount of IgG and IgM secreted by B cells was analysed from cell-free 
supernatant using the total human IgG flex set (BD Biosciences) and human IgM flex set (BD 
Biosciences) respectively. The IgG and IgM could not be multiplexed and therefore had to be 
used separately. The capture bead diluents, detection reagent diluents and sample or standard 
diluents were available as a separate buffer kit - human immunoglobulin master buffer kit (BD 
Biosciences). The CBA assay was performed according to the manufacturer’s instructions. 
Briefly, 50 µL of capture beads (diluted 1:50 with capture bead diluent) were mixed with 50 µL 
of standard (refer Table 2.2) or test samples (diluted 1:2 with sample diluent) and incubated for 1 
h at room temperature. This was followed by adding 50 µL PE detection reagent (diluted 1:50 
with detection reagent diluent) and further incubation for 2 h at room temperature. Samples were 
washed with 150 µL wash buffer, the pellet was again resuspended in 100 µL wash buffer and 
samples were acquired using a FACS array (BD Biosciences). Data analysis was done on FCAP 
array v3 software. 
 
Table 2.2: Standard concentrations of IgG/IgM flex set CBA assay 
 Concentration (ng/mL) in each dilution 
Assay 
Top 
Standard 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 
IgG 430.0 215.0 107.5 53.8 26.9 13.4 6.7 3.4 1.7 
IgM 910.0 455.0 227.5 113.8 56.9 28.4 14.2 7.1 3.6 
  
2.3.10. B cell proliferation 
The B cells harvested after 48 h of co-culture were seeded in 96 well-U bottom plates at a 
concentration of 1x10
5
 per well and incubated for a further 16 hours in a 37°C/5% CO2 incubator 
35 
 
with 1 µCi 
3
H-thymidine per well being added for the final 8 hours of incubation. The 
3
H-
thymidine labelled cells were then harvested onto a glass fibre filter mat (filter mat) 90 x120mm 
(Perkin Elmer) and analysed using a MicroBeta
2
 plate reader (Perkin Elmer). Results were 
expressed as average counts per minute (CPM) of triplicate test wells. 
2.4. Autologous PTEC-T cell immuno-modulation methods 
2.4.1. CD4+ T cell culture media 
All CD4
+
 T cells cultures were performed in Complete Medium (CM-AB) consisting of 
RPMI 1640, supplemented with 10% heat-inactivated human AB serum, 100U/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, 0.1mM non-essential amino 
acids, 10mM HEPES buffer solution (all from Life Technologies), and 50 M 2-
mercaptoethanol. 
2.4.2. Isolation of CD4+ T cells and purity staining 
CD4
+
 T cells were isolated from the CD14 flow–through (refer 2.5.3) using positive 
selection with CD4 micro-beads (Miltenyi) based on the manufacturer’s instructions. Briefly, 107 
CD14
-
 flow-through cells were treated with 20 μL CD4 micro-beads and incubated for 15 min at 
4°C. Excess micro-beads were removed by diluting 1:50 with MACS buffer and centrifuged at 
400xg for 5 min. The supernatant was discarded and the pellet was passed through an LS column 
fitted to a magnet. The CD4 positive cells bind to the column, while all the CD4 negative cells 
flow through the column. The column was separated from the magnet and CD4
+
 T cells were 
eluted out of the column. 
The purity of CD4
+ 
T cells eluted from the column was analysed by staining them with 
FITC, PE, APC, and PO conjugated monoclonal antibodies against CD4, CD14, CD20 and CD3. 
Conjugated mouse IgG1 and IgG2a served as isotype controls. The concentrations of these 
antibodies were pre-optimised in our Lab and previously published [45]. For a brief protocol, 
refer to section 2.3.2. The purity of CD4
+
 T cells was reported as the percentage of cells positive 
for CD4, CD3 and negative for CD20 and CD14. 
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2.4.3. Activation of PTEC for PTEC-T cells co-culture 
Prior to co-culture, the autologous PTEC were made up to a concentration of 1-1.5x10
5
 
cells per mL and aliquots of 200 µL per well were added into the wells of a polystyrene 96 flat-
well plate (Corning) and bottom chambers of polystyrene transwell 96 well culture plate 
(Corning). Following 8 h of seeding, the PTEC were activated with 100 ng/mL IFN-γ (R&D 
systems) and re-incubated for a further 16-18 h. The concentration of IFN-γ was pre-optimised in 
our Lab as previously published [45]. After a 24-26 h culture period, PTEC proliferation was 
stopped by exposing them to γ-irradiation at 3000 cGy.  
2.4.4. PTEC-T cell co-culture 
Two different methods were followed to set-up autologous PTEC and T cell co-culture – 
contact dependent and contact independent. For PTEC-T cell contact dependent co-culture, 
CD4
+
 T cells were made up to a final concentrations of 1x10
6
 cells/mL and aliquots of 200 µL 
per well were added to the wells of polystyrene 96 flat-well plates previously seeded with 
activated and irradiated PTEC. 200 µL was also added to the empty wells as a control (Ctrl-T 
cells). 
To set-up contact independent co-cultures, CD4
+
 T cells were made up to a final 
concentration of 2x10
6
 cells/mL and aliquots of 100 µL per well were added on top of the 
polycarbonate membrane of a transwell 96 well culture plate. The media covering the PTEC in 
the bottom chamber was replaced with 100 µL of CM-AB. For controls, 100 µL of CD4
+
 T cell 
solution was added onto the membrane of empty wells, while the bottom chamber had only 100 
µL of CM-AB. 
2.4.5. PTEC-T cell blocking studies 
To identify the mechanism behind the immuno-regulatory effects of autologous PTEC, 
surface molecule PD-L1, intracellular IDO and soluble HLA-g were neutralised within the 
PTEC-T cell co-culture. For brief protocol refer to section 2.3.5. 
2.4.6. Activation of CD4+ T cells 
The CD4
+
 T cells were activated using 40µg/mL Phytohemagglutinin (PHA) (Sigma-
Aldrich) or antibodies against the TCR CD3 (0.5µg/mL) (Sanquin) and the co-stimulatory 
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molecule CD28 (0.1µg/mL) (Sanquin). Following 72 h of culture, the effect of autologous PTEC 
on T cells were studied by analysing T cell surface antigens, T cell proliferation, T cell cytokines 
and HPLC quantitation of soluble tryptophan and kynurenine.   
2.4.7. CD4+ T cell activation markers 
PTEC-T cells or Ctrl-T cells harvested after 72 h of co-culture were treated with FITC, PE 
and APC conjugated monoclonal antibodies against CD4, CD69 and CD25. Conjugated mouse 
IgG1 served as an isotype control. For a brief protocol, refer to section 2.3.6. Expression of 
surface markers was reported as the percentage of cells expressing selected surface markers. 
2.4.8. CD4+ T cell proliferation 
Following a 64 h culture period, the Ctrl-T cells and PTEC-T cells were pulsed with 1 µCi 
3
H-thymidine per well and further incubated for another 8 hours. The 
3
H-thymidine labelled cells 
were then harvested onto a glass fibre filter mat (filter mat) 90 x120mm  and analysed using a 
MicroBeta
2
 plate reader. Results were expressed as average CPM of triplicate test wells. 
2.4.9. Th1/Th2 cytokine analysis kit (CBA) 
Cell free supernatants of PTEC-T cells and Ctrl-T cells from individual experiments were 
harvested following the 72 h culture period and stored at -80°C until analysed. IL-2, IL-4, IL-6, 
IL-10 and TNF were analysed using a multiplex human Th1/Th2 cytokine kit II (CBA) (BD 
Biosciences) according to manufacturer’s instructions. For a brief protocol, refer to section 2.3.8.  
2.4.10. IFN-γ ELISA kit 
Th1 cytokine IFN-γ from PTEC-T cell and Ctrl-T cell supernatant was analysed using a 
Human IFN-γ ELISA (Biolegend). Briefly, 16-18 h prior to running the ELISA, human IFN-γ-
specific monoclonal antibody was coated on a 96 flat well plate (Thermo scientific) and 
incubated at 4°C. Following incubation, the plate was washed and unknown samples or standards 
were added and incubated for 2 h at room temperature. Bound IFN-γ was detected by adding 
biotin-conjugated detection antibody. This antibody-antigen-antibody sandwich was revealed 
using avidin-horse radish peroxidise (Avidin-HRP) and TMB substrate reaction for 15 min. The 
reaction was then stopped by adding 2N H2SO4 stop solution and absorbance read at 450nm 
using a Synergy H4 hybrid reader (BioTek). 
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2.4.11. Quantitation of tryptophan and kynurenine  
To assess the activity of IDO, PTEC-T cell and Ctrl-T cell supernatant was tested for the 
levels of IDO enzyme substrate tryptophan and end product kynurenine using HLPC (kindly 
performed at Chemical Pathology - Queensland Health, under the supervision of Dr. Brett 
McWhinney). Results were reported as the ratio of kynurenine to tryptophan concentration 
(μmol/L) measured by HPLC. 
2.5. Autologous PTEC-dendritic cell immuno-modulation methods 
2.5.1. DC cell culture media 
All DC cultures were performed in Complete Medium (CM-AB) consisting of RPMI 
1640, supplemented with 10% heat-inactivated human AB serum, 100U/ml penicillin, 100μg/ml 
streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, 0.1mM non-essential amino acids, 
10mM HEPES buffer solution (Life Technologies), and 50 M 2-mercaptoethanol. 
2.5.2. Isolation of Blood DC  
Isolation of CD1c
+ 
BDC was performed by two magnetic separation steps using the CD1c 
(BDCA-1) dendritic cell isolation kit II (Miltenyi Biotech). In the first step CD1c expressing B 
cells were removed by labelling with CD19 micro-beads and subsequent depletion using an LS 
column. In the second step, the BDC were positively selected by indirect magnetic labelling with 
CD1c biotin and anti-biotin micro beads. Briefly, according to manufacturer’s instructions, 108 
PBMC were simultaneously treated with 100 µL Fc receptor blocking reagent, 100 µL CD19 
micro-beads and 100 µL CD1c biotin and incubated for 15 min at 4°C with mixing every 5 min. 
Following incubation, the cells were washed and passed through the LS column placed in the 
magnetic field. The CD19
+
 B cells stick to the column and all the CD19 negative cells flow out 
of the column. These flow-through cells were treated with 100 µL anti-biotin micro beads, 
incubated for 15 min at 4°C with mixing every 5 min and passed through a second LS column. 
CD1c
+
 BDC bind to the column while all the other cells pass out of the column. The column was 
separated from the magnetic field and the BDC were eluted out of the column and used in 
downstream autologous experiments. CD19
+
 B cells were also eluted from the column and 
preserved in liquid nitrogen until further use. 
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2.5.3. Isolation of CD14+ monocytes  
Monocytes were isolated from the CD19 flow through (refer 2.3.2) based on the cell 
surface expression of CD14 antigen. CD19
-
 flow through cells were treated with CD14 micro-
beads (Miltenyi Biotech) and CD14
+ monocytes were isolated based on manufacturer’s 
instructions. Briefly, 10
7
 CD19
-
 flow through cells were treated with 20 μL CD14 micro-beads 
and incubated for 15 min at 4°C with mixing every 5 min. Excess micro-beads were removed by 
diluting PBMC 1:50 with MACS buffer and centrifugation at 400xg for 5 min. The supernatant 
was discarded and the pellet was passed through an LS column fitted to a magnet. The CD14
+
 
monocytes bind to the column, while all the CD14 negative cells flow through the column. The 
column was separated from the magnet and monocytes were eluted out of the column. The flow 
through cells were used for CD4
+
 T cell isolations (refer 2.4.2).  
2.5.4. Purity of BDC and monocytes 
The purity of BDC or monocytes eluted from columns was analysed by staining them with 
FITC, PE, APC, PO and peridinin chlorophyll protein complex (PerCP) conjugated monoclonal 
antibodies against CD3, CD14, CD20, CD4 and HLA-DR. Conjugated mouse IgG1 and IgG2a 
served as isotype controls. For brief protocol, refer to section 2.3.2. The purity of BDC was 
reported as the percentage of cells positive for HLA-DR and negative for CD14, CD20, CD4 and 
CD3. Similarly, the purity of monocytes was reported as the percentage of cells positive for 
CD14, HLA-DR and negative for CD20, CD4 and CD3. 
2.5.5. Activation of PTEC for PTEC-DC co-culture 
Prior to PTEC-BDC co-culture, the autologous PTEC were seeded at a concentration of 1-
1.5x10
5
 cells per mL and aliquots of 200 µL per well were added into the wells of a 96-flat well 
culture plate. Similarly, prior to PTEC-monocyte co-culture, aliquots of 1000 µL per well were 
added into the wells of a polystyrene 24 well plate  and bottom chamber of a 0.4µM pore size 
polystyrene transwell-24 well plate  to establish contact dependent and independent co-culture 
systems respectively. 
Following 8 h of seeding, the PTEC were activated with 100 ng/mL IFN-γ and re-
incubated for a further 16-18 h. After a 24-26 h culture period, PTEC proliferation was stopped 
by exposing them to γ-irradiation at 3000 cGy. 
40 
 
2.5.6. PTEC-BDC co-culture 
Purified BDC (refer 2.5.2) were adjusted to a final concentration of 2x10
6
 cells per ml and 
200 µL per well aliquots were added into the wells of activated PTEC (PTEC-BDC) (refer 2.5.5) 
or empty wells as controls (Ctrl-BDC) and cultured for 24 hours alone or with 50 µg/mL 
polyinosinic:polycytidylic acid (poly (I:C)) (Sigma-Aldrich), a synthetic double stranded RNA 
analogue. 
2.5.7. PTEC and monocyte co-cultures 
Two different methods were followed to set-up autologous PTEC and monocyte co-
cultures – contact dependent and contact independent.  For contact dependent co-cultures, the 
monocytes (purity >95%) (refer 2.5.3) were made up to a final concentration of 1x10
6
 cells per 
mL in CM-AB supplemented with 1000 U/mL IL-4 and 800 U/mL GM-CSF and 1 mL was 
added into the wells of a polystyrene 24 well plate  previously seeded with activated and 
irradiated PTEC. 1 mL was also added into the empty wells of the plate as a control. 
To set-up contact independent co-cultures, monocytes (refer 2.5.3) were made up to a final 
concentration of 5x10
6
 per mL in CM-AB supplemented with 1000 U/mL IL-4 and 800 U/mL 
GM-CSF and 200 μL aliquots were added on top of a 0.4µM pore size polystyrene membrane of 
a transwell-24 well plate. The DM media covering the PTEC in the bottom chamber was 
replaced with 800 µL CM-AB supplemented with 1000 U/mL IL-4 and 800 U/mL GM-CSF. For 
controls, the top chamber had 200 μL aliquots of monocytes and the bottom chamber had only 
800 µL of CM-AB supplemented with 1000 U/mL IL-4 and 800 U/mL GM-CSF. 
Both the culture systems were incubated for 5 days to differentiate monocytes into MoDC. 
The MoDC harvested from the co-culture wells and control wells were labelled as PTEC-MoDC 
and Ctrl-MoDC respectively.  
For maturation, PTEC-MoDC and Ctrl-MoDC were further cultured for 24 h in the 
presence of 50 μg/mL poly(I:C). 
The PTEC-MoDC and Ctrl-MoDC harvested after differentiation and maturation were 
used to study the antigen up-take function (refer 2.5.9), expression of surface antigens (refer 
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2.5.10), secretion of inflammatory cytokines (refer 2.5.13) and capability to stimulate allogeneic 
CD4
+
 T cells in a mixed leukocyte reaction (Allo-MLR) (refer 2.5.12). 
2.5.8. PTEC-MoDC Blocking studies 
To identify the mechanisms behind the immuno-regulatory effects of autologous PTEC on 
the differentiation of monocytes into MoDC, surface molecule PD-L1, intracellular molecule 
IDO, soluble immuno-regulatory cytokine IL-10 and HLA-g were neutralised within the PTEC-
monocyte co-culture. 
For IL-10 blocking, 5 μg/mL anti-human IL-10 blocking antibody (R&D systems) was 
added into the PTEC or control wells following the set-up of PTEC-monocyte co-culture. Refer 
to section 2.3.5 for a brief protocol of PD-L1, sHLA-g and IDO blocking. 
2.5.9. Antigen up-take (Latex beads and dextran) 
The phagocytic and endocytic abilities of BDC or MoDC were tested by using FITC-Latex 
beads (Sigma-Aldrich) and FITC-Dextran (Sigma-Aldrich) respectively. Briefly, 2.5x10
4
 Ctrl-
BDC or PTEC-BDC and day 5 harvested Ctrl-MoDC or PTEC-MoDC were resuspended in 100 
μL CM-AB in ultra low attachment 96-well U bottom culture plates (Costar). The cells were then 
treated with FITC-Latex beads at a concentration of 1:1500 cell:bead ratio and FITC-Dextran at 
1 mg/mL. FITC-Latex beads were incubated with the cells for 90 min and FITC-Dextran for 60 
min in a 37°C/5% CO2 incubator. As a control, the up-take experiment was performed at 4°C, or 
prior to antigen up-take, DC were incubated for 45 min with 50 μg/mL (or 100 μM) Cytochalasin 
D (Sigma-Aldrich) inhibitor. The results for up-take of FITC-Latex beads were reported as the 
percentage of FITC positive cells, while FITC-Dextran up-take was reported as mean 
fluorescence intensity (MFI) of FITC positive cells.  
2.5.10. Staining for DC surface antigens 
BDC or MoDC harvested following differentiation and maturation were treated with FITC, 
PE, APC, PerCP, PO, allophycocyanin-cyanin7 (APC-Cy7), phycoerythrin-cyanin7 (PE-Cy7), 
and violet 450 (V450)-conjugated monoclonal antibodies against CD14, CD274 (PD-L1), 
CD11c, CD40, CD83, CD86, CD80, CD209 (DC-SIGN) and HLA-DR (Life Technologies). 
Conjugated mouse IgG1 or IgG2b were used as isotype controls. For a brief protocol, refer to 
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section 2.3.2. Cell acquisition was performed on a FACS Canto II using BD FACS-Diva 
software. Expression of surface markers was reported as the delta mean fluorescence intensity 
(ΔMFI). 
2.5.11. Intra-cellular staining of MoDC for IL-10 
For intra-cellular staining of IL-10, PTEC-MoDC or Ctrl-MoDC were pre-incubated with 
1μL/mL Golgi-Stop (BD Biosciences) for 12 h and then fixed and permeabilized with 250μL of 
fixation/permeabilization solution (BD Biosciences) for 20 min on ice. The cells were then 
washed with fixation/permeabilization buffer (BD Biosciences) and stained with 0.5μg IL-10 
APC or IgG isotype control (both from BD Biosciences). Stained cells were washed with 
fixation/permeabilization buffer and resuspended in MACS buffer. Cell acquisition was 
performed on a FACS Canto II using BD FACS-Diva software. Expression of intra-cellular IL-
10 was reported as the % cells positive for IL-10 APC. 
2.5.12. Allogeneic mixed leukocyte reaction 
An allogeneic mixed leukocyte reaction (Allo-MLR) was used to determine the functional 
ability of poly (I:C) matured BDC or MoDC to stimulate allogeneic CD4
+
 T cell responses. For 
this assay, allogeneic CD4
+
 T cells were isolated by depleting non-CD4
+
 T cells from whole 
PBMC (negative selection) using a CD4
+
 T cell isolation kit II (Miltenyi biotech) according to 
manufacturer’s instructions. To set-up the assay, poly I:C matured BDC or MoDC were seeded 
in a round bottom 96 well plate as triplicates at a concentration of 2.5x10
4
 cells per well followed 
by a serial dilution of 1:2. The responding allogeneic CD4
+
 T cells were seeded at a 
concentration of 1x10
6
 cells per well. The cells were cultured for 5 days and levels of 
proliferation were assessed by pulsing allogeneic CD4
+
 T cells with 1 µCi 
3
[H]-Thymidine  for 
the last 8 h of culture. The rate of cell proliferation was detected as counts per minute (CPM).  
2.5.13. DC cytokine analysis inflammation kit (CBA) 
Cell free supernatants of BDC or MoDC from individual experiments were harvested 
following differentiation and maturation and stored at -80°C until analysed. IL-1β, IL-6, IL-8, 
IL-10, IL-12p70 and TNF were analysed using a multiplex cytometric bead array (CBA) (BD 
Biosciences) according to manufacturer’s instructions. For a brief protocol, refer to section 2.3.8. 
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2.5.14. Soluble HLA-g ELISA 
Quantitative measurement of sHLA-G in the PTEC-MoDC and Ctrl-MoDC samples were 
performed using a sHLA-G ELISA (Bio Vendor). Briefly, standards and test samples were added 
into the ELISA plate pre-coated (by the manufacturer) with capture antibody and incubated for 
16-20 h at 4°C. Following incubation, the plate was washed and a conjugate solution was added 
to form an antibody-antigen-antibody sandwich. This reaction was revealed by adding a 
substrate solution and incubating for 25-30 min. The reaction was stopped and the absorbance 
read within 5 min at 450nm using a Synergy H4 hybrid reader. 
2.5.15. Quantitative reverse transcription-polymerase chain reaction 
The level of mRNA expression of TLR3 on Ctrl and PTEC-MoDC and T cell transcription 
factors such as T-bet, FoxP3, RORC and GATA3 from allogeneic CD4
+
 T cell when cultured in 
the presence of Ctrl- and PTEC-BDC or Ctrl- and PTEC-MoDC were analysed using 
quantitative reverse transcription-polymerase chain reaction (RT-PCR). The protocol of this 
assay involves the following steps: 
 Total RNA extraction  
 Reverse Transcription 
 Real time PCR 
2.5.15.1. Total RNA extraction 
Total RNA was isolated from cells using an Absolute RNA Microprep Kit (Stratagene) 
according to manufacturer’s instructions. Briefly, 1-5x105 cells were lysed using 100µL lysis 
buffer supplemented with 0.7 µL of β-mercaptoethanol and vortexed for 30 s. The cell lysate was 
diluted with 1 volume of 70% ethanol, passed through an RNeasy elute column and centrifuged 
for 1 min at ≥8000 x g. The cell lysate attached to the column was washed with 600µL of low 
salt wash buffer, and spun again for 1 min at ≥8000 x g.  For genomic DNA digestion, DNase 
solution was added and the column was incubated for 15 min at 37°C. The column was washed 
once with 500µL high salt wash buffer and twice with 600µL low salt wash buffer. Finally, the 
column was dried and total RNA was eluted using 15µL elution buffer. 
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2.5.15.2. Reverse Transcription 
Synthesis of complementary DNA (cDNA) was performed using the Superscript III reverse 
transcriptase (RT) kit (Life Technologies). Briefly, aliquots of 0.1-1μg total RNA (11μl) were 
incubated with 1μl oligo-(dT)15 primer (500ng; Roche) and 1μl dNTP mixture (10mM; Life 
Technologies) at 65ºC for 5 min and then chilled on ice for 1 min. Following this, 4μl 5x first-
strand buffer, 1μl 0.1M DTT, 1μl RNaseOUT (40U) and 1μl Superscript III RT (200U) were 
added to the mixture. The 20μl reaction was then incubated for 30-60 min at 50ºC. Enzymes 
were subsequently heat-inactivated at 70ºC for 15min and samples were then treated with 1.33μl 
RNase H (2U; Promega) for 30min at 37ºC. The cDNA samples at this stage were stored for a 
short duration at -20°C. 
2.5.15.3. Quantitative Real-time Polymerase chain reaction 
The RT-PCR for TLR3, T-bet, FoxP3, RORC, GATA3 and house-keeping gene Ubiquitin 
C (UBC) was performed with SuperArray RT
2
 qPCR primers (QIAGEN) (refer Table 2.3) and  
 
RT
2
 SYBR Green master-mix (QIAGEN). UBC was used for the normalisation of 
complementary DNA input, and real time PCR reactions were performed using a Rotor-Gene Q 
thermal cycler (QIAGEN). The real-time PCR was performed according to the conditions 
mentioned in Table 2.4. Data analysis was performed using Rotorgene software (QIAGEN) and 
the delta delta Ct (ΔΔ Ct) method.   
 
 
Table 2.3: Superarray RT2 qPCR Primers 
Gene Name Description Catalogue No. 
Product Size 
(bp) 
UBC Ubiquitin C PPH00223E 88 
TLR3 Toll-like receptor 3 PPH01803E 97 
TBX21 T-box 21 (T-bet) PPH00396A 136 
GATA-3 GATA binding protein 3 PPH02143A 167 
FOXP3 Forkhead box P3 PPH00029B 132 
RORC Retinoic acid-related orphan receptor γt PPH05877A 128 
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Table 2.4: RT-PCR cycling conditions 
Cycles Duration Temperature Comments 
1 10 min 95°C Initial denaturation 
45 
15 s 
1 min 
95°C 
60°C 
 
Perform fluorescence data collection 
 
2.6. Statistical analysis 
Statistical comparisons between groups were performed using a paired, non-parametric, 
Wilcoxon matched-pairs signed rank t-test. P values ≤ 0.05 are considered statistically 
significant. A P-value <0.05 is denoted by *, <0.005 is denoted by ** and <0.001 by ***. Data 
where applicable are expressed as the mean ± standard deviation (SD) from triplicate test 
samples of a human donor or the mean ± standard error mean (SEM) from means of test samples 
from multiple human donors. Statistical tests were performed using GraphPad Prism 6.0 analysis 
software.  
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Chapter 3: The effect of autologous PTEC on 
CD1c
+
 DC 
3.1. Introduction 
DC are professional AgPC that play a role in inducing and regulating immune responses. As 
discussed in the literature review, DC are a heterogonous population divided into MoDC and 
BDC [224]. BDC are further divided into CD11c
-
 pDC and CD11c
+
 mDC. pDC are identified by 
surface markers such as CD303 (BDCA-2) and CD304 ( BDCA-4) [225]. mDC are further 
delineated into three phenotypically distinct subtypes CD16
+
 DC, CD1c
+
 (BDCA-1
+
) DC and 
CD141
+
 (BDCA-3
+
) DC [226]. Although all human DC are capable of antigen up-take and 
initiating immune responses, DC subset specific specialised functions have also been reported 
[227, 228]. The functions of MoDC with respect to kidney inflammation will be discussed in 
chapter 4. The pDC subset in humans makes up about 0.8% of peripheral PBMC. Functionally, 
in various disease conditions, pDC have shown to play an inhibitory role by secreting IFN-α 
IFN-β, which then play a major role against viral infections or by inducing IL-10 producing Treg 
cells [229, 230]. A few studies have also shown that pDC can cross-present antigens to CD4
+
 and 
CD8
+
 T cells [231, 232]. Further investigation is necessary to fully identify their physiological 
role. CD141
+
 mDC constitute about 3% of the mDC population [226] and are generally 
considered as the major cross-presenting DC population in humans [233, 234]. CD16
+
 DC 
comprise the largest subset of DC among the mDC population in humans, constituting 
approximately 50% of the lineage
- 
and HLA-DR
+
 cells [226] and playing an important role in 
anti-bacterial immune responses [235]. Characterisation of these cells based on gene expression 
has shown that CD16
+
 cells cluster with mouse neutrophils and monocytes but not with mDC 
[236]. Transcriptional profiling and hierarchical clustering of the non-activated DC populations 
indicated that CD16
+
 DC arise from separate precursor, whereas CD1c
+
 and CD141
+
 DC subsets 
may have a common origin and rather represent two different stages of a similar population 
[235]. Based on these results the true lineage of CD16
+
 DC remains controversial, and therefore, 
this DC subset was excluded from our studies. CD1c
+
 DC comprises about 20% of the mDC 
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population in peripheral blood [226]. In kidney, CD1c
+
 DC  are the major BDC population 
reported in both the healthy [237] and diseased [216] tubulointerstitium. As discussed in section 
1.6.1, the existence of DC in the tubulointerstitium places them in close proximity to receive 
signals from perturbed PTEC [237] and contribute to the progression of the disease. Because of 
its relative abundance in peripheral blood and reports indicating they play a role in kidney 
disease pathology, we chose to identify the regulatory effect of autologous PTEC on CD1c
+ 
DC 
in an inflammatory situation. Our lab has previously published that PTEC down regulate 
autologous T and B cell proliferation. However, it remains unclear if the immune regulation 
occurs through direct interactions with B- and T- cells or through professional AgPC. Therefore, 
in this study we investigated if autologous PTEC skewed CD1c
+
 DC towards an immature state 
which would then down-regulate T cell responses.     
3.2. Hypothesis 
The primary objective of this chapter was to study the influence of IFN-γ activated 
autologous PTEC on activation, maturation and function of preformed CD1c
+
 BDC.  We 
hypothesised that autologous PTEC negatively regulate CD1c
+
 BDC maturation and function. 
3.3. Aims 
The specific aims of this chapter are: 
 To study the effect of IFN-γ activated autologous PTEC on CD1c+ BDC activation 
and maturation. 
 To study the effect of IFN-γ activated autologous PTEC on CD1c+ BDC function. 
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3.4. Experimental design 
 
The CD1c+ DC (grey box) were cultured in the absence (Ctrl-BDC) or presence (PTEC-BDC) of IFN-γ activated autologous PTEC for 24 h 
(orange box). Simultaneously, the Ctrl- and PTEC-BDC were activated with poly(I:C) (purple box). Following 24 h of co-culture and poly(I:C) 
activation, readouts such as phenotype analysis, Ag up-take, cytokine profiling and allogeneic MLR assays were performed.   
Figure 3.1. Experimental design to study the effect of IFN-γ activated autologous PTEC on CD1c+ DC. 
  
3.5. Results 
3.5.1. CD1c+ BDC purification 
Autologous CD1c
+
 BDC were purified from PBMC obtained from whole blood of PTEC 
donors (section 2.5.2). CD1c
+
 BDC were isolated by first depleting CD19
+
 B cells and enriching 
CD1c
+
 BDC using a commercially available immuno-magnetic selection kit. The purity of the 
isolated CD1c
+
 BDC was determined by the surface expression of lineage
-
, HLA-DR
+
, CD11c
+
 
and CD1c
+
 (Figure 3.2) antigens which were determined using flow cytometry. The mean purity 
of CD1c
+
 BDC from 12 donors was 81.6% ± 10.8% SD. 
 
3.5.2. CD1c+ BDC matured in the presence of autologous PTEC express high 
levels of PD-L1, CD86 and varying levels of HLA-DR and CD83  
To investigate the effect of autologous PTEC on the expression of immuno-regulatory 
molecules on CD1c
+
 BDC, the CD1c
+
 BDC were co-cultured with IFN-γ activated PTEC 
(PTEC-BDC) or without PTEC (Ctrl-BDC) for 24 h. In various studies, TLR3, a sensor for cell 
necrosis during inflammation [238], is shown to be upregulated on CD1c
+
 BDC and respond to 
poly(I:C) stimulation [234, 239, 240]. Therefore, PTEC-BDC and Ctrl-BDC cultures were also 
maintained for 24h with poly(I:C) stimulation. The expression of antigen presenting molecule 
A representative scatter plot of purified CD1c+ BDC gated on live single cells. The first plot 
represents purified CD1c+ BDC defined as HLA-DR+ lineage- cells, the second plot represents 
them as HLA-DR+ CD11c+ cells and the last plot represents them as CD11c+ CD1c+. The dot plots 
are representative of a single experiment. 
 
Figure 3.2. Purification of the CD1c+ BDC subset. 
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HLA-DR, co-stimulatory molecules CD86, activation molecule CD83 and down-regulatory 
molecule PD-L1 was determined using fluorochrome conjugated monoclonal antibodies as 
outlined in section 2.5.10. Both Ctrl-BDC and PTEC-BDC up-regulated the expression of HLA-
DR, CD86, CD83 and PD-L1 following 24h incubation. However, the levels of CD86 (Figure 
3.3A), CD83 (Figure 3.3C) and PD-L1 (Figure 3.3D) were generally higher in the PTEC-BDC 
cultures compared to Ctrl-BDC cultures.  
In response to poly(I:C) maturation, PTEC-BDC significantly up-regulated CD86 (Figure 
Surface expression of (A) CD86, (B) HLA-DR, (C) CD83 and (D) PD-L1 by CD1c+ BDC. Bar graph: 
Antigen expression by CD1c+ BDC freshly isolated (0h) or after 24 hour co-culture without (-) or 
with (+) autologous, IFNγ-activated PTEC in the absence (24h) or presence (24h PIC) of 50μg/ml 
maturation stimuli poly I:C. The bar graphs represent the mean values for four to nine individual 
donors. Line graph: Antigen expression by CD1c+BDC matured with poly I:C in the absence (Ctrl-
BDC) or presence of autologous PTEC (PTEC-BDC) in four to nine individual donors. Surface 
expression was measured by flow cytometry (gated on live, single, lineage- HLA-DR+ cells) and 
expressed as the delta mean fluorescent intensity (MFI). Statistical comparisons between two 
groups were performed using a two-tailed Wilcoxon signed rank test. 
Figure 3.3. Surface antigen expression of CD1c+ BDC. 
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3.3A), PD-L1 (Figure 3.3D) and down regulated CD83 (Figure 3.3C) in all donors compared to 
Ctrl-BDC. Levels of HLA-DR (Figure 3.3B, 24h PIC) was generally reduced in most donors in 
the presence of PTEC compared to Ctrl-BDC. Collectively, these data suggest that in the 
presence of autologous PTEC, the BDC are skewed towards a less mature, tolerogenic 
phenotype. 
3.5.3. CD1c+ BDC have elevated levels of endocytic and phagocytic capacity in 
the presence of autologous PTEC 
Immature DC have a greater capacity to take up foreign antigen via receptor mediated 
endocytosis and phagocytosis than mature DC. This is because as they mature, DC gradually lose 
the capacity to up-take antigen and increase their capacity to present antigen to T cells. Thus, 
monitoring the antigen-uptake capacity of our cultured CD1c BDC would provide information 
on their maturation status. 
Antigen up-take via receptor mediated endocytosis and phagocytosis of immature CD1c
+
 
BDC was tested in vitro by utilising soluble dextran and non-soluble latex beads respectively. To 
investigate the effect of autologous PTEC on the antigen up-take capability of these cells, Ctrl-
BDC or PTEC-BDC harvested from 24 h and 24h PIC cultures were treated with FITC dextran at 
Figure 3.4. Antigen up-take of Ctrl-BDC and PTEC-BDC. 
(A) Phagocytosis of FITC-latex beads and (B) receptor mediated endocytosis of FITC-dextran by 
BDC co-cultured without (-) or with (+) autologous, IFN-γ activated PTEC in the absence (24h) or 
presence (24h PIC) of 50µg/mL poly I:C.  Up-take was measured by flow cytometry (gated on 
live, single CD11c+ HLA-DR+ cells) and is presented as mean values for three donors (bar graph) 
and in three individual donors (line graph). Up-take of dextran is represented as FITC-mean 
fluorescent intensity (MFI) and phagocytosis as % cells positive for FITC. 
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1 mg/mL and FITC latex beads at the cell:beads ratio of 1:1500. For a negative control, the BDC 
along with their respective antigens (latex beads/dextran) were cultured at 4°C. Both 
unstimulated and poly(I:C) matured PTEC-BDC displayed greater levels of endocytosis and 
phagocytosis than their Ctrl-BDC counterparts (Figure 3.4).  
3.5.4. CD1c+ BDC matured in the presence of autologous PTEC produced low 
level of IL-10 
To gain an insight into the regulatory role of autologous PTEC on the cytokine secretion 
function of CD1c
+
 BDC, we examined the production of inflammatory cytokines from 
supernatants obtained from unstimulated and matured Ctrl-BDC or PTEC-BDC co-cultures as 
outlined in section 2.5.13. The effect of autologous PTEC on CD1c
+
 BDC-derived IL-6 or IL-8 
could not be measured because PTEC themselves produce high levels of these cytokines.  In 
addition, CD1c
+
 BDC-derived TNF-α was not measured because PTEC alone produced minimal 
levels which were further increased 2- to 10-fold when exposed to poly(I:C) (Figure 3.5A). IL-
12p70 and IL-1β did not reach detectable levels in any of the CD1c+ BDC culture supernatants. 
IL-10 was undetectable in all 24 hour cultures, but levels increased dramatically in PIC 
stimulated cultures, with DC cultured in the presence of autologous PTEC producing lower 
levels of IL-10 than Ctrl-BDC (Figure 3.5B). 
(A) Bar graph: TNF-α secretion by PTEC in the absence (24h) or presence (24h PIC) of poly(I:C) 
stimulation. The bar graph represents mean values for two donors. Line graph: TNF-α production 
by PTEC in the absence (24h) or presence (24h PIC) of poly(I:C) stimulation in 2 individual donors. 
(B) Bar graph: Secretion of IL-10 by CD1c+ BDC when cultured without (-) or with (+) IFN-γ activated 
autologous PTEC in the absence (24h) or presence (24h PIC) of poly(I:C) stimulation. The bar graph 
represents mean values for twelve donors. Line graph: IL-10 production by poly(I:C) matured Ctrl- 
or PTEC-BDC in twelve individual donors. Statistical comparisons between two groups were 
performed using a two-tailed Wilcoxon signed rank test. 
  
Figure 3.5. Cytokine secretion by Ctrl-BDC and PTEC-BDC. 
53 
 
3.5.5. CD1c+ BDC matured in the presence of autologous PTEC are less 
capable of stimulating allogeneic CD4
+
 T cell proliferation  
(A) Allogeneic CD4+ T cell proliferation induced by poly(I:C) matured Ctrl- and PTEC-BDC in a 
representative donor at increasing DC:T cell ratios and (B) in 7 individual donors at a 1:8 DC:T cell 
ratio. Proliferation was measured by 3[H]-thymidine incorporation and expressed as counts per 
minute (CPM) after 5 days. (C, D) Secretion of T effector cell cytokine IFN-γ and IL-2 respectively in 
the allogeneic MLR at a 1:8 DC:T cell ratio is presented as the mean values for five donors (bar 
graph) and five individual donor experiments (line graph). (E, F, G and H) mRNA expression of Th1 
transcription factor T-bet, Th2 transcription factor GATA, Th17 transcription factor RORC and Treg 
transcription factor FoxP3  respectively in the allogeneic MLR at a 1:8 DC:T cell ratio is presented as 
the mean values for three donors (bar graph) and three individual donor experiment (line graph). 
Statistical comparisons between two groups were performed using a two-tailed Wilcoxon signed 
rank test. 
 
Figure 3.6. CD1c+ BDC induced allogeneic CD4+ T cell proliferation. 
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To more fully evaluate the influence of autologous PTEC on the function of CD1c
+
 BDC, 
we compared the ability of poly(I:C) matured Ctrl- and PTEC-BDC to induce CD4
+
 T cell 
responses in an allogeneic MLR. Consistent with their lower expression of HLA-DR and CD83 
and elevated PD-L1 levels, PTEC-BDC were significantly less effective at stimulating allogeneic 
CD4
+
 T cell proliferation than Ctrl-BDC (Figure 3.6 A and B). In an effort to determine whether 
the Ctrl- or PTEC-BDC population were able to skew responding T cells towards different T 
helper subsets, cytokine levels and transcription factors were monitored at the end of the culture 
period. PTEC-BDC did not preferentially skew CD4
+
 T cells towards a Th1 subset as indicated 
by similar levels of Th1 cytokine IFN-γ and IL-2 (Figure 3.6 C, D) when compared with Ctrl-
BDC. There were no detectable levels of Th2 cytokines IL-4 or IL-10 from Ctrl- or PTEC-BDC 
cultures. The mRNA levels of Th1 transcription factor T-bet (Figure 3.6 E), Th2 transcription 
factor GATA (Figure 3.6 F), Th17 transcription factor RORC (Figure 3.6 G) and Treg 
transcription factor FoxP3 (Figure 3.6 H) were similar between Ctrl- and PTEC-BDC. These 
results suggest that autologous PTEC play a specialised role in skewing BDC towards a less 
mature state to inhibit CD4
+
 T cell proliferation. 
3.6. Discussion 
In this chapter, the immuno-regulatory effect of autologous PTEC on preformed CD1c
+
 
BDC was investigated. To achieve this, PTEC was pre-treated for 24 h with pro-inflammatory 
cytokine IFN-γ to mimic an inflammatory micro-environment and co-cultured with CD1c+ BDC 
for 24 h with and without activation with poly(I:C). The protocol of isolating autologous PTEC 
from kidney tissue is well established in our lab and has been previously published [45]. 
Poly(I:C) was used to activate BDC. This is a double-stranded RNA analogue that binds 
and activates through TLR3. Even though CD1c
+
 BDC express low levels of TLR3, our previous 
studies [241] have demonstrated good responses to this activation agent based upon activation 
molecule and cytokine up-regulation. The poly(I:C) was sourced from SIGMA-ALDRICH and 
was not tested for contamination of LPS endotoxin - therefore, there may have been some 
concomitant stimulation via TLR4.   
CD1c
+
 BDC were isolated using CD1c
+
 microbeads and magnetic column separation 
techniques. CD1c is a surface antigen used for classifying a subset of the heterogeneous mDC 
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population [242]. The purity of this population was determined by staining for surface antigens. 
CD1c
+
 BDC stain positive for MHC-II and negative for lineage specific markers (Figure 3.2). 
The inclusion of lineage markers allows the identification of contaminating B cells, T cells, 
monocytes and NK cells based on the expression of specific markers such as CD19, CD3, CD14 
and CD56 respectively [226]. In the present study the purity of CD1c
+
 BDC was performed by 
including CD11c and CD1b/c monoclonal antibodies along with lineage and MHC-II in our 
staining protocol. The results obtained from these different gating techniques were similar 
(Figure 3.2), suggesting that a homogenous population of CD1c
+
 BDC was successfully 
obtained. 
The effect of autologous PTEC on the phenotype of poly (I:C) activated BDC was 
investigated using fluorochrome conjugated monoclonal antibodies against antigen presenting 
molecule HLA-DR, co-stimulatory molecule CD86, activation marker CD83 and immuno-
regulatory molecule PD-L1. Although Ctrl- and PTEC-BDC expressed minimum levels of 
surface antigens following 24 h of culture, upon activation with poly(I:C), PTEC-BDC expressed 
low levels of  CD83 and MHC-II when compared with Ctrl-BDC (Figure 3.3 C and B). In 
addition, PTEC-BDC significantly up-regulated the expression of the PD-L1 compared to Ctrl-
BDC (Figure 3.3 D). This molecule is known to inhibit both CD4
+
 and CD8
+
 T cell responses 
([221] and section 1.9.3). Interestingly, the presence of PTEC led to a greater up-regulation of 
CD86 on BDC compared to Ctrl-BDC (Figure 3.3 A). This molecule binds to co-stimulatory 
receptor CD28 to enhance the TCR-mediated T cell activation, but also to regulatory receptor 
CTLA-4 to inhibit T cell proliferation [56]. These results suggest that PTEC-BDC are skewed 
towards a less mature phenotype when compared with Ctrl-BDC.  
The suggestion that PTEC maintain BDC in a less mature phenotype was supported by our 
observation of elevated levels of antigen up-take via endocytosis and phagocytosis (Figure 3.4 A 
and B), a function associated with immature DC in the steady state [243]. Studies have shown 
that the primary function of immature DC is antigen up-take via endocytosis or phagocytosis. 
However, processing and presentation of antigen to T cells requires maturation of DC [244, 245]. 
Thus, immature DC would be expected to have a greater antigen up-take capacity than mature 
DC. The results indicate that the PTEC-BDC following maturation retain elevated levels of 
56 
 
antigen up-take capacity when compared with Ctrl-BDC, indicating that functionally they retain 
immature BDC characteristics.    
We then examined the effect of autologous PTEC on the anti- or pro- inflammatory 
cytokine producing ability of BDC. Our results indicate that PTEC-BDC produced low levels of 
anti-inflammatory cytokine IL-10 (Figure 3.5 B). We believe that the low levels of IL-10 
secreted by PTEC-BDC may function synergistically with the immature phenotype of PTEC-
BDC to facilitate an immuno-regulatory DC function.   
 Perhaps the ultimate functional read-out of DC maturity is antigen presentation to T cells. 
This can be analysed by the presentation of common peptides, such a those derived from the 
influenza virus, to autologous T cells and monitoring the response by MHC-pentamer analysis. 
However, as these assays are very difficult to perform and are restricted to donors with specific 
HLA haplotypes, it was decided to use the surrogate assay of allogeneic stimulatory capacity 
instead. As can be seen from the results, BDC cultured in the presence of autologous PTEC were 
indeed inferior to Ctrl-BDC at stimulating an allogeneic response in foreign T cells, confirming 
their immature/regulatory phenotype. This was despite the fact that they produced lower levels of 
anti-inflammatory cytokine IL-10 which is known to inhibit allogeneic CD4
+ 
T cell responses. 
One may speculate that the greater levels of CD86 expressed by PTEC-BDC may bind with 
CTLA-4 (rather than co-stimulatory ligand CD28), resulting in negative-regulation of CD4
+
 T 
cell responses [56]. In addition, this down-regulation was not accompanied by either Th1, Th2, 
Th17 or Treg polarised responses, as indicated by similar levels of T cell subset transcription 
factors T-bet, FoxP3, GATA, RORC and cytokines IFN-γ and IL-2 between Ctrl- and PTEC-
BDC (Figure 3.6). 
 Collectively, all these results indicate that IFN-γ activated autologous PTEC regulate 
infiltrating preformed BDC towards an anti-inflammatory and less mature phenotype which 
subsequently may down-regulate T cell responses and minimise tissue damage and onset of 
CKD. At this point in order, to fully dissect this novel observation, it was decided to use a more 
readily available DC population. MoDC have been reported in kidney tissue, and have been 
extensively studied as a surrogate DC population in various immunotherapy trials [246-248]. 
Monocytes are numerous in peripheral blood and relatively easy to differentiate into MoDC in 
vitro. Therefore, the effect of autologous PTEC on monocyte differentiation into MoDC and on 
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the function of fully differentiated MoDC was next investigated. This work is presented in 
chapter 4. 
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Chapter 4: The effect of autologous PTEC on 
monocyte derived DC 
4.1. Introduction 
Results from the previous chapter demonstrated that autologous PTEC skew CD1c
+
 BDC 
towards a tolerogenic function. This chapter extends this work by examining the effect of 
activated autologous PTEC on another population of DC, MoDC. 
 Since the frequency of preformed BDC in blood is low, various studies have used in vitro 
generated MoDC to understand the function of DC in pathological conditions.  As monocytes 
constitute about 10-15% of human leukocytes, they are readily available in large numbers from 
peripheral blood. Functionally, in vivo, they migrate to sites of inflammation and depending upon 
the stimuli, differentiate into macrophages or DC to stimulate an immune response. It has been 
demonstrated in vitro that monocytes differentiate into MoDC when stimulated with a cytokine 
cocktail of GM-CSF and IL-4 [249, 250]. Furthermore, these MoDC have a typical DC 
morphology and express high levels of MHC-I and II, DC-SIGN, CD1a, CD11c, CD40 and 
ICAM-1. In addition, following differentiation into MoDC, monocytes completely lose the 
expression of classical monocyte marker CD14. MoDC can also stimulate allogeneic T cell 
responses more effectively than whole PBMC and when matured, up-regulate MHC-II, co-
stimulatory molecules and effectively present antigens to autologous T cells [249, 251]. 
In the human kidney, monocytes capable of differentiating into MoDC have been detected 
in the tubulointerstitium of patients with proliferative GN [217]. Consistent with this study, 
Segerer et al observed a strong and localised tubulointerstitial infiltration of DC-SIGN
+
 cells in 
GN patients, suggested to be MoDC [215, 252]. Therefore, the primary objective of this chapter 
was to study the influence of IFN-γ activated autologous PTEC on the differentiation, maturation 
and function of MoDC.   
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4.2. Hypothesis 
Autologous PTEC regulate MoDC differentiation and function towards an anti-
inflammatory, less mature phenotype. 
4.3. Aims 
The specific aims of this chapter are: 
 To study the effect of IFN-γ activated autologous PTEC on CD14+ monocyte to 
MoDC differentiation and maturation. 
 To study the effect of IFN-γ activated autologous PTEC on MoDC function. 
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4.4. Experimental design 
 
The CD14+ monocytes (red box) were differentiated into MoDC in the absence (Ctrl-MoDC) or presence (PTEC-MoDC) of IFN-γ activated 
autologous PTEC for 5 days (yellow box). Following differentiation, Ctrl- and PTEC-MoDC were matured with poly(I:C) for 24h (purple box). 
To analyse the autocrine effect of IL-10 secreted by MoDC, the monocyte and autologous PTEC co-cultures during differentiation were 
supplemented with blocking antibody for IL-10 (green box). Readouts including phenotype analysis, cytokine profiling and antigen up-take 
were obtained following differentiation and phenotype analysis, cytokine profiling and allo-MLR were obtained following maturation. 
Figure 4.1. Experimental design to study the effect of IFN-γ activated autologous PTEC on MoDC. 
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4.5. Results 
4.5.1. Purity of CD14+ monocytes 
CD14
+
 monocytes were purified from PBMC obtained from whole blood or the CD1c
+
 
BDC flow through of autologous PTEC donors (refer to section 2.5.4). CD14
+
 monocytes were 
isolated using a commercially available immuno-magnetic selection kit (refer to section 2.5.3). 
The mean purity of CD14
+
 monocytes from 8 donors was 92.9% ± 3.3% SD. The purity of the 
isolated CD14
+
 monocytes was determined by the surface expression of CD14 and absence of 
CD3 and CD20 (Figure 4.2) antigens, which were determined using flow cytometry.  
 
4.5.2. MoDC differentiated in the presence of PTEC retain CD14 and express 
low levels of HLA-DR, CD86 and high levels of PD-L1 
Monocytes were differentiated into MoDC in the absence (Ctrl-MoDC) and presence of 
IFN-γ activated autologous PTEC (PTEC-MoDC) for 5 days. The presence of PTEC did not alter 
MoDC viability or recovery (data not shown). Differentiation of monocytes into MoDC was 
Figure 4.2. Purification of CD14+ monocytes. 
 Gated on live single cells, the first plot represents CD14+ monocytes defined as CD14+ and CD3- 
cells, while the second plot represents monocytes as CD14+ and CD20- cells. The dot plots are 
representative of a single experiment. 
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determined by the expression of DC-SIGN (CD209) and this marker was upregulated by both 
Ctrl- and PTEC-MoDC, indicating the monocyte cultures progressed along the MoDC pathway 
(Figure 4.3 A and B). However, following differentiation, PTEC-MoDC, unlike Ctrl-MoDC, 
retained significant expression of the classical monocyte marker CD14 (p=0.03), indicating 
PTEC mediated inhibition of monocyte into MoDC differentiation (Figure 4.3 A and C). 
Figure 4.3. Surface antigen expression of MoDC differentiated in the absence (Ctrl-MoDC) or 
presence (PTEC-MoDC) of autologous PTEC. 
(A) Representative experiment for the surface expression of CD14 and DC-SIGN. (B-F) Surface 
expression of DC-SIGN (B), CD14 (C), HLA-DR (D), CD86 (E) and PD-L1 (F) by Ctrl- and PTEC-MoDC 
represented as mean values of four to six donors (bar graph) and four to six individual donor 
experiments (line graph). Surface expression was measured by flow cytometry and reported as delta 
mean fluorescence intensity (Delta MFI) (MFI test-MFI isotype control). Statistical comparisons 
between the two groups were performed using a two-tailed Wilcoxon signed rank test.  
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Furthermore, the same PTEC-MoDC population displayed low levels of antigen presenting 
molecule HLA-DR (Figure 4.3 D), co-stimulatory molecule CD86 (p=0.05) (Figure 4.3 E) and 
significantly increased expression of immuno-regulatory molecule PD-L1 (p=0.02) (Figure 4.3 
F), suggesting that MoDC differentiated in the presence of autologous PTEC display a less 
mature or tolerogenic phenotype. 
4.5.3. Monocytes differentiated in the presence of PTEC display elevated 
levels of phagocytosis  
To further examine the functional consequence of the immature phenotype of PTEC-
MoDC, we tested the antigen up-take and cytokine secretion ability of PTEC-MoDC. Antigen 
up-take function was tested by analysing the endocytic and phagocytic capacity of PTEC-MoDC 
by using FITC labelled dextran (1 mg/mL) and FITC latex beads (cell:beads ratio of 1:1500) 
respectively. It is well established that immature DC have a greater antigen up-take capacity than 
mature DC. The results suggest that PTEC-MoDC retain enhanced levels of phagocytosis 
compared to Ctrl-MoDC, supporting the observation that these cells are less mature (Figure 4.4). 
However, there were minimal differences in the endocytic ability of either MoDC group.  
 
Figure 4.4. Antigen up-take by monocytes differentiated in the absence (Ctrl-MoDC) or presence 
(PTEC-MoDC) of autologous PTEC. 
(A) Antigen up-take by receptor mediated endocytosis of FITC-dextran and (B) phagocytosis of FITC-
latex beads by Ctrl- and PTEC-MoDC at 4°C and 37°C as measured by flow cytometer (gated on live-
single cells) and is presented as mean values for four donors (bar graph) and four individual donors 
(line graph). The up-take of FITC dextran is reported as mean fluorescence intensity (MFI) in bar 
graph and delta MFI (MFI of 37°C - MFI of 4°C) in line graph. The up-take of FITC latex beads is 
reported as the percentage of cells positive for FITC. 
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4.5.4. Monocytes differentiated in the presence of PTEC display elevated 
levels of anti-inflammatory cytokine IL-10 
To identify the cytokines secreted by MoDC in the presence of autologous PTEC, culture 
supernatants were analysed using CBA technology. PTEC-MoDC significantly up-regulated the 
secretion IL-10 (p=0.02) and IL-1β (p-0.007) (Figure 4.5 A and B) when compared with Ctrl-
The expression of (A) IL-10 and (B) IL-1β by both Ctrl- and PTEC-MoDC presented as mean values 
for eight to nine donors (bar graph) and eight to nine individual experiments (line graph) as 
determined using flow cytometric bead array (CBA). Statistical comparisons between the two 
groups were performed using a two-tailed Wilcoxon signed rank test. (C) The dot plots represent 
IL-10 intracellular staining on autologous PTEC cultured in IL-4 and GM-CSF media, Ctrl- and PTEC-
MoDC at time points day 1, 3 and 5. The X-axis represents CD45 and Y-axis represents IL-10. 
Figure 4.5. Secretion of IL-10 and IL-1β by both Ctrl- and PTEC-MoDC. 
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MoDC. CBA analysis of PTEC alone demonstrated no production of IL-10 or IL-1β (data not 
shown).  Furthermore, to confirm that MoDC were the primary source of the IL-10, intracellular 
staining was undertaken. As can be seen from Figure 4.5 C, only MoDC produced IL-10 at all-
time points analysed. This anti-inflammatory cytokine IL-10 is known to inhibit monocyte to 
MoDC differentiation [253], therefore, in our autologous PTEC-monocyte co-cultures, IL-10 
was blocked to identify the autocrine effect on MoDC differentiation.  
4.5.5. The IL-10 secreted by PTEC-MoDC has a partial autocrine effect in 
retaining the levels of CD14  
The Ctrl- and PTEC-MoDC that were differentiated in the presence of IL-10 blocking 
Expression of surface antigens (A) DC-SIGN, (B) CD14, (C) HLA-DR, (D) CD86 and (E) PD-L1 by Ctrl-
MoDC, PTEC-MoDC and PTEC-MoDC supplemented with blocking antibody for IL-10 presented as 
mean values for nine donors (bar graph) and nine individual donor (line graph) experiments. 
Surface expression was measured by flow cytometry (gated on live, single cells) and reported as 
delta MFI (MFI test-MFI isotype control). Statistical comparisons between the two groups were 
performed using a two-tailed Wilcoxon signed rank test. 
Figure 4.6. Effect of IL-10 blocking on the surface antigens expressed by Ctrl- and PTEC-MoDC. 
 
66 
 
antibody were stained for the expression of surface antigens. Our results indicate that blocking 
IL-10 resulted in less CD14 being retained on PTEC-MoDC from four out of eight donors 
(Figure 4.6 B). Although this was not significant, these numbers do suggest that IL-10 can have 
an autocrine effect in regulating the surface expression of CD14 and the subsequent maintenance 
of MoDC in an immature state. There was no substantial effect on HLA-DR, CD86 and PD-L1 
expression levels in the presence of IL-10 blocking (Figure 4.6 C, D and F). 
4.5.6. IL-10 secreted by MoDC had no autocrine effect on the secretion of pro-
inflammatory cytokine IL-1β  
We next investigated the effect of IL-10 blocking on IL-1β secreted by MoDC by 
analysing supernatants obtained from Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC cultured with 
IL-10 blocking antibody. Our results show that blocking IL-10 did not change the levels of IL-1β 
secreted by PTEC-MoDC in six individual donors (Figure 4.7). This suggests that IL-10 secreted 
by MoDC has no autocrine effect on the secretion of pro-inflammatory cytokine IL-1β.  
Secretion of  IL-1β by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC supplemented with blocking 
antibody for IL-10 presented as mean values for six donors (bar graph) and six individual 
donors (line graph) experiments as determined using a flow cytometric bead array.  
 
Figure 4.7. Effect of IL-10 blocking on the secretion of IL-1β by PTEC-MoDC. 
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4.5.7. PTEC exert their modulatory effect primarily during monocyte to 
MoDC differentiation 
In preliminary experiments, following differentiation, both Ctrl- and PTEC-MoDC were 
harvested and matured for 24 h without or with autologous PTEC. Poly(I:C), a double stranded 
RNA analogue that functions through TLR3 which is largely associated with tissue necrosis 
during inflammation [238, 254], was used as a maturation stimulus. Our results indicate that 
phenotypic changes remain similar whether PTEC were present or absent during the maturation 
phase (Figure 4.8), suggesting that autologous PTEC exert their modulatory effect primarily 
Figure 4.8. Surface antigen expression of MoDC matured with or without autologous PTEC. 
The delta mean fluorescence intensity (MFI of sample-MFI of isotype) of (A) HLA-DR (n=2), (B) 
CD86 (n=2), (C) CD83 (n=1) and (D) PD-L1 (n=2) expressed on Ctrl- and PTEC-MoDC matured 
with 50 µg/mL poly(I:C) in the presence or absence of autologous PTEC. 
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during monocyte to MoDC differentiation. Therefore, it was decided to perform all future MoDC 
maturation experiments without the presence of autologous PTEC.  
4.5.8. Poly(I:C) matured PTEC-MoDC express low levels of HLA-DR, CD86 
and CD83 
As the maturation stimulus poly(I:C) functions through TLR3, the effect of autologous 
PTEC on the MoDC expression of TLR3 was analysed by measuring the level of TLR3 mRNA 
expressed by Ctrl- and PTEC-MoDC using reverse transcription-polymerase chain reaction (RT-
PCR). Our results shows significantly elevated levels of TLR3 expression by PTEC-MoDC 
Figure 4.9. TLR 3 and surface antigen expression of Ctrl- or PTEC-MoDC. 
(A) mRNA expression of poly(I:C) matured Ctrl- and PTEC-MoDC in one representative donor 
(bar graph) and three individual donors (line graph). Surface expression of (B) HLA-DR, (C) 
CD86, (D) CD83 and (E) PD-L1 presented as mean values for three to six donors (bar graph) 
and three to six individual donors (line graph). Surface expression was measured by flow 
cytometry and expressed as delta MFI. Statistical comparisons between the two groups were 
performed using a two-tailed Wilcoxon signed rank test. 
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(p=0.04) (Figure 4.9 A). Following the activation of Ctrl- and PTEC-MoDC using poly(I:C) for 
24 h, the phenotype of Ctrl- and PTEC-MoDC was examined. In spite of having higher levels of 
TLR3 expression, PTEC-MoDC displayed significantly lower expression of HLA-DR (p=0.05) 
(Figure 4.9 B) and CD86 (p=0.03) (Figure 4.9 C). The expression of activation marker CD83 
was induced on Ctrl-MoDC following poly(I:C) maturation in three out of four donors, while its 
expression was inhibited on PTEC-MoDC (Figure 4.9 D). Upon maturation, the levels of PD-L1 
were similar between Ctrl- and PTEC-MoDC (Figure 4.9 E). These results suggest that, despite 
the fact that PTEC-MoDC strongly up-regulated the receptor machinery required for PIC 
signalling, they still remained in a less mature state than their Ctrl-MoDC counterparts. 
4.5.9. Poly(I:C) matured PTEC-MoDC secrete less pro-inflammatory 
cytokines 
The supernatants of Ctrl- and PTEC-MoDC were analysed using a CBA assay to identify 
the effect of autologous PTEC on the cytokine secretion profile of poly(I:C) matured MoDC. 
Results show that PTEC-MoDC secreted reduced levels of Th1 inducing cytokine IL-12p70 in 
all donors (Figure 4.10 A) and elevated levels of anti-inflammatory cytokine IL-10 (Figure 4.10 
Figure 4.10. Cytokine secretion by Ctrl- and PTEC-MoDC following maturation with poly(I:C). 
(A) IL-12p70, (B) IL-10 and (C) TNF-α secretion by poly(I:C) matured Ctrl- and PTEC-MoDC presented as 
mean values for four to five donors (bar graph) and four to five individual donors (line graph) as 
determined using a flow cytometric bead array. 
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B) compared to Ctrl-MoDC. The levels of TNF-α were lower in three out of five donors PTEC-
MoDC compared to Ctrl-MoDC (Figure 4.10 C). Preliminary experiments demonstrated that 
PTEC alone produce TNF-α (Figure 3.5) in response to poly(I:C) stimulation. However, the 
maturation of MoDC was performed in the absence of autologous PTEC, ensuring measurable 
TNF-α was produced solely from MoDC. These results indicate that autologous PTEC have 
attenuated the Th1 inducing capacity of matured MoDC. 
4.5.10. MoDC differentiated in the presence of autologous PTEC induce weak 
Th1 responses 
The ability of MoDC to induce allogeneic CD4
+
 T cell proliferation is a classical function 
of MoDC. Therefore, the ability of poly(I:C) matured Ctrl- and PTEC-MoDC to stimulate 
allogeneic CD4
+
 T cell responses was determined using an MLR assay. Results show that PTEC-
MoDC were less effective in stimulating allogeneic CD4
+
 T cell proliferation in multiple donors 
(Figure 4.11 A and B). This was consistent with the decreased level of expression of antigen 
presenting molecule HLA-DR and co-stimulatory ligand CD86 by matured PTEC-MoDC 
(Figure 4.3 D and E).  In an effort to determine whether the Ctrl- or PTEC-MoDC population 
were able to skew responding T cells towards different T helper subsets, cytokine levels and 
transcription factors were monitored using a CBA assay and RT-PCR respectively at the end of 
the culture period. The PTEC-MoDC were poor at skewing CD4
+
 T cells towards a Th1 
response, as indicated by significantly decreased expression of Th1 cytokine IFN-γ (p=0.03) 
(Figure 4.11 C) and IL-2 (p=0.03) (Figure 4.11 D) when compared with Ctrl-MoDC. RT-PCR 
analysis showed that PTEC-MoDC also induced significantly lower levels of Th1 transcription 
factor mRNA T-bet (p=0.01) (Figure 4.11 E) and higher expression of Treg transcription factor 
mRNA FoxP3 (p=0.04) (Figure 4.11 F) in responding CD4
+
 T cells. There were no detectable 
levels of Th2 cytokine IL-4 and no difference between the expression of Th2 transcription factor 
mRNA GATA3 between Ctrl- and PTEC-MoDC. Collectively, these results suggest that PTEC-
MoDC are weak inducers of Th1 responses.  
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Figure 4.11. Allogeneic stimulatory capacity of poly(I:C) matured Ctrl- and PTEC-MoDC. 
Allogeneic CD4+ T cell proliferation induced by poly(I:C) matured Ctrl- and PTEC-MoDC in (A) a 
representative donor experiment at a increasing DC:T cell ratio and (B) in five individual donors at 
a 1:8 DC:T cell ratio. Proliferation was assessed by 3[H]-thymidine incorporation and reported as 
counts per minute (CPM). (C) Secretion of Th1 cytokine IFN-γ and (D) IL-2 in allogeneic MLR 
experiments at a 1:8 DC:T cell ratio. (E) mRNA expression of Th1 transcription factor T-bet and (F) 
Treg transcription factor FoxP3 presented as mean values for four to six donors (bar graph) and 
four to six individual donor experiments (line graph). Statistical comparisons between the two 
groups were performed using a two-tailed Wilcoxon signed rank test. 
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4.6. Discussion 
The infiltration of various immune cells into the renal interstitium during kidney damage is 
characteristic of host responses to a variety of chemotactic agents secreted by damaged PTEC. 
Various studies have shown that infiltrating DC are located in the vicinity of the damaged PTEC, 
suggesting that PTEC may regulate DC function, thereby contributing to the pathogenesis of the 
disease process (section 1.6.1). We have reported in chapter 3 that autologous PTEC skew 
preformed CD1c
+
 BDC towards a tolerogenic state by regulating their surface phenotype and 
function. In this chapter, we developed an in vitro model to test the hypothesis that autologous 
PTEC may also regulate MoDC differentiation, maturation and function towards an immature 
state. This was demonstrated by PTEC-MoDC retaining elevated levels of CD14, expressing low 
levels of HLA-DR and CD86, expressing elevated levels of PD-L1, and producing elevated 
levels of anti-inflammatory cytokine IL-10. Importantly, these tolerogenic features outweigh the 
pro-inflammatory cytokine IL-1β secreted by PTEC-MoDC, as highlighted by the functional 
suppression of T cell responses in all donors tested. 
Our results show that CD14
+
 monocytes cultured with and without autologous PTEC had 
differentiated along the MoDC pathway, as indicated by the expression of the DC specific 
marker DC-SIGN (CD209). This surface antigen gradually increases over time as monocytes 
differentiate into MoDC [252]. However, PTEC-MoDC retained the expression of monocyte 
marker CD14, which is normally lost upon differentiation into MoDC [249], and expressed low 
levels of HLA-DR and CD86 when compared with Ctrl-MoDC, indicating an immature 
phenotype. This observation is in line with other studies in which monocytes differentiated into 
MoDC in the presence of epithelial cells of non-renal origin displayed a similar immature 
phenotype [255].  
The findings that MoDC differentiated in the presence of autologous PTEC also 
demonstrated enhanced levels of phagocytosis, a function associated with immature DC [243], 
supports the notion that PTEC-MoDC are not fully differentiated/matured. The levels of antigen 
up-take via receptor mediated endocytosis were similar between Ctrl- and PTEC-MoDC. This 
could be because MoDC were generated in an autologous setting, as other studies have shown 
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that MoDC generated in contact with allogeneic PTEC display elevated levels of antigen up-take 
via endocytosis [256].  
The major findings of the cytokine profile studies were that PTEC-MoDC secrete 
significantly elevated levels of IL-10 and IL-1β. This finding is somewhat counter-intuitive as 
IL-10 is an anti-inflammatory cytokine whilst IL-1β is an inflammatory cytokine. However, 
overall, our observed results of an immature phenotype would support a dominant role of the 
anti-inflammatory cytokine IL-10. In others studies, this molecule has also been shown to 
suppresses monocyte to MoDC differentiation [253]. Thus it is tempting to speculate that the 
primary mechanisms by which autologous PTEC induce immature MoDC is via the induction of 
autocrine IL-10 from the monocytes themselves. Supporting this hypothesis, when IL-10 was 
blocked, the retention of CD14 on PTEC-MoDC was decreased in 50% of our donors. These 
results highlight the role of IL-10 in autologous PTEC regulation of MoDC function. However, 
the fact that the IL-10 regulatory pathway was apparent in only 50% of donors suggests the 
possibility of other mechanisms of autologous PTEC being involved in down modulating MoDC 
function.  
Following differentiation, Ctrl- and PTEC-MoDC were matured, in the absence of PTEC, 
using poly(I:C), a ligand for TLR3. Our results demonstrate that PTEC-MoDC express 
significantly higher levels of TLR3, suggesting an increased sensitivity to poly(I:C) stimulation. 
Interestingly, however, following activation with poly(I:C), PTEC-MoDC expressed lower levels 
of activation marker CD83, antigen presenting molecule HLA-DR and co-stimulatory molecule 
CD86 than Ctrl-MoDC. These findings were partly reminiscent of the data of Verkade et al, who 
observed significantly lower expression of CD83, HLA-DR and CD86 on mature MoDC 
differentiated from monocytes obtained from CKD patients compared to control patients [257].  
In addition to a less mature phenotype, poly(I:C) matured PTEC-MoDC also secreted 
lower levels of the Th1 inducing cytokine IL-12p70 and elevated levels of regulatory cytokine 
IL-10 when compared with poly(I:C) matured Ctrl-MoDC. These results agree with a recent 
human study in which allogeneic PTEC suppressed the level of IL-12p70 and up-regulated the 
levels of IL-10 secreted by lipopolysaccharide matured MoDC [256], thereby suggesting that 
PTEC immune modulation of MoDC is dependent on the interaction between the PTEC and 
monocyte/MoDC, but independent of the maturation stimulus.  
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 The secretion of elevated levels of IL-10 is consistent with the immuno-regulatory 
phenotype of PTEC-MoDC. IL-10 has also been shown to be protective in various immune 
mediated kidney diseases. For instance, in a crescentic GN mouse model, administration of IL-10 
prevented crescent formation, renal impairment and attenuated proteinuria [258]. In another 
study using a mesangial proliferative GN rat model, administration of IL-10 diminished the 
influx of immune cells into the glomeruli and reduced the proliferation of mesangial cells [259]. 
More specifically, other studies have shown that renal DC can attenuate renal function by 
secreting IL-10. In an IRI mouse model, depletion of renal DC was associated with low levels of 
IL-10 and persistent kidney injury [156]. In another study involving the cisplatin-induced 
nephrotoxic mouse model, Tadagavadi et al demonstrated that IL-10 secreted by DC was partly 
responsible for reducing nephrotoxicity as measured by serum creatinine levels [260]. All of 
these studies indicate a protective role for IL-10 within the diseased kidney. Our results 
significantly add to these findings and implicate PTEC as a central player in the induction of IL-
10 from MoDC under inflammatory conditions. 
Smedt et al have shown that exogenous addition of IL-10 during maturation impairs the in 
vivo ability of DC to secrete IL-12 and to induce Th1 responses [261]. Interestingly, the PTEC-
MoDC in our study secreted elevated levels of IL-10, which may have had an autocrine effect to 
inhibit Th1 inducing cytokine IL-12. Supporting this concept, PTEC-MoDC, in an allogeneic 
MLR, were also poor inducers of the Th1 cytokine IFN-γ and the Th1 transcription factor T-bet. 
There is evidence for predominantly Th1 nephritogenic immune responses in various forms of 
human GN, including crescentic GN and membranoproliferative GN [262]. However, the role of 
MoDC in regulating the Th1 responses in these forms of kidney pathology requires further 
investigation. Our results show that, in addition to a weak Th1 response, PTEC-MoDC induce 
strong mRNA expression of FoxP3, a marker for Treg, in allogeneic CD4
+
 T cells. The ability of 
Treg to suppress Th1 mediated immune responses has been demonstrated in an experimental 
model of GN [263], while numbers of Treg has been shown to inversely correlate with disease 
stage in LN patients [264]. However, the putative role of MoDC in stimulating this regulatory 
mechanism has not been documented. Collectively, our results indicate that autologous PTEC 
modulate differentiation of monocytes into MoDC by skewing them towards an anti-
inflammatory, less mature phenotype, likely via an autocrine IL-10 mechanism. The next chapter 
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will continue this research to more fully define this mechanism of PTEC immune modulation, 
which may enable us to identify specific pathways to target for early intervention in response to 
deteriorating kidney function.  
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Chapter 5: The mechanisms of autologous PTEC 
modulating MoDC function 
5.1. Introduction 
As demonstrated in chapter 4, the presence of autologous PTEC skew MoDC to become 
phenotypically less mature and functionally less stimulatory.  In this chapter the mechanisms by 
which these regulatory steps occur were investigated. As an initial step in this process, CD14
+
 
monocytes were differentiated into MoDC in the presence or absence of autologous PTEC in two 
different culture systems – contact dependent (CD) and contact independent (CI). The CD 
system allows physical contact between autologous PTEC and CD14
+
 monocytes during 
differentiation (Figure 5.1 A). In the CI culture system, autologous PTEC and CD14
+
 monocytes 
are separated using a 0.4μM pore size semi-permeable membrane which allows only sharing of 
culture media and diffusion of soluble particles (Figure 5.1 B). These two culture systems 
allowed us to identify whether autologous PTEC regulate MoDC differentiation and function by 
surface expressed molecules (CD mechanism) or by soluble factors (CI mechanism). Following 
Figure 5.1. Set-up of autologous PTEC and monocyte co-cultures for differentiation into MoDC. 
Two different culture systems (A) Contact Dependent (CD) and (B) Contact Independent (CI) were 
used to identify the molecules participating in the PTEC immune-modulation mechanism. The CD 
culture system allowed physical contact between monocytes and autologous PTEC, whilst in the CI 
culture system, the monocytes and autologous PTEC were separated into different chambers.  
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the elucidation of both CD and CI mechanisms of immune regulation, the molecules 
participating in these mechanisms were investigated. As discussed in the Literature Review, 
human PTEC express immuno-regulatory molecules including sHLA-G, PD-L1 and IDO, which 
may participate in these CD or CI mechanisms. The specific role of these molecules in 
modulating MoDC phenotype and function was investigated by blocking the activity of these 
molecules within the PTEC-MoDC co-culture. 
5.2. Hypothesis 
Autologous PTEC regulate MoDC phenotype and function through defined CD and/or CI 
mechanisms. 
5.3. Aims 
 To identify whether autologous PTEC regulate MoDC phenotype and function 
through CD or CI mechanisms.  
 To identify the immuno-regulatory molecules participating in these CD or CI 
mechanisms.  
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5.4. Experimental design 
 
The CD14+ monocytes (red box) were differentiated into MoDC in the absence (Ctrl-MoDC) or presence (PTEC-MoDC) of IFN-γ activated 
autologous PTEC for 5 days in a contact dependent culture system (yellow box) and contact independent culture system (sky blue box). To 
identify the regulatory mechanisms of autologous PTEC on MoDC, blocking experiments were performed (green box). In these 
experiments, the PD-L1 expressed on the surface of autologous PTEC was blocked prior to co-cultures with monocytes. The IDO and sHLA-
G of autologous PTEC were inhibited by supplementing the autologous PTEC-monocyte co-cultures with IDO inhibitor 1-MT and blocking 
antibody for sHLA-G. Readouts such as phenotype analysis, cytokine profiling and allo-MLR were obtained following differentiation. 
Figure 5.2. Experimental design to identify the mechanisms of IFN-γ activated autologous PTEC regulating MoDC phenotype and 
function. 
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5.5. Results 
5.5.1. Autologous PTEC modulate the expression of HLA-DR, CD86 and 
CD80 by contact independent mechanisms and CD14 and PD-L1 by 
both contact dependent and contact independent mechanisms 
In both CD and CI culture systems the progression of CD14
+
 monocyte differentiation into 
MoDC was confirmed by the expression of the DC marker DC-SIGN (Figure 5.3 A) in both the 
absence and presence of PTEC. The expression of CD14 was retained at elevated levels by 
PTEC-MoDC when compared with Ctrl-MoDC from both CD and CI culture systems but the 
Expression of surface antigens (A) DC-SIGN, (B) CD14, (C) HLA-DR, (D) CD86, (E) CD80 and (F) PD-L1 
by Ctrl- and PTEC-MoDC from CD and CI culture systems is presented as mean values for five to 
seven donors (bar graph) and five to seven individual donor (line graph) experiments. Surface 
expression was measured by flow cytometry (gated on live, single cells) and reported as delta MFI 
(MFI test-MFI isotype control). Statistical comparisons between the two groups were performed 
using a two-tailed Wilcoxon signed rank test. 
 
 
Figure 5.3. Effect of autologous PTEC on surface antigens expressed by Ctrl- and PTEC-MoDC 
differentiated in contact dependent (CD) or contact independent (CI) culture systems. 
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level of CD14 was considerably less on PTEC-MoDC in the CI culture system when compared 
with PTEC-MoDC from the CD culture system (Figure 5.3 B). The expression of HLA-DR was 
down regulated by PTEC-MoDC in three out of six donors in the CD culture system and in all 
donors from the CI culture system (Figure 5.3 C). The expression of CD86 on PTEC-MoDC was 
down regulated in all donors in both CD and CI culture systems (Figure 5.3 D) and CD80 was 
upregulated (Figure 5.3 E) by PTEC-MoDC in four out of six donors in the CD system and in 
five out of six donors in the CI system, when compared with Ctrl-MoDC. The expression of PD-
L1 was up regulated on PTEC-MoDC in both CD and CI culture systems, but this upregulation 
was only significant (p=0.03) in the CD culture system (Figure 5.3 F).  
5.5.2. Autologous PTEC modulate IL-10 secretion by MoDC through CD 
mechanisms  
To identify the regulatory mechanism of autologous PTEC on MoDC cytokine secretion, 
we analysed the supernatant of Ctrl- and PTEC-MoDC from both CD and CI culture systems. 
PTEC-MoDC secreted elevated levels of IL-10 in all five donors when compared with Ctrl-
MoDC within the CD culture system. However, this increased IL-10 expression was ablated in 
the CI culture system (Figure 5.4 A).  
Secretion of anti-inflammatory cytokines IL-10 by Ctrl- and PTEC-MoDC  from CD and CI culture 
systems represented as mean values for five donors (bar graph) and five individual donor (line 
graph) experiments as determined using a flow cytometric bead array.  
Figure 5.4. Secretion of IL-10 by Ctrl- and PTEC-MoDC from CD and CI culture systems. 
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5.5.3. PTEC-MoDC from both CD and CI culture systems were less effective 
in stimulating allogeneic CD4
+
 T cell responses   
To identify the mechanism through which autologous PTEC module MoDC to down-
regulate allogeneic CD4
+
 T cell responses, allo-MLR assays were set-up utilising Ctrl- and 
PTEC-MoDC obtained from CD and CI culture systems. The allo-MLR assay was set-up for 5 
days and proliferation was assessed by labelling the cells with 
3
[H]-thymidine. PTEC-MoDC 
were less effective at stimulating CD4
+
 T cell responses when compared with their respective 
Ctrl-MoDC from both CD and CI culture systems. However, in all donors, PTEC-MoDC from 
CI cultures appeared more capable of T cell stimulation than PTEC-MoDC from CD cultures, 
suggestive of a partially contact-mediated mechanism of PTEC suppression (Figure 5.5 A-C).  
5.5.4. PTEC express immuno-regulatory molecules PD-L1, sHLA-G and IDO 
To identify the molecules participating in the CD and CI mechanisms, PTEC were treated 
without (Ctrl-PTEC) or with IFN-γ (IFN-γ-PTEC) and their expression of PD-L1, HLA-G and 
IDO were analysed. Previously published results from our Laboratory have shown that IFN-γ up-
regulates the expression of PD-L1 on the surface of human PTEC [45]. In this present study, this 
observation was re-confirmed by demonstrating elevated levels of PD-L1 expression on IFN-γ-
PTEC when compared with Ctrl-PTEC (Figure 5.6 A).  
Allogenic CD4+ T cell proliferation induced by Ctrl- and PTEC-MoDC from CD and CI cultures in three 
individual donors (A, B and C) at 1:8 MoDC:T cell ratio. Proliferation was measured by 3[H]-thymidine 
incorporation and expressed as counts per minute (CPM) after 5 days. 
Figure 5.5. Allogenic stimulatory capacity of Ctrl- and PTEC-MoDC from CD and CI cultures. 
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The expression of both surface and soluble isoforms of HLA-G by Ctrl- and IFN-γ-PTEC 
were analysed using mRNA analysis, intracellular and surface staining and ELISA assay. The 
mRNA analysis and intracellular staining demonstrated elevated levels of HLA-G mRNA and 
intracellular protein in IFN-γ-PTEC when compared with Ctrl-PTEC (Figure 5.6 B and C). 
However, surface staining of both Ctrl- and IFN-γ-PTEC failed to demonstrate the expression of 
HLA-G (data not shown). Interestingly, elevated levels of sHLA-G were detected by ELISA 
Immuno-regulatory molecules expressed by PTEC cultured in the absence (Ctrl-PTEC) or presence of 
IFN-γ (IFN-γ-PTEC). (A) Expression of surface antigen PD-L1 represented as mean values for three 
donors (bar graph) and three individual donors (line graph) using flow cytometry. (B) Expression of 
HLA-G mRNA (n=1) using real-time PCR. (C) Intracellular expression of HLA-G (n=1) using flow 
cytometry. (D) Soluble HLA-G levels produced by PTEC represented as mean values for three donors 
(bar graph) and three individual donors (line graph) using ELISA. (E) mRNA IDO expression 
represented as mean values for four donors (bar graph) and four individual donors (line graph) using 
real-time PCR analysis. (F) Intracellular expression of IDO represented as mean values for seven 
donors (bar graph) and seven individual donors (line graph) using flow cytometry. (G) IDO activity 
measured as the ratio of kynurenine and tryptophan represented as mean values for three donors 
(bar graph) and three individual donors (line graph).  Statistical comparisons between the two 
groups were done using a two-tailed Wilcoxon signed rank test. The intracellular staining and mRNA 
analysis was performed by Ms. Xiangju (Annie) Wang, Queensland Health. HPLC analysis of culture 
supernatants to determine IDO activity was performed at chemical pathology under the supervision 
of Dr. Brett McWhinney, Queensland Health. 
 
Figure 5.6. Immuno-regulatory molecules expressed by PTEC. 
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assay (Figure 5.6 D) in the supernatants of IFN-γ-PTEC. These results suggest that autologous 
PTEC when activated with IFN-γ express elevated level of sHLA-G but do not express 
detectable surface HLA-G.  
The expression of intracellular enzyme IDO was analysed by mRNA analysis and 
intracellular protein staining. The results demonstrated that IDO mRNA (Figure 5.6 E) and 
intracellular protein (p=0.015) (Figure 5.6 F) were up-regulated on IFN-γ-PTEC when compared 
with control PTEC. Furthermore, as IDO is involved in the breakdown of the essential amino 
acid tryptophan into kynurenine, Ctrl-PTEC and IFN-γ-PTEC culture supernatants were assayed 
for their kynurenine/tryptophan ratio as a functional read-out of IDO enzyme activity. IFN-γ-
PTEC supernatants showed much higher levels of kynurenine relative to tryptophan than Ctrl-
PTEC supernatants, confirming an increased IDO biological activity from these cells (Figure 5.6 
G).  
5.5.5. sHLA-G expressed by autologous PTEC partly mediates the expression 
of HLA-DR on MoDC  
To identify the effect of sHLA-G secreted by autologous PTEC on MoDC, the monocyte 
and autologous PTEC co-cultures were supplemented with blocking antibody for sHLA-G 
during differentiation. Following differentiation, the Ctrl- and PTEC-MoDC were harvested and 
stained for surface antigen expression. The blocking of sHLA-G reversed HLA-DR expression 
on PTEC-MoDC when compared with Ctrl-MoDC, where two out of three donors demonstrated 
a partial restoration in the expression of this molecule (Figure 5.7 C). The expression of CD14, 
CD86, CD80 and PD-L1 were not affected with sHLA-G blocking (Figure 5.7 B, C, D, E and F).  
5.5.6. sHLA-G expressed by autologous PTEC partly mediates the secretion of 
IL-10 by MoDC  
Cytokine levels in the supernatants of MoDC cultures were examined following 
differentiation of Ctrl- and PTEC-MoDC with blocking antibody to sHLA-G. The levels of IL-10 
were partly reduced in two out of three donors in the presence of blocking antibody to sHLA-G 
(Figure 5.8). This result was somewhat surprising given that our CD/CI experiments (Figure 5.4) 
indicated a CD mechanism was responsible for the elevated IL-10 from MoDC in the presence of 
INF-γ activated autologous PTEC. 
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Figure 5.7. Effect of sHLA-G blocking on surface antigens expressed by Ctrl- and PTEC-
MoDC. 
Expression of surface antigens (A) DC-SIGN, (B) CD14, (C) HLA-DR, (D) CD86, (E) CD80 and 
(F) PD-L1 by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC supplemented with blocking antibody 
for sHLA-G in a representative donor (bar graph) and two to three individual donor (line 
graph) experiments. Surface expression was measured by flow cytometry (gated on live, 
single cells) and reported as delta MFI (MFI test-MFI isotype control).  
 
Secretion of IL-10 by Ctrl-MoDC, PTEC-MoDC 
and PTEC-MoDC differentiated with blocking 
antibody for sHLA-G represented as mean values 
for three donors (bar graph) and three individual 
donor (line graph) experiments as determined 
using a flow cytometric bead array.  
 
Figure 5.8. Effect of sHLA-G blocking on the 
secretion of IL-10 by PTEC-MoDC. 
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5.5.7. PD-L1 expressed by autologous PTEC mediates the expression of PD-
L1 on MoDC  
To investigate the effect of PTEC-expressed PD-L1 on MoDC phenotype and function, 
anti-PD-L1 blocking antibody was added to PTEC cultures and then washed out before the 
Expression of surface antigens (A) DC-SIGN, (B) CD14, (C) HLA-DR, (D) CD86, (E) CD80 and 
(F) PD-L1 by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC with blocking antibody for PD-L1 
represented as mean values for eight to nine donors (bar graph) and eight to nine 
individual donor (line graph) experiments. Surface expression was measured by flow 
cytometry (gated on live, single cells) and reported as delta MFI (MFI test-MFI isotype 
control). Statistical comparisons between the two groups were done using a two-tailed 
Wilcoxon signed rank test. 
 
Figure 5.9. Effect of PTEC PD-L1 blocking on surface antigens expressed by Ctrl- and 
PTEC-MoDC. 
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addition of monocytes. Our results show that Ctrl- and PTEC-MoDC were differentiated down 
the DC pathway as indicated by the expression of DC-SIGN (Figure 5.9 A). Furthermore, as 
always, the PTEC-MoDC retained expression of CD14 (p=0.007) (Figure 5.9 B), down regulated 
the expression of HLA-DR (Figure 5.9 C) and CD86 (p=0.003) (Figure 5.9 D) and up-regulated 
the expression of CD80 (p=0.03) (Figure 5.9 E) and PD-L1 (p=0.003) (Figure 5.9 F) when 
compared with Ctrl-MoDC. The blocking of PD-L1 on autologous PTEC did not affect the 
differentiation process, as evidenced from the expression of DC-SIGN (Figure 5.9 A). However, 
PTEC PD-L1 blocking significantly decreased (p=0.01) PD-L1 expression on PTEC-MoDC 
(Figure 5.9 F). The expression of other surface antigens was not influenced by PTEC PD-L1 
blocking.  
5.5.8. PD-L1 expressed by autologous PTEC does not regulate the secretion of 
IL-10 by MoDC  
To investigate the regulatory effect of PD-L1 expressed by autologous PTEC on the 
Secretion of IL-10 by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC with blocking antibody for 
PD-L1 represented as mean values for seven donors (bar graph) and seven individual 
donor (line graph) experiments as determined using a flow cytometric bead array. 
Statistical comparisons between the two groups were done using a two-tailed Wilcoxon 
signed rank test. 
 
 
Figure 5.10. Effect of PD-L1 blocking on the secretion of IL-10 by Ctrl- and PTEC-MoDC. 
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cytokine secretion function of MoDC, the supernatants obtained from Ctrl- and PTEC-MoDC 
co-cultures following PD-L1 blocking were analysed by CBA assay. There were no differences 
between the blocked and un-blocked cultures (Figure 5.10), indicating that PTEC expressed PL-
L1 was not involved in the regulation of observed elevated cytokine expression levels.  
5.5.9. IDO activity of autologous PTEC was effectively inhibited using IDO 
inhibitor 1-MT 
Previous studies have shown that IDO activity was inhibited using the inhibitor 1-MT 
[128]. Therefore 1-MT was used in PTEC-MoDC co-cultures to inhibit the activity of IDO. The 
supernatants from these cultures were harvested and the activity of IDO and its effective bocking 
using 1-MT was measured using HPLC and reported as the ratio of kynurenine and tryptophan.  
The results demonstrate that the ratio of kynurenine and tryptophan was significantly 
increased in the supernatant of PTEC-MoDC co-culture when compared with Ctrl-MoDC 
(p=0.03). This ratio was significantly decreased when the PTEC-MoDC co-culture was 
supplemented with IDO inhibitor 1-MT (Figure 5.11). Collectively, these results suggest that 
autologous PTEC express a functionally active form of IDO which can be effectively inhibited 
using 1-MT. 
Figure 5.11. Effect of 1-MT on the activity of IDO expressed by IFN-γ activated PTEC within the 
PTEC-MoDC co-culture. 
The activity of IDO as measured by the ratio of kynurenine (Kyn) and tryptophan (Trp) in the 
supernatants of Ctrl-MoDC, PTEC-MoDC and MoDC differentiated in the presence of IDO activity 
inhibited autologous PTEC (PTETC-MoDC+1-MT). The Kyn and Trp levels were detected using HPLC 
under the supervision of Dr. Brett McWhinney, Queensland Health. The bar graph represents the 
mean of six donors and the line graph represents individual donors. Statistical comparisons 
between the two groups were done using a two-tailed Wilcoxon signed rank test. 
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5.5.10.  IDO activity of autologous PTEC regulates the expression of CD14, 
CD80 and PD-L1 on MoDC  
To investigate the effect of intra-cellular enzyme IDO on the phenotype of PTEC-MoDC, 
we supplemented PTEC-monocyte co-cultures with IDO inhibitor 1-MT. Following 
differentiation, Ctrl- and PTEC-MoDC were harvested and stained for surface antigens. Results 
Figure 5.12. Effect of IDO blocking on surface antigens expressed by Ctrl- and PTEC-MoDC. 
Expression of surface antigens (A) DC-SIGN, (B) CD14, (C) HLA-DR, (D) CD86, (E) CD80 and (F) PD-L1 
by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC supplemented with IDO inhibitor 1-MT represented as 
mean values for nine to ten donors (bar graph) and nine to ten individual donor (line graph) 
experiments. Surface expression was measured by flow cytometry (gated on live, single cells) and 
reported as delta MFI (MFI test-MFI isotype control). Statistical comparisons between the two 
groups were done using a two-tailed Wilcoxon signed rank test. 
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indicate that PTEC-MoDC in all donors, upon differentiation, retained the expression of CD14 
(p=0.01) (Figure 5.12 B), down-regulated the expression of HLA-DR (p=0.002) (Figure 5.12 C) 
and CD86 (p=0.002) (Figure 5.12 D) and up-regulated the expression of CD80 (p=0.03) (Figure 
5.12 E) and PD-L1 (p=0.005) (Figure 5.12 F). Blocking IDO decreased the expression of CD14 
in five out of seven donors and significantly down-regulated the expression of CD80 (p=0.009) 
(Figure 5.12 E) and PD-L1 (p=0.009) (Figure 5.12 F), whilst having no effect on HLA-DR and 
CD86 levels.  
5.5.11. IDO activity of autologous PTEC regulates the secretion of IL-10  
To investigate the effect of IDO on the cytokine secretion function of MoDC, we analysed 
the supernatant obtained from Ctrl- and PTEC-MoDC co-cultures. Our results show that PTEC-
MoDC significantly up-regulate the expression of IL-10 (Figure 5.13) when compared with Ctrl-
MoDC. Blocking IDO activity partly down-regulated the expression of IL-10 by PTEC-MoDC 
in six out of seven donors (Figure 5.13).  
Secretion of IL-10 by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC supplemented with IDO inhibitor 1-
MT represented as mean values for seven donors (bar graph) and seven individual donor (line 
graph) experiments as determined using a flow cytometric bead array. Statistical comparisons 
between the two groups were done using a two-tailed Wilcoxon signed rank test. 
 
Figure 5.13. Effect of IDO blocking on the secretion of IL-10 by PTEC-MoDC. 
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5.5.12. IDO activity of autologous PTEC partly regulates the allogeneic 
response-inducing function of MoDC 
As shown previously, PTEC-MoDC significantly down-regulated the proliferative response of 
allogeneic CD4
+
 T cells (section 4.5.10). In the process of identifying the immune-suppressive 
mechanism/s, it was speculated that the elevated levels of PD-L1 expressed on PTEC-MoDC 
could be the molecules involved in the down-regulation of allogeneic responses. Furthermore, as 
IDO activity of autologous PTEC partly mediated the up-regulation of these molecules (Figure 
5.12 E and F), it is expected that MoDC differentiated in the presence of IDO inhibited 
autologous PTEC (PTEC-MoDC+1-MT) should have a greater T cell-inducing capacity when 
compared to PTEC-MoDC. To confirm this hypothesis, an allo-MLR assay was set-up using 
Ctrl-MoDC, PTEC-MoDC and MoDC differentiated in the presence of IDO activity inhibited 
autologous PTEC (PTEC-MoDC+1-MT). The results obtained supported this hypothesis because 
PTEC-MoDC+1-MT had a greater allogeneic-stimulating function than PTEC-MoDC alone, as 
indicated by a partially restored CD4
+
 T cell proliferation in four out of five donors (Figure 
5.14). Therefore, our results suggest that the IDO activity of autologous PTEC may indirectly 
Figure 5.14. Allogeneic stimulatory capacity of Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC with 
IDO inhibitor 1-MT. 
Allogeneic CD4+ T cell proliferation induced by Ctrl-MoDC, PTEC-MoDC and PTEC-MoDC 
supplemented with IDO inhibitor 1-MT represented as mean values for five donors (bar graph) 
and five individual donors (line graph) at a 1:8 MoDC:T cell ratio. Proliferation was measured by 
3[H]-thymidine incorporation and expressed as counts per minute (CPM) after 5 days. 
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suppress the T cell-stimulating function of MoDC by up-regulating the expression of PD-L1 on 
MoDC.  
5.6. Discussion 
As previously shown in chapter 4, MoDC differentiated in the presence of autologous 
PTEC phenotypically retain the monocyte marker CD14, express low levels of HLA-DR and 
CD86 and up-regulate PD-L1. Furthermore, they secrete elevated levels of regulatory cytokine 
IL-10 and are less effective at stimulating allogeneic responses. These characteristics make them 
functionally behave as a tolerogenic cell. In the current chapter, the mechanisms behind PTEC 
skewing of MoDC towards a tolerogenic function were investigated (Table 5.1). In this process, 
the initial step was to identify whether PTEC immune modulation occurs through molecules 
expressed on the surface of PTEC or soluble factors secreted by PTEC. To achieve this, two 
different culture systems, CD or CI, were established. Both Ctrl- and PTEC-MoDC from CD and 
CI culture systems were harvested and analysed for surface antigen expression. Although the 
intensity of the expression of CD14, HLA-DR, CD86, CD80 and PD-L1 on Ctrl- and PTEC-
MoDC varied between CD and CI culture systems, the overall pattern of expression of these 
molecules suggested that autologous PTEC regulated CD14, HLA-DR, CD80 and CD86 by CI 
mechanisms and PD-L1 through both CD and CI mechanisms. 
The mechanism/s of autologous PTEC regulation of MoDC function, including their 
cytokine profiles and their ability to stimulate allogeneic CD4
+
 T cell responses, were also 
investigated by using Ctrl- and PTEC-MoDC derived from both CD and CI culture systems. 
Autologous PTEC up-regulated the expression of IL-10 from MoDC through a CD mechanism. 
The allo-MLR assay showed that PTEC-MoDC from both CD and CI culture systems were less 
effective at stimulating allogeneic CD4
+
 T cell proliferation than Ctrl-MoDC. However, a partial 
restoration in T cell stimulation by PTEC-MoDC from CI cultures compared to PTEC-MoDC 
from CD cultures suggests that autologous PTEC inhibit the allogeneic-inducing function of 
MoDC through both CD and CI mechanisms.  
Following the identification of CD or CI regulatory mechanisms behind the expression of 
phenotypic markers and the function of MoDC, molecules participating in these mechanisms 
were investigated. The up-regulation of immuno-regulatory molecule PD-L1 on autologous 
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PTEC was reported in our previous publication [45]. In the present study, it was re-confirmed 
that in a steady-state, autologous PTEC express low levels of PD-L1. This expression was up-
regulated approximately four fold when treated with IFN-γ, which is in line with previous studies 
involving murine and human PTEC [75, 221, 222]. The expression of PD-L1 on PTEC and their 
role in various kidney diseases has been discussed in chapter 1 (section 1.5.3). Therefore, this 
surface expressed molecule was investigated as a possible candidate in our observed CD culture 
effects.  
 
Table 5.1. Summary of results showing the mechanisms of autologous PTEC 
regulating MoDC phenotype, cytokine profile and function 
MoDC molecules and 
function 
Mechanisms of autologous 
PTEC regulating MoDC 
molecule expression and 
function 
Immuno-regulatory 
molecules of autologous 
PTEC 
CD14 CD/CI IDO 
HLA-DR CI sHLA-G 
CD86 CI ? 
CD80 CI ? 
PD-L1 CD/CI PD-L1/IDO 
IL-10 CD 
sHLA-G/IDO-mediated-CD-
mechanisms 
Allogeneic response inducing 
function 
CD/CI 
IDO via the regulation of PD-
L1 expression on MoDC 
 
Blocking PD-L1 on the surface of autologous PTEC partly inhibited the expression of PD-
L1 on the surface of MoDC. This suggests that PD-L1 expressed on autologous PTEC was the 
molecule involved in the CD mechanism which mediated PD-L1 up-regulation on MoDC. The 
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blocking PD-L1 antibody (clone: 29E.2A3) used to neutralise the PD-L1 expressed on the 
surface of autologous PTEC was different from the antibody used to identify the expression of 
PD-L1 (clone: MIH1) on the surface of MoDC, and therefore, the decreased expression of PD-
L1 on MoDC was not due to binding of the same epitope by these different antibodies. The 
secretion of IL-10 by MoDC was not affected by PD-L1 blocking, even though IL-10 was 
regulated through a CD mechanism.  
The expression of HLA-G was investigated as molecule participating in CI mechanisms of 
PTEC immuno-modulation. HLA-G mRNA and intracellular staining showed that autologous 
PTEC up-regulate the molecule in response to IFN-γ stimulation. However, the surface staining 
of autologous PTEC did not detect surface bound isoforms of HLA-G. Interestingly, the analysis 
of Ctrl- and IFN-γ-PTEC supernatants demonstrated elevated levels of sHLA-G in IFN-γ treated 
PTEC supernatant. A previous study by Kronsteiner et al [256] reported that PTEC alone do not 
secrete sHLA-G, despite elevated levels detected in PTEC-MoDC co-cultures. However, unlike 
our study, Kronsteiner et al did not culture PTEC with IFN-γ, which induces the expression of 
sHLA-G. Furthermore, the authors speculated that the elevated levels of sHLA-G within their 
co-cultures was derived from the MoDC [256]. Contrary to this, our Ctrl-MoDC cultures alone 
do not secrete sHLA-G (data not shown) or express surface isoforms of HLA-G. Functionally, 
the role of sHLA-G has been demonstrated to be beneficial in various clinical conditions 
including pregnancy, transplantation and various inflammatory diseases [265, 266]. In kidney 
models, the presence of sHLA-G in plasma samples has been shown to be associated with better 
graft acceptance following kidney transplantation [267, 268].  
By blocking sHLA-G, the expression of HLA-DR was restored in two out of three donors. 
The other surface antigens were not affected. This result shows that autologous PTEC can 
regulate HLA-DR expression on MoDC through a CI mechanism mediated by sHLA-G. 
Interestingly, blocking sHLA-G partly decreased the quantity of IL-10 secreted by PTEC-MoDC 
in two out of three donors, despite IL-10 being regulated through a CD mechanism by 
autologous PTEC. Based on this result, it was hypothesised that secretion of sHLA-G by 
autologous PTEC may function in an autocrine manner to up-regulate surface antigens such as 
PD-L2, CD40 or ICOS-L (not identified in the present study) which may subsequently induce 
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MoDC to secrete elevated levels of IL-10. This hypothesis will be tested as more autologous 
donors become available. 
The expression of IDO, another putative molecule participating in the CI PTEC regulatory 
mechanism, was demonstrated to be up-regulated by autologous PTEC in response to IFN-γ 
stimulation. Furthermore, the elevated level of kynurenine in IFN-γ-PTEC supernatants 
demonstrates that this IDO was biologically active. Functionally, IDO plays an 
immunosuppressive role during pregnancy by catalysing tryptophan, an essential amino acid 
required for T cell responses [127]. The role of IDO in the kidney under various pathological 
conditions has been discussed in chapter 1 (section 1.5.5). However, the present study was the 
first to investigate the role of IFN-γ induced IDO expression by PTEC in modulating autologous 
immune responses.  
The primary immuno-modulatory function of IDO operates via a CI function by depleting 
tryptophan in the media. Inhibiting IDO activity by 1-MT partially decreased the levels of CD14 
retained by PTEC-MoDC and partially inhibited the up-regulation of CD80 and PD-L1, further 
supporting the CI regulation of these molecules by autologous PTEC. With autologous PTEC 
regulating the expression of PD-L1 on MoDC by both CD and CI mechanisms (as defined in our 
transwell assays), these blocking experiments suggest that IDO and PD-L1 were the molecules 
participating in these CI and CD mechanisms respectively. The regulatory effect of blocking 
both molecules together will be tested as more autologous donors become available.    
Interestingly, inhibiting the activity of IDO decreased the quantity of IL-10 secreted by 
PTEC-MoDC, despite IL-10 being regulated through a CD mechanism. Based on this result, it 
was hypothesised that depletion of tryptophan in the culture media induced the expression of 
other unidentified surface antigens (possibly PD-L2, CD40 or ICOS-L) on autologous PTEC, 
which could then stimulate MoDC to secrete elevated levels of IL-10 through a CD mechanism. 
Although, tryptophan depletion through IDO activity is the principle mechanism of immune-
regulation [129], other studies have demonstrated the role of kynurenine or other kynurenine 
pathway metabolites in down-regulating immune cell responses [130, 131]. Therefore, the 
kynurenine rich micro-environment in our culture systems may also have an autocrine effect on 
PTEC in up-regulating other unidentified regulatory molecules, which then play a role in 
regulating IL-10 secretion by MoDC through a CD mechanism.  The unidentified immuno-
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regulatory molecules up-regulated on autologous PTEC and their stimulatory signal, whether it is 
the tryptophan depleted micro-environment or the effect of kynurenine or other kynurenine 
pathway by-products, will be elucidated as more autologous donors become available.  
Previous studies have shown that IDO is expressed by MoDC when matured with poly(I:C) 
[269] or treated with pro-inflammatory cytokines such as IFN-γ [270]. In the present study, as 
the MoDC were used following differentiation, they were immature, and therefore, should not be 
expressing IDO (based on a study by Dagmar Von Bubnoff et al, [269]). Therefore, the 1-MT 
used in the PTEC-MoDC co-culture should have inhibited the IDO activity on autologous PTEC 
alone and not affected the MoDC in the co-culture. This was further confirmed when no 
differences was observed in the phenotypic profiles of Ctrl-MoDC cultured in the absence or 
presence of 1-MT (data not shown).  
 The PTEC-MoDC differentiated in both CD and CI culture systems were shown to induce 
lower levels of allogeneic responses when compared with Ctrl-MoDC. Interestingly, PTEC-
MoDC differentiated in the presence of IDO inhibiter 1-MT partly restored the T cell-stimulating 
function of PTEC-MoDC. This may have been related to the observed lower expression of PD-
L1 and CD80. PD-L1 is a well known down-modulatory molecule for T cells and decreased 
expression of this molecule on MoDC would theoretically allow greater T cell allogeneic 
responses. On the other hand, CD80 binds with co-stimulatory molecule CD28, inducing T cell 
proliferation. However, CD80 also binds with higher affinity and avidity to CTLA-4 [56] to 
inhibit T cell proliferation [59, 60]. Thus, lower expression of CD80 on stimulating MoDC may 
also contribute to greater T cell allogeneic responses. This suggests that IDO was the molecule 
partly involved in the CI mechanism of down-regulation of allogeneic-responses by PTEC-
MoDC. Collectively, all these results suggest that autologous PTEC skew MoDC towards a less 
mature phenotype and function through complex CD and CI mechanisms which are mediated by 
various immuno-regulatory molecules including sHLA-G, PD-L1 and IDO. 
 Our group has also reported that autologous PTEC down-regulate the proliferation of 
CD4
+
 T cells [45]. The mechanism and the molecules involved in this down-regulation were 
studied in similar CD and CI culture systems and blocking experiments. These results are 
presented in the following chapter.  
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Chapter 6: The effect of autologous PTEC on 
CD4
+
 T cell function 
6.1. Introduction 
Kidney disease is often characterised by the infiltration of mononuclear leukocytes into the 
renal interstitium [271], with PTEC thought to mediate this disease process in various human 
kidney diseases [272]. Our results from previous chapters indicate that under an inflammatory 
micro-environment, autologous PTEC regulate preformed BDC and MoDC phenotype and 
function via the expression of surface bound, soluble or intracellular immuno-regulatory 
molecules. In addition, our lab has previously published that autologous PTEC down-regulate 
CD4
+
 T cell responses [45]. As discussed in the literature review, T cells are a population of 
immune cells that form a major part of adaptive immune response and defend the host body 
against foreign antigens. Naive T cells generally require 3 signals for full activation [179]. The 
first signal is provided by the presentation of the MHC-peptide complex (cellular fragments of an 
antigen bound to an MHC molecule) on the surface of an AgPC which is recognised by the TCR 
complex on a responding T cell. Signal 2 is the interaction of co-stimulatory ligands CD80 and 
CD86 on AgPC with their receptor CD28 on T cells, thereby inducing T cell responses [54]. In 
addition, CD80 and CD86 bind with high affinity and avidity with CTLA-4 [56], inhibiting the T 
cell responses [59]. However, the expression of CD28 or CTLA-4 T cells depends on the 
stimulating factors from the surrounding micro-environment [56]. Finally, signal 3 is given by 
cytokines secreted by AgPC which drive the T cell subset pathway [37, 38]. The roles of T cells 
in various kidney diseases and PTEC in modulating T cell function under these disease 
conditions are discussed within the literature review. This chapter extends work from our 
previous publication [45] by identifying the mechanisms through which autologous PTEC down-
regulate CD4
+
 T cell responses. As an initial step, whether this down-regulation occurs through 
the expression of surface antigens or by soluble factors is identified by establishing CD or CI 
culture systems. Subsequently, the molecules participating in these mechanisms are investigated 
by blocking experiments. 
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6.2. Hypothesis 
The primary objective of this chapter was to study the influence of IFN-γ activated 
autologous PTEC on the function of CD4
+
 T cells.  We hypothesised that autologous PTEC 
down-regulate CD4
+
 T cells function via specific contact-dependent or contact-independent 
mechanisms 
6.3. Aims 
 To identify whether autologous PTEC regulate CD4+ T cell phenotype and function 
through CD or CI mechanisms.  
 To identify the immuno-regulatory molecules participating in these CD or CI 
mechanisms.  
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6.4. Experimental design 
 
The CD4+ T cells (lavender box) were cultured in the absence (Ctrl-T cells) or presence (PTEC-T cells) of IFN-γ activated autologous PTEC for 
3 days in a contact dependent culture system (yellow box) and contact independent culture system (sky blue box). To identify the 
regulatory mechanisms of autologous PTEC on CD4+ T cells, blocking experiments (green box) were performed. In these experiments, the 
PD-L1 expressed on the surface of autologous PTEC was blocked prior to co-culture with CD4+ T cells. The IDO activity of autologous PTEC 
was inhibited by supplementing the autologous PTEC-T cell co-cultures with IDO inhibitor 1-MT. Following 3 days of co-culture, readouts 
such as phenotype analysis, cytokine profiling and proliferation were obtained. 
Figure 6.1. Experimental design to identify the mechanisms of IFN-γ activated autologous PTEC regulating CD4+ T cell phenotype and 
function.  
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6.5. Results 
6.5.1. Autologous PTEC down-regulate CD4+ T cell proliferation through CD 
mechanisms 
Our laboratory has previously published that autologous PTEC down-regulate CD4
+
 T cell 
proliferation when the latter are stimulated with PHA or anti-CD3/28 [45]. In this PhD project, 
the mechanisms behind this down-regulation were investigated. In this process, CD4
+
 T cells 
were cultured in the absence (Ctrl-T cells) or presence (PTEC-T cells) of IFN-γ activated 
autologous PTEC in a CD or CI culture system. The results demonstrate that autologous PTEC 
significantly down-regulate CD4
+
 T cell proliferation when stimulated with PHA (p=0.03) 
(Figure 6.2 A) or anti-CD3/28 (p=0.03) (Figure 6.2 B) in a CD culture system. However, in CI 
culture systems, when contact between the 2 cell populations was prevented, the significance of 
these results was lost (Figure 6.2 A and B). These results suggest that autologous PTEC down-
regulated CD4
+
 T cell proliferation through CD mechanisms. 
  
Proliferation of CD4+ T cells 
cultured in the absence (Ctrl-T cells) 
or presence (PTEC-T cells) of IFN-γ 
activated autologous PTEC in CD or 
CI culture systems stimulated with 
(A) PHA or (B) anti-CD3/28. The bar 
graph represents the mean values 
for 6 donors and the line graph 
shows 6 individual donors. The 
proliferation results are 
represented as counts per minute 
(CPM). Statistical comparisons 
between the two groups were done 
using a two-tailed Wilcoxon signed 
rank test. 
Figure 6.2. CD4+ T cell proliferation 
assay in contact dependent (CD) 
or contact independent (CI) 
culture systems. 
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6.5.2. Autologous PTEC regulate the expression of activation markers CD25 
and CD69 on activated CD4
+
 T cells 
To determine the effect of autologous PTEC on the expression of activation markers, Ctrl- 
and PTEC-T cells from both CD and CI culture systems were stained for surface expression of 
CD25 and CD69. The results demonstrate that PTEC-T cells from the CD culture system 
expressed elevated levels of CD25 (Figure 6.3 A) and significantly elevated levels of CD69 
(Figure 6.3 B) when stimulated with PHA. This elevated antigen expression on PTEC-T cells 
was, however, absent in response to PHA in the CI culture system. Levels of surface antigen 
expression in response to anti-CD3/28 were more variable, with little difference in expression of 
The expression of activation markers (A) CD25 and (B) CD69 by Ctrl- and PTEC-T cells from CD and 
CI culture systems in response to PHA and anti-CD3/28 stimulation. The bar graphs represent the 
mean of five to six donors and the line graphs shows individual donors. The results are represented 
as percentage of cells expressing CD25 or CD69. Statistical comparisons between the two groups 
were done using a two-tailed Wilcoxon signed rank test. 
  
Figure 6.3. Percentage of CD4+ T cells in CD and CI culture system expressing CD25 and CD69. 
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CD25 between Ctrl-T cells and PTEC-T cells in either culture system (Figure 6.3 A). However, a 
strong trend for increased levels of CD69 on PTEC-T cells in response to anti-CD3/28 was 
observed in both the CD (4 out of 5 donors expressing higher levels) and CI (3 out of 5 donors) 
culture systems (Figure 6.3 B).  
6.5.3. Autologous PTEC regulate the cytokine profile of CD4+ T cells through 
both CD and CI mechanisms  
In the previous publication from our lab [45], it was demonstrated that T cells produced 
high levels of cytokines in response to stimulation with anti-CD3/28 when compared to PHA 
stimulation. Therefore, the cytokine profiles investigated in this study were obtained from Ctrl- 
and PTEC-T cells stimulated with anti-CD3/28. The results demonstrate that PTEC-T cells from 
Ctrl- and PTEC-T cells stimulated with anti-CD3/28 and cultured in CD and CI culture system for 3 
days. The supernatants were then harvested and analysed for (A) IFN-γ, (B) IL-2, (C) IL-10, (D) IL-4 
and (E) TNF-α using CBA. The bar graphs represent means of five donors and line graphs show 
individual donors. Statistical comparisons between the two groups were done using a two-tailed 
Wilcoxon signed rank test. 
 
Figure 6.4. Cytokine profile of Ctrl-T cells and PTEC-T cells from both CD and CI cultures. 
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the majority of donors produced lower levels of IFN-γ, IL-10 and TNF-α and higher levels of IL-
2 and IL-4 when compared with Ctrl-T cells from CD culture systems (Figure 6.4). Similar 
trends were observed for all cytokines in CI culture systems, except for IL-10 which showed 
elevated secretion by PTEC-T cells in three out of five donors. These results strongly suggest 
that autologous PTEC regulate IL-10 expression by CD4
+
 T cells by expressing both surface 
antigens (CD) and soluble factors (CI) and regulate secretion of IFN-γ, TNF-α, IL-2 and IL-4 by 
CD4
+
 T cells by secreting soluble factors (CI) alone. 
6.5.4. PD-L1 and IDO expressed by autologous PTEC play only a minor role 
in down-regulating CD4
+
 T cell proliferation  
To identify the PTEC-derived molecules participating in the down-regulation of 
autologous CD4
+
 T cell responses, PD-L1 and IDO were blocked on PTEC. The results 
demonstrate that blocking PD-L1 played only a minor role in regulating CD4
+
 T cell 
proliferation where one out of four donors and two out of four donors showed minor restoration 
of proliferation when the CD4
+
 T cells were stimulated with PHA and anti-CD3/28 respectively 
(Figure 6.5 A and B). Likewise, inhibiting IDO activity also had a minor role in regulating CD4
+
 
T cell proliferation where two out of four donors showed minor restoration of proliferation when 
CD4
+
 T cells were stimulated with PHA and three out of five donors showed minor restoration of 
proliferation when CD4
+
 T cells were stimulated with anti-CD3/28 (Figure 6.5 C and D). 
Furthermore, inhibiting IDO activity and blocking PD-L1 together of autologous PTEC 
demonstrate insignificant restoration of CD4
+
 T cell proliferation (Figure 6.5 E) suggesting that 
PD-L1 and IDO play only a minor role in regulating the proliferative responses of activated 
CD4
+
 T cells. 
6.5.5. PD-L1 and IDO expressed by autologous PTEC regulate the cytokine 
profiles of CD4
+
 T cells  
To investigate the effect of PD-L1 and IDO blocking on the cytokines profile of CD4
+
 T 
cells, the supernatants from anti-CD3/28 stimulated Ctrl- and PTEC-T cells were analysed using 
CBA technology. The results demonstrate that blocking PD-L1 or IDO had no effect on TNF-α 
secretion by CD4
+
 T cells (Figure 6.6 A and B). However, blocking PD-L1 on autologous PTEC 
partly restored IL-10 secretion by CD4
+
 T cells in all three donors (Figure 6.6 C), whilst 
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Co-cultures of anti-CD3/28 stimulated CD4+ T cells and IDO inhibited or PD-L1 
blocked autologous PTEC for cytokine analysis using CBA. The supernatants were 
harvested following 3 days of co-culture and analysed for TNF-α, IL-10 and IL-4 when 
PD-L1 (A, C and E) or IDO (B, D and F) were inhibited on autologous PTEC. The bar 
graphs represent mean values for three donors and the line graphs shows individual 
donors. The CBA analysis of supernatants from blocking experiments was performed 
by Ms. Sadia Afrin.  
 
Figure 6.6. Effect of PD-L1 and IDO blocking on CD4+ T cell cytokine profiles. 
Co-cultures of (A) PHA stimulated CD4+ T cells and PD-L1 blocked autologous 
PTEC, (B) anti-CD3/28 stimulated CD4+ T cells and PD-L1 blocked autologous 
PTEC, (C) PHA stimulated CD4+ T cells and IDO inhibited autologous PTEC, (D) 
anti-CD3/28 stimulated CD4+ T cells and IDO inhibited autologous PTEC and (E) 
anti-CD3/28 stimulated CD4+ T cells and both PD-L1 and IDO blocked autologous 
PTEC. The bar graphs represent the mean values for four to five donors and line 
graphs show individual donors. Proliferation was measured by 3[H]-thymidine 
incorporation and expressed as counts per minute (CPM) after 3 days. 
Figure 6.5. Effect of PD-L1 and IDO blocking on CD4+ T cell proliferation. 
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inhibiting IDO activity prevented CD4
+
 T cells producing elevated level of IL-4 in two out of 
three donors (Figure 6.6 F).  
6.6.   Discussion 
Our lab has previously published that autologous PTEC down-regulate CD4
+
 T cell 
responses [45]. In this study the mechanisms behind this down-regulation were investigated by 
establishing CD and CI culture systems to identify whether the down-regulation was mediated by 
the interactions of surface molecules expressed on autologous PTEC and CD4
+
 T cells or 
mediated by soluble factors secreted by autologous PTEC. The results suggest that autologous 
PTEC down-regulate CD4
+
 T cell proliferation primarily through a CD mechanism (Table 6.1). 
Blocking experiments were performed to further identify the role of PD-L1 in these CD 
mechanisms. Previous studies have shown that the interaction of PD-L1 with its ligand PD-1 
provides an inhibitory signal to T and B cells [69, 76]. In addition, our previous research has 
demonstrated a partial role for PD-L1 in inhibiting T cell proliferation [45]. The results from the 
present study showed insignificant restoration of CD4
+
 T cell proliferation following PD-L1 
blocking. Based on this, we propose that PD-L1 may not always provide inhibitory signals. 
Supporting this observation, other research has suggested that PD-L1 may provide positive 
signals via an interaction with an unknown receptor on the cytoplasmic portion of the PD-1 
receptor itself [273, 274]. Other explanations for the observed lack of a PD-L1 effect on T cell 
proliferation within this study could include variations in PD-1 expression on responding T cells, 
the genetic variability of this cohort of donors compared to our previous cohort and finally a 
technical problem with the antibody blocking studies.   
Despite autologous PTEC suppressing CD4
+
 T cell proliferation through a CD mechanism, 
IDO blocking also demonstrated a minor restoration of CD4
+
 T cell proliferation, suggesting that 
“IDO-mediated-CD-mechanism” were involved in down-regulating CD4+ T cell responses.  
Collectively, these results suggest that PD-L1 or IDO up-regulated on autologous PTEC 
played only a minor role in the CD mechanism mediating suppression of CD4
+
 T cell responses. 
Our lab anticipates investigating the role of other regulatory molecules expressed by autologous 
PTEC such as sHLA-g, PD-L2 or CD40 in modulating CD4
+
 T cell responses as more 
autologous donors become available. 
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Table 6.1. Summary of results showing the mechanisms of autologous PTEC 
regulating CD4+ T cell function  
CD4
+
 T cell molecules 
Mechanisms of autologous PTEC 
regulating CD4
+
 T cell molecules 
Proliferation CD (both PD-L1 and IDO play a minor role) 
CD25 CD 
CD69 CD 
IFN-γ CI 
IL-2 CI 
TNF-α CI 
IL-10 CD/CI (partly mediated by PD-L1) 
IL-4 CI (partly mediated by IDO) 
 
Our previous observation showed, in addition to their low proliferation rate, elevated levels 
of activation markers CD25 and CD69 being expressed on PTEC-T cells [45]. In this chapter, the 
mechanism/s by which autologous PTEC regulate the expression of these molecules was 
investigated through CD and CI culture systems. Our results suggest that autologous PTEC 
modulate the expression of CD25 and CD69 on CD4
+
 T cells by expressing surface antigens. 
The molecules participating in these regulatory mechanisms will be investigated as more 
autologous donors become available. 
The overall results of our PTEC-T cell cytokine profiling shows a down-regulation of IFN-
γ, IL-10 and TNF-α and up-regulation of IL-2 and IL-4. These results are partly in line with our 
previously published data [45], except for IL-2, which was elevated in the cohort of donors used 
in this present study. The CD and CI experiments suggest that autologous PTEC regulate the 
CD4
+
 T cell cytokine IFN-γ, IL-2, TNF-α and IL-4 by CI mechanisms alone and IL-10 by both 
CD and CI mechanisms. These results indicate that autologous PTEC modulate CD4
+ 
T cell 
cytokine secretion by a complex interaction of both soluble factors and surface antigens. 
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Although PD-L1 and IDO had no effect on PTEC-T cell proliferation, the cytokine profiles 
of PTEC-T cells were partly regulated by the expression of PD-L1 and the activity of IDO 
produced by autologous PTEC (Table 6.1). Blocking PD-L1 partly restored the IL-10 levels 
secreted by PTEC-T cells, suggesting that PTEC-expressed PD-L1 was the regulatory molecule 
participating in the suppression of IL-10 production by CD4
+
 T cells. To identify the molecule 
participating in the CI regulation of IL-10 secretion by CD4
+
 T cells, IDO activity was also 
inhibited in autologous PTEC. This did not restore the levels of IL-10 expressed by PTEC-T 
cells, indicating that IDO was not the molecule mediating this CI regulation. Interestingly, 
inhibiting IDO activity resulted in similar levels of IL-4 expressed by both Ctrl- and PTEC-T 
cells. This suggests that PTEC-expressed IDO was responsible for mediating the CI regulation of 
IL-4 expression by CD4
+
 T cells. The analysis of Th1 cytokine IFN-γ from blocking studies will 
be performed as more autologous donors become available.  
Collectively, the results of this chapter (Table 6.1) show that autologous PTEC down-
regulate CD4
+
 T cell responses through CD mechanisms and the cytokine profile of CD4
+
 T cells 
by both CD and CI mechanisms. The regulatory molecules IDO and PD-L1 of autologous PTEC 
play only a minor role in regulating these functions of CD4
+
 T cells.  The next chapter will 
continue this research in identifying the mechanisms of autologous PTEC regulation of B cell 
antibody secretion and the molecules mediating these mechanisms.  
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Chapter 7: The effect of autologous PTEC on B 
cell function 
7.1. Introduction 
B lymphocytes form an important component of the humoral immune system and one of 
the main functions of these cells is to produce immunoglobulin. The development of B cells 
begins in the bone marrow with the differentiation of precursor-B-cells into immature B cells. 
These immature B cells are broadly classified into non-classical B-1 B cells and classical B-2 B 
cells. These immature B cells migrate into the secondary lymphoid organs where they are 
activated following interactions with specific antigens. The activation of these immature B cells 
occurs via two different mechanisms. The classical B-2 B cells are activated via a T cell 
dependent pathway. Briefly, a B-2 B cell recognises an antigen through its surface expressed 
BCR, internalises the antigen, processes the antigen and forms a complex with MHC-II for 
presentation to responding T cells [165]. The activation of non-classical B-1 B cells is via a T 
cell independent pathway, where the B cell recognises antigen like polysaccharides and lipids 
independently of the BCR [163]. Antigen signalling through surface and intracellular receptors, 
including TLR, plays a prominent role in activating B cells through T cell independent 
mechanisms [275]. The activation of immature B cells differentiates them into either antibody 
producing plasma cells or memory B cells.  
Various studies have shown that B cells play a prominent role in various disease 
conditions. For instance, impairment in the activation process of B cells has shown to contribute 
towards auto-immune disorders and hypersensitivity. The role of B cells in various kidney 
diseases has been previously discussed in the literature review of this Thesis (B cells and kidney 
disease). In all these disease settings, the existence of B cells in the tubulointerstitium places 
them in close proximity to receive signals from perturbed PTEC [276]. Our lab has previously 
published that autologous PTEC down-regulate autologous B cell proliferative responses [45]. In 
this current PhD study, the effect of autologous PTEC on B cell phenotype and functions, 
including antibody production and cytokine secretion, were investigated. Furthermore, the 
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mechanisms of autologous PTEC regulation of B cell functions are identified utilising CD or CI 
culture system. Furthermore, the molecules participating in these mechanisms are identified 
utilising neutralising antibodies or inhibitors.    
7.2. Hypothesis 
The primary objective of this chapter was to study the influence of IFN-γ activated 
autologous PTEC on the function of CD19
+
 B cells.  We hypothesised that autologous PTEC 
down-regulate CD19
+
 B cell function. 
7.3. Aims 
The specific aims of this chapter are: 
 To study the effect of IFN-γ activated autologous PTEC on CD19+ B cell function 
including proliferation and antibody production.  
 To identify whether IFN-γ activated autologous PTEC regulate CD19+ B cell 
function through CD or CI mechanisms.  
 To identify the molecules participating in these CD or CI mechanisms.  
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7.4. Experimental design 
The CD19+ B cells (light orange box) were cultured in the absence (Ctrl-T cells) or presence (PTEC-T cells) of IFN-γ activated autologous 
PTEC for 3 days in a contact dependent culture system (yellow box) and contact independent culture system (sky blue box). To identify the 
regulatory mechanisms of autologous PTEC on CD19+ B cells, blocking experiments (green box) were performed. In these experiments, the 
PD-L1 expressed on the surface of autologous PTEC was blocked prior to co-culture with CD19+ B cells. The IDO activity and sHLA-G of 
autologous PTEC was inhibited by supplementing the autologous PTEC-B cell co-cultures with IDO inhibitor 1-MT and blocking antibody 
for sHLA-G. Following 3 days of co-culture, readouts such as number of cells producing antibody, phenotype analysis, cytokine profiling 
and proliferation were obtained. 
Figure 7.1. Experimental design to identify the mechanisms of IFN-γ activated autologous PTEC regulating CD19+ B cell phenotype and 
function. 
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7.5. Results 
7.5.1. Purity of autologous B cells 
Autologous CD19
+
 B cells were purified from PBMC obtained from the whole blood of 
PTEC donors using a commercially available immuno-magnetic selection kit (section 2.3.2). The 
mean purity of CD19
+
 B cells from 13 donors was 93.5% ± 3.3% SD. The purity of the isolated 
CD19
+
 B cells was determined by the surface expression of CD20 and absence of CD3 
(represents T cells) and CD14 (represents monocytes) antigens (Figure 7.2), which were 
determined using flow cytometry.  
7.5.2. Autologous PTEC inhibit the proliferative responses of activated B cells 
Our Lab has previously shown that poke weed mitogen (PWM) or surface bound IgM 
stimulated CD19
+
 B cells demonstrate a lower proliferation rate when cultured in the presence of 
IFN-γ activated autologous PTEC compared to control cultured B cells [45]. In the present study, 
using a different cohort of donors, it was demonstrated that activated PTEC significantly down-
Gated on live single cells, the first plot represents B cells defined as CD20+ and CD3– cells and the 
second plot represents B cells defined as CD20+ and CD14- cells. The dot plots are representative of 
a single experiment. 
 
Figure 7.2. Purification of autologous B cells. 
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regulated PWM stimulated B cell proliferative responses (Figure 7.3 A). In addition, when B 
cells were activated with a cocktail of imidazoquinoline compound R848 and recombinant IL-2 
(rhIL-2) and cultured in the presence of autologous PTEC, down-regulation was observed in five 
out of seven donors. These findings suggest that autologous PTEC down-regulate B cell 
responses independent of their activation stimuli.       
7.5.3. Autologous PTEC prevent the shift of naive B cells towards a blast cell 
phenotype 
To determine whether autologous PTEC regulate the phenotype of activated B cells, the 
expression of activation cell marker CD38 and blast cell marker CD27 were analysed using flow 
cytometry. Compared to Ctrl-B cells, the expression of CD38 was up-regulated on PTEC-B cells 
in all donors when activated with PWM or R848/rhIL-2 cocktail. However, the expression of 
CD27 was down-regulated on PTEC-B cells in three out of four donors when stimulated with 
PWM and in all donors when stimulated with R848/rhIL-2. These results suggest that autologous 
PTEC prevent the shift of B cells towards a blast cell phenotype. 
Purified B cells were cultured in the absence (Ctrl-B cells) or presence (PTEC-B cells) of IFN-γ 
activated autologous PTEC and stimulated with poke weed mitogen (PWM) (50 µg/mL) (A) or a 
combination of imidazoquinoline compound R848 (1 µg/mL) and recombinant IL-2 (10 ng/mL) (B) 
for 3 days. Proliferation was measured by adding 5 µCi/mL 3H-Thymidine in the Ctrl- and PTEC-B 
cells co-culture for the last 8 hours. The results are represented as counts per minute (CPM). The 
bar graphs represent the means of seven donors and the line graphs shows individual donors. 
Statistical comparisons between the two groups were performed using a two-tailed Wilcoxon 
signed rank test.  
Figure 7.3. Activated PTEC down-regulate autologous CD19+ B cell proliferative responses. 
112 
 
 
7.5.4. Autologous PTEC regulate B cells cytokine profile 
B regulatory cells are defined by the expression of anti-inflammatory cytokine IL-10 [277, 
278]. However, Cherukuri et al have shown that human B regulatory cells can also secrete pro-
inflammatory cytokine TNF-α in addition to IL-10. Therefore, the authors suggested that the 
actual ratio of IL-10/TNF-α would represent a better indicator of B regulatory cell function 
Figure 7.4. Autologous PTEC skew naive B cells towards a regulatory cell phenotype. 
The expression of surface antigens - activation marker CD38 (A and B) and blast cell marker CD27 (C 
and D) on Ctrl- and PTEC-B cells when stimulated with PWM (50 µg/mL) or an R848 (1 µg/mL) /rhIL-
2 (10 ng/mL) cocktail for three days. The results are represented as percentage of cells expressing 
CD38 or CD27. The bar graphs represent the means of four donors and the line graphs show 
individual donors.   
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[279]. In the present study, to determine whether autologous PTEC modulate B cell cytokine 
profiles, the supernatants from Ctrl- and PTEC-B cell cultures were analysed for the expression 
of IL-10, TNF-α and IL-1β using CBA technology. The results were presented as the ratio of IL-
10/TNF-α, indicating whether autologous PTEC skew naive B cell towards a functionally active 
B regulatory cell type. The PWM activated PTEC-B cells had significantly lower IL-10/TNF-α 
ratios (p=0.03) when compared with Ctrl-B cells (Figure 7.5 A). When activated with 
Figure 7.5. Autologous PTEC modulate B cells cytokine profile. 
Purified B cells were cultured in the absence (Ctrl-B cells) or presence (PTEC-B cells) of IFN-γ 
activated autologous PTEC and stimulated with PWM (50 µg/mL) or R848 (1 µg/mL)/rhIL-2 (10 
ng/mL) cocktail. Supernatants were harvested and the cytokines IL-10, TNF-α and IL-1β were 
quantified using a CBA kit. The results are presented as the ratio of IL-10/TNF-α (A and B) and pg/mL 
for IL-1β (C and D). The bar graphs represent the means of four to five donors and the line graphs 
represent individual donors. Statistical comparisons between the two groups were performed using 
a two-tailed Wilcoxon signed rank test. 
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R848/rhIL-2, higher IL-10/TNF-α ratios were observed in PTEC-B cells from five out of eight 
donors (Figure 7.5 B). These results suggest that PTEC may skew B cell cytokine profiles along 
different pathways dependent upon the activation stimulus. However, the overall results suggest 
that autologous PTEC do not skew naive B cells towards a functionally active B regulatory cell. 
Compared to Ctrl-B cells, the expression of IL-1β was elevated in PTEC-B cells stimulated with 
PWM or R848/rhIL-2 in the majority of donors (Figure 7.5 C and D).      
7.5.5. Autologous PTEC down-regulate the number of B cells producing 
antibody 
The lower expression of blast cell marker CD27 on PTEC-B cells lead us to examine their 
capacity for antibody production. The number of B cells producing total IgG or IgM was 
measured using an ELISPOT assay. Compared to Ctrl-B cells, there was a significant reduction 
Purified B cells were 
cultured in the absence 
(Ctrl-B cells) or presence 
(PTEC-B cells) of IFN-γ 
activated autologous PTEC 
and stimulated with PWM 
(50 µg/mL) or R848 (1 
µg/mL)/rhIL-2 (10 ng/mL) 
cocktail. The number of Ctrl- 
and PTEC-B cells secreting 
total IgG (A and B) or IgM (C 
and D) was determined 
using an ELISPOT assay. 
Each spot developed 
represents an individual cell 
producing IgG or IgM. The 
bar graphs represent the 
means of six donors and the 
line graphs represent 
individual donors. Statistical 
comparisons between the 
two groups were performed 
using a two-tailed Wilcoxon 
signed rank test. 
Figure 7.6. Autologous PTEC 
down-regulate the number 
of B cells producing total 
IgG or IgM. 
115 
 
in the number of PTEC-B cells producing total IgG (Figure 7.6 A and B) and IgM (Figure 7.6 C 
and D) upon stimulation with PWM (p=0.03) or R484/rhIL-2 (p=0.03). These results 
demonstrate, for the first time, that autologous PTEC regulate the antibody producing function of 
B cells. 
7.5.6. Autologous PTEC down-regulate the quantity of soluble IgG or IgM 
produced by B cells 
To determine whether autologous PTEC regulate the quantity of IgG or IgM secreted by 
activated B cells, supernatants from Ctrl- and PTEC-B cells were harvested and the total amount 
of soluble IgG or IgM was determined using CBA technology. IgG levels were lower in PTEC-B 
cells in three out of four donors when stimulated with PWM and in five out of five donors when 
simulated with R848/rhIL-2 (Figure 7.7 A and B). IgM levels were also reduced in PTEC-B cells 
in all donors when stimulated with PWM and in three out of five donors when stimulated with 
R848/rhIL-2 (Figure 7.7 C and D). Overall, the results support our findings described above 
where activated autologous PTEC decrease the actual number of B cells producing antibody, 
Purified B cells were cultured 
in the absence (Ctrl-B cells) or 
presence (PTEC-B cells) of 
IFN-γ activated autologous 
PTEC and stimulated with 
PWM (50 µg/mL) or R848 (1 
µg/mL)/rhIL-2 (10 ng/mL) 
cocktail. Supernatants were 
harvested and soluble IgG (A 
and B) or IgM (C and D) was 
quantified using CBA 
technology. The bar graphs 
represent the means of four 
to five donors and the line 
graphs represent individual 
donors. 
Figure 7.7. Autologous PTEC 
suppress the quantity of IgG or 
IgM secreted by B cells. 
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resulting in less antibody overall in these cultures.  
7.5.7. Autologous PTEC down-regulate the number of B cells secreting total 
IgG or IgM through a contact dependent mechanism 
To determine the mechanism/s of how autologous PTEC suppress the number of B cells 
producing total IgG or IgM, activated B cells were co-cultured with autologous PTEC in CD and 
CI culture systems. Following 3 days of culture, the number of cells producing total IgG or IgM 
Purified B cells were cultured 
in contact dependent (CD) or 
contact independent (CI) 
systems in the absence (Ctrl-
B cells) or presence (PTEC-B 
cells) of IFN-γ activated 
autologous PTEC and 
stimulated with PWM (50 
µg/mL) or R848 (1 
µg/mL)/rhIL-2 (10 ng/mL). 
The number of Ctrl- and 
PTEC-B cells from the CD 
culture system secreting total 
IgG (A and B) or IgM (C and D) 
and from the CI culture 
system secreting total IgG (E 
and F) or IgM (G and H) was 
determined using an ELISPOT 
assay. Each spot developed 
represents an individual cell 
producing IgG or IgM. The bar 
graphs represent the means 
of three donors and the line 
graphs represent individual 
donors. 
Figure 7.8. Autologous PTEC 
suppress the number of B 
cells secreting IgG or IgM 
through contact dependent 
mechanisms. 
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was identified using an ELISPOT assay. The number of PTEC-B cells secreting total IgG 
(Figure 7.8 A and B) or IgM (Figure 7.8 C and D) when activated with PWM or R848/rhIL-2 
cocktail was considerably less when compared with Ctrl-B cells in our CD culture system. 
However, in the CI culture system, the number of Ctrl-B cells and PTEC-B cells producing IgG 
(Figure 7.8 E and F) or IgM (Figure 7.8 G and H) in response to the two different stimuli was 
overall similar. These results suggest that autologous PTEC down-regulate the number of B cells 
secreting total IgG or IgM through CD mechanism/s.    
7.5.8. PD-L1 expressed on autologous PTEC partly regulates the secretion of 
total IgG and IgM by B cells 
To determine the PTEC-expressed molecule involved in the CD suppression of PTEC-B 
Purified B cells were cultured in the absence (Ctrl-B cells) or presence (PTEC-B cells) of IFN-γ 
activated autologous PTEC and stimulated with PWM (50 µg/mL) or R848 (1 µg/mL)/rhIL-2 (10 
ng/mL). In blocking experiments, anti-PD-L1 (αPD-L1) (10 µg/mL) was added to the monolayer of 
IFN-γ activated autologous PTEC for 3 h prior to co-culture with B cells (PTEC-B cells+αPD-L1). The 
number of Ctrl-B cells, PTEC-B cells and PTEC-B cells+αPD-L1 secreting total IgG (A and B) or IgM (C 
and D) was determined using an ELISPOT assay. Each spot developed represents an individual cell 
producing IgG or IgM. The bar graphs represent the mean values for three to four donors and the 
line graphs represent individual donors. 
 
Figure 7.9. PD-L1 expressed on autologous PTEC partly regulates the secretion of IgG and IgM. 
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cells, PD-L1 on autologous PTEC was blocked prior to the set-up of co-cultures. There was a 
partial restoration in the number of PTEC-B cells from three out of four donors secreting total 
IgG (Figure 7.9 A) and in all donors secreting IgM (Figure 7.9 C) when B cells were stimulated 
with PWM. The majority of donors showed no restoration in IgG or IgM when PTEC-B cells 
were stimulated with R848/rhIL-2 (Figure 7.9 B and D). These results suggest that PD-L1 
expressed on autologous PTEC may be partly involved in the CD mechanism of down-regulating 
the secretion of total IgG and IgM by B cells. 
7.5.9. IDO expressed by autologous PTEC partly regulates the secretion of 
IgM by B cells 
To determine whether an “IDO-mediated-CD-mechanism” was involved in the reduced 
Purified B cells were cultured in the absence (Ctrl-B cells) or presence (PTEC-B cells) of IFN-γ 
activated autologous PTEC and stimulated with PWM (50 µg/mL) or R848 (1 µg/mL)/rhIL-2 (10 
ng/mL) cocktail. In blocking experiments, PTEC-B cell co-cultures were supplemented with IDO 
inhibitor 1-MT (1500 µM/mL) (PTEC-B cells+1-MT). The number of Ctrl-B cells, PTEC-B cells and PTEC-
B cells+1-MT secreting total IgG (A and B) or IgM (C and D) was determined using an ELISPOT assay. 
Each spot developed represents an individual cell producing IgG or IgM. The bar graphs represent the 
mean values for three donors and the line graphs represent individual donors.  
 
 
Figure 7.10. IDO expressed by autologous PTEC partly regulates the secretion of soluble IgM by B 
cells. 
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numbers of PTEC-B cells secreting total IgG or IgM, co-cultures were supplemented with 1-MT 
during the entire culture period to inhibit the IDO activity of IFN-γ activated autologous PTEC. 
Following 48h of culture period, the Ctrl- and PTEC-B cells were harvested and subjected to an 
ELISPOT assay to determine the number of B cells secreting total IgG and IgM. Two out of 
three donors showed a partial restoration in the number of B cells secreting IgM when activated 
with PWM or R848/rhIL-2 (Figure 7.10 C and D). Most donors showed no restoration in the 
number of PTEC-B cells producing total IgG (Figure 7.10 A and B). These results suggest that 
autologous PTEC can, by up-regulating IDO, indirectly modulate the total number of B cells 
secreting IgM. 
7.5.10. sHLA-G expressed by autologous PTEC regulate the secretion of IgM 
by B cells 
To determine whether a “sHLA-G-mediated-CD-mechanism” was involved in the reduced 
Figure 7.11. sHLA-G expressed by autologous PTEC partly inhibits the secretion of soluble IgM 
by B cells. 
Purified B cells were cultured in the absence (Ctrl-B cells) or presence (PTEC-B cells) of IFN-γ 
activated autologous PTEC and stimulated with PWM (50 µg/mL) or R848 (1 µg/mL)/rhIL-2 (10 
ng/mL) cocktail. In blocking experiments, PTEC-B cell co-cultures were supplemented with sHLA-g 
(10 µg/mL) (PTEC-B cells+sHLA-G). The number of Ctrl-B cells, PTEC-B cells and PTEC-B cells+sHLA-
G secreting total IgG (A and B) or IgM (C and D) was determined using an ELISPOT assay. Each spot 
developed represents an individual cell producing IgG or IgM. The bar graphs represent the means 
of three to four donors and the line graphs represent individual donors.  
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numbers of PTEC-B cells secreting total IgG or IgM, co-cultures were supplemented with 
blocking antibody for sHLA-G during the entire culture period. The Ctrl- and PTEC-B cells were 
then harvested and an ELISPOT assay was set-up to identify the number of cells secreting total 
IgG and IgM. In the presence of blocking antibody, two out of four donors and two out of three 
donors showed partial restoration in the number of PTEC-B cells producing IgM when activated 
with PWM and R848/rhIL-2 respectively (Figure 7.11 C and D). No restoration was observed in 
the number of PTEC-B cells producing IgG when compared with Ctrl-B cells (Figure 7.11 A and 
B). These results suggest that autologous PTEC can, by up-regulating sHLA-G, indirectly 
regulate the total number of B cells secreting IgM. 
7.6. Discussion 
In this chapter, the mechanisms by which autologous PTEC regulate CD19
+
 B cell function 
were investigated. To achieve this, CD19
+
 B cells were co-cultured with IFN-γ activated 
autologous PTEC and stimulated with PWM or a cocktail of R848/rhIL-2. Previous studies have 
shown that PWM effectively activates B cells as demonstrated by elevated levels of B cell 
proliferation and immunoglobulin secretion [280, 281]. However, the mechanism of PWM 
activation remains unclear. Bekeredjian-Ding et al [282] have suggested that contaminating 
TLR-stimulating-molecules in the commercially available PWM are the potential substances that 
activate naive B cells. They further suggest that these contaminating TLR-stimulating-molecules 
could be LPS (ligand for TLR4), lipopeptides from bacterial origin (ligand for TLR2) or 
bacterial DNA (ligand for TLR9). As human B cells do not express TLR4 without initial 
activation [283, 284], the maturation of B cells through PWM stimulation could be a result of 
TLR2 or TLR9 stimulation [282] and even potentially TLR4 stimulation following activation by 
these other TLR.  
R848 is a low molecular weight compound of imidazoquinoline family which activates B 
cells through TLR7 [285] or TLR8 [286]. Bishop et al have demonstrated that the intracellular 
signalling pathway of R848 overlaps with the CD40-CD40L mediated activation of B cells. This 
involves the activation of stress-activated protein kinase and the NF-κB family of transcription 
factors [287]. In the present study, R848 was used in conjunction with recombinant IL-2. IL-2 
has been shown to act as a growth factor for activated B cells, inducing proliferation of B 
121 
 
lymphocytes [288]. Jahnmatz et al have compared different compounds to activate B cells in 
vitro for the purpose of ELISPOT assay and have shown the utilisation of R848 in combination 
with IL-2 as an effective activator [289]. Another study has demonstrated the synergistic role of 
IL-2 when used with R848 in activating the NF-κB family of transcription factors in human NK 
cells [290]. Therefore, in our study, IL-2 may have similarly played a supportive role during B 
cell stimulation with R848. However, this theory has to be confirmed in human B cells. 
The effect of autologous PTEC on B cell proliferation was examined using a 
3
[H]-
thymidine incorporation assay. Our Lab has previously shown that autologous PTEC 
significantly down-regulate B cell proliferation when stimulated with PWM or surface bound 
IgM [45]. In the present study, using a different cohort of donors, it was demonstrated that 
autologous PTEC significantly suppressed B cell proliferation when stimulated with PWM. In 
addition, autologous PTEC also down-regulated proliferation of B cells stimulated with 
R848/rhIL-2 in the majority of donors tested. These results indicate that autologous PTEC 
regulate B cell responses irrespective of the activation stimulus. 
Based on this decreased proliferation, it was hypothesised that autologous PTEC may also 
down-regulate the activation of B cells. However, the phenotypic analysis of PTEC-B cells 
showed elevated levels of activation marker CD38. The correlation between decreased 
proliferation and elevated levels of activation marker is hard to establish, suggesting that the 
observed down-modulation of B cell function possibly involves multiple complex processes. 
 In an attempt to clarify this, the effect of autologous PTEC on the expression of other B 
cell markers including CD27 was investigated. Depending upon the intensity of CD27 
expression, B cells are classified into naive B cells, plasma cells or memory B cells. Naive B 
cells are CD27
-
, memory cells are CD27
+
 and plasma cells are CD27
++
 [291, 292]. Our results 
showed that both PWM and R848/rhIL-2 activated Ctrl-B cells were CD27
++
, suggesting that 
they were plasma cells. However, when B cells were co-cultured in the presence of autologous 
PTEC, the expression of CD27 was considerably down-regulated. This suggests that autologous 
PTEC could prevent the differentiation of B cells towards a plasma cell phenotype.  
In a recently published study involving human volunteers, it was demonstrated that human 
B regulatory cells are CD19
+
 CD24
+
 CD38
+
 and have high IL-10/TNF-α ratios [279]. In line 
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with this publication, the B cells utilised in our study were CD19
+
 and when activated and co-
cultured with autologous PTEC, expressed high levels of CD38. Therefore, it was speculated that 
autologous PTEC may induce the shift of naive B cells towards a functionally active B 
regulatory cell. However, our cytokine analyses showed significantly reduced IL-10/TNF-α 
ratios for PTEC-B cells stimulated with PWM, suggesting that they were not a functionally 
active B regulatory cell, despite a regulatory cell phenotype. Interestingly, when PTEC-B cells 
were stimulated with R848/rhIL-2, elevated IL-10/TNF-α ratios were observed in the majority of 
donors, but this result failed to reach significance. These findings confirm the complexity of 
these interactions, demonstrating that stimuli that signal through different TLR may well be 
modified in a different manner by autologous PTEC. This anomaly will be investigated as more 
autologous donors become available.  
To identify the effect of autologous PTEC on B cell function, the antibody producing 
ability of B cells was investigated. Upon activation of B cells, IgM is the first antibody secreted, 
following which they undergo class switching and secrete different isotypes including IgG and 
IgA. In the present study, due to limited B cell numbers, the regulatory effect of autologous 
PTEC on B cell secretion of IgM and IgG were only investigated. The results demonstrate that 
autologous PTEC significantly decreased the number of B cells secreting total IgG or IgM when 
stimulated with PWM or R848/rhIL-2. Also, the quantity of soluble IgG or IgM secreted by 
these cells was down-regulated. Importantly, this decrease was not due to the lower proliferation 
rate of PTEC-B cells as following 2 days of stimulation-co-culture, B cells were harvested and 
equal cell numbers were seeded in ELISPOT assays. 
 The transwell experiments showed that the decreased numbers of PTEC-B cells secreting 
IgG or IgM were a result of CD regulatory mechanisms. In the process of identifying the 
molecules participating in this mechanism, the immuno-regulatory molecule PD-L1 up-regulated 
on the surface of autologous PTEC was blocked. This resulted in partial restoration of the 
number of PWM-activated PTEC-B cells producing antibody. However, when the B cells were 
activated with TLR7/8 ligand R848, blocking PD-L1 on autologous PTEC did not restore the 
number of antibody secreting B cells. This observation could be attributed to an inverse 
relationship between the TLR mediated activation of B cells and the intensity of PD-1 surface 
expression. For instance, Zhong et al [293] have shown a negative correlation between PD-1 
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expression and TLR mediated activation of murine B cells. It is possible that a similar reaction 
may have occurred in our R848-activated human PTEC-B cells, resulting in decreased 
expression of PD-1, and therefore, non-restoration of the suppressed number of antibody 
producing B cells when PD-L1 was blocked on autologous PTEC. 
Despite the lack of PD-L1/PD-1 R848-initiated interaction between autologous PTEC and 
activated B cells, the decreased number of antibody secreting PTEC-B cells could be the effect 
of undefined immuno-regulatory molecules being up-regulated on autologous PTEC. These 
molecules could be up-regulated on PTEC as an outcome of IFN-γ activation or in response to 
elevated IDO activity or sHLA-G. As hypothesised in chapter 5, IDO activity and sHLA-G may 
result in the expression of un-identified immuno-regulatory molecule/s via autocrine interactions 
with autologous PTEC. These molecules may then down-regulate B cell function through a CD 
mechanism. This hypothesis was experimentally supported via the partial restoration of antibody 
secreting PTEC-B cells during blockade of IDO activity and sHLA-G. Our Lab anticipates 
identifying these PTEC surface molecules as more donors become available. 
 Collectively, the results of this chapter show autologous PTEC down-regulate B cell 
functions including proliferative responses and antibody secretion. The mechanism of this down-
regulation was primarily through cell-to-cell interactions. These interactions were mediated via 
the combined effect of PD-L1 expression on autologous PTEC and undefined regulatory 
molecules up-regulated as a result of IFN-γ activation or elevated IDO activity or sHLA-G 
stimulation. 
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Chapter 8: Conclusion and future directions 
Injuries to the kidney such as proteinuria, hypoxia, toxin exposure or infection lead to 
tubulointerstitial inflammation. Such inflammation is a pre-requisite for remodelling of damaged 
kidney tissue, and may result in resolution with no clinical outcome. However, on-going 
persistent damage to the kidney from these insults, often in association with activation of 
resident and infiltrating immune cells and the release of danger associated molecular patterns 
(DAMP) and other pro-inflammatory factors released by dying kidney cells, can induce long-
lasting sterile inflammatory responses. These responses result in impairment of renal function, 
the development of CKD and eventually ESKD [294, 295]. Various studies have shown that 
impaired renal function associates better with damage to the interstitium irrespective of initial 
injury [7, 296]. Therefore, understanding the reactions occurring between the kidney 
parenchymal cells, primarily PTEC, and immune cells residing in the interstitium, may enable us 
to identify specific pathways to target for early intervention in response to deteriorating kidney 
function. Although neutrophils and macrophages play important roles in inflammatory responses 
and subsequent fibrosis in the kidney, our research is focussed on how PTEC in the interstitium 
modulate T cell, B cell and DC responses, which have been shown to be pivotal in numerous 
clinical and animal models of kidney disease [295, 297, 298].  
As discussed in chapter 1 and in the results chapters of this thesis, PTEC represent major 
players in the kidney disease process, where they are responsible for the recruitment of immune 
cells required for tissue re-modelling in the inflammatory state, and importantly, the control and 
modulation of these immune cells to prevent uncontrolled inflammation. It could be 
hypothesized that when these roles are successful, minor tissue insults and damage are resolved 
with no clinical outcome. However, where this PTEC modulation is insufficient, uncontrolled 
inflammation may result in kidney damage with significant clinical outcomes. In such a scenario 
PTEC themselves could further contribute to the disease process as they become damaged and 
necrotic, providing DAMP to further activate inflammatory DC populations. 
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In the disease state, PTEC within the interstitium, secrete a range of pro-inflammatory factors including RANTES, MCP-1 and IL-8 (1 in 
schematic). These PTEC-derived chemokines and cytokines recruit T/B lymphocytes and DC which secrete pro-inflammatory cytokines such as 
IFN-γ, IFN-α and TNF-α (2). The PTEC as a response to these cytokines up-regulate immuno-regulatory molecules such as MHC-II, sHLA-G, IDO 
and PD-L1 (3). The sHLA-G produced by PTEC interacts directly with MoDC to down-regulate the expression of MHC-II, which is essential for 
the activation of T/B lymphocytes (4). The sHLA-G may also have an autocrine effect on PTEC (5) resulting in the up-regulation of un-identified 
immuno-regulatory molecules (6), which may directly interact with MoDC and B cells to down-modulate their responses. The immuno-
regulatory molecule IDO up-regulated on IFN-γ activated PTEC creates a micro-environment devoid of tryptophan (7). As a response to the 
tryptophan depleted micro-environment, elevated levels of PD-L1 and IL-10 were induced by MoDC. These MoDC were also less effective in 
inducing CD4+ T cell responses (8). The tryptophan–depleted micro-environment may also have an autocrine effect on PTEC (9), resulting in the 
up-regulation of un-identified immuno-regulatory molecules (6 in schematic), which, in turn, interact with MoDC to up-regulate anti-
inflammatory cytokine IL-10 and with B cells to down-regulate their antibody producing function. 
 
 
 
 
 
 
 
 
Figure 8.1. Autologous PTEC regulate the response of T cells, B cells, preformed blood DC and MoDC via the expression of sHLA-G, PD-L1 
and IDO. 
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Perturbed PTEC secrete a range of pro-inflammatory cytokines and chemotactic molecules 
which help to attract immune cells such as DC, T cells and B cells into the interstitium [22, 23, 
299-301]. Recent studies suggest that renal DC are critical players in maintaining the health-
disease equilibrium of the kidney [302], whilst T cells and B cells are well described effector 
cells in immunological renal diseases and are reported to be directly pathological and associated 
with a poor prognosis [173, 196, 207, 295, 303-306]. The majority of these studies indicate that 
these cells migrate and reside in the interstitium of the kidney where they would be ideally 
placed to interact and receive signals from the basolateral sides of PTEC. The objectives of this 
PhD were to identify the mechanisms by which PTEC in the interstitium regulate kidney immune 
cell functions. 
Under healthy homeostatic conditions, there are resident monocytes and DC in the 
interstitium performing normal tissue surveillance functions. In the disease state, the PTEC 
within the interstitium, secrete a range of pro-inflammatory factors (discussed in chapter 1, 
section 1.4), including RANTES (CCL5), MCP-1(CCL2), IFN-γ-induced protein 10 (IP-
10/CXCL10) and IL-8 (CXCL8) (1 in Figure 8.1). These PTEC-derived chemokines and 
cytokines activate the resident immune cells and further recruit T/B lymphocytes and DC via 
their ligands, chemokine receptors CCR1-5, CXCR1 and CXCR3. However our understanding of 
what happens next, i.e. the mechanism of direct cell-cell interactions between PTEC and cells of 
the inflammatory infiltrate in the tubulointerstitium and how immune cell behaviour is 
subsequently modified, is very limited. The work undertaken during my PhD fills this gap by 
identifying some of the mechanisms by which PTEC regulate these immune cell responses and 
control inflammation during the process of tissue repair and regeneration.  
According to the results in chapter 3, despite culturing preformed BDC in a pro-
inflammatory rich environment consisting of IFN-γ activated autologous PTEC, the resultant 
CD1c
+
 BDC were poor allogeneic stimulators and induced weak inflammatory Th1 responses. In 
addition, the results presented in chapter 4 show that when MoDC were differentiated in the 
presence of activated autologous PTEC, they also displayed an immature, tolerogenic phenotype, 
with low levels of antigen presenting molecule MHC-II, low levels of co-stimulatory molecule 
CD86, elevated levels of immuno-regulatory molecule PD-L1, down-regulated expression of the 
pro-inflammatory cytokine TNF-α and elevated levels of anti-inflammatory cytokine IL-10. 
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These MoDC were also weak inducers of allogeneic T cell responses and elevated the expression 
of Treg transcription factor FoxP3 in allogeneic T cell assays.  
Interestingly, PTEC-MoDC also secreted elevated levels of inflammatory cytokine IL-1β. 
As discussed in Chapter 4, we found this result unusual and somewhat counter-intuitive as IL-1β 
and IL-10 have opposing functions. However, due to the observed immature/tolerogenic 
phenotype of PTEC-MoDC and the fact that they were functionally less allogeneic, we speculate 
that the anti-inflammatory IL-10 from these cells predominated in function to negate possible IL-
1β inflammatory effects. The reduced levels of inflammatory cytokine TNF-α and elevated levels 
of anti-inflammatory cytokine IL-10, along with the induction of Treg would be expected to 
assist in protecting the kidney during inflammatory type kidney diseases. For instance, Mu et al 
reported that the injection of a viral vector containing IL-10 into the kidneys of a rat model of 
CKD resulted in improved outcomes in this model. The primary mechanism was identified as the 
down-regulation of the chemokines MCP-1 and RANTES, resulting in lower numbers of 
monocytes and T cells being recruited to the tubulointerstitium [307]. Based on this and our in 
vitro results, we speculate that autologous PTEC stimulate MoDC to secrete elevated levels of 
IL-10 to control the progression of inflammation by dampening the infiltration of immune cells 
into the interstitium. Therefore, up-regulating IL-10 could be a novel therapeutic approach to 
control the progression of inflammation during kidney injury. 
Treg are also shown to be beneficial in various kidney disease models. In a kidney 
reperfusion-injury model, the presence of Treg has been shown to enhance the healing process 
by down-regulating the pro-inflammatory cytokines secreted by other T cell subsets in the 
interstitium [210]. In an adriamycin nephropathy murine model, transfecting CD4
+
 T cells with 
the FoxP3 gene to induce Treg resulted in significantly less tubular damage and interstitial 
infiltrates of immune cells [213]. In an experimental GN mouse model, administration of Treg 
significantly attenuated the development of glomerular damage and decreased the infiltration of 
other immune cells [212]. Collectively, all these studies emphasize the protective role of Treg 
cells against immunological renal injury. In our present study, the ability of MoDC differentiated 
in the presence of autologous PTEC to induce Treg could be an additional mechanism through 
which autologous PTEC suppress on-going inflammation.    
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Our lab has previously published that autologous PTEC down-regulate T and B cell 
responses [45]. The results presented in chapter 6 and 7 are the continuation of this work which 
demonstrate that autologous PTEC down-regulate T and B cell responses through both CD and 
CI mechanisms. Furthermore, my PhD is the first to demonstrate that PTEC cultured in an 
inflammatory micro-environment significantly down-regulate the antibody producing function of 
B cells in the context of an autologous human setting. These findings have major ramifications 
when one considers the importance of inappropriate antibody production by B cells in numerous 
kidney diseases such as immune-complex GN, anti-neutrophil cytoplasmic antibody (ANCA)-
vasculitis, IgA nephropathy and LN. It is becoming clearer that B cells in many of these diseases 
are able to secrete local antibody within the kidney that contributes to immune-complex 
formation and other renal damage. A recent publication by Chang et al [308] examined 
individual B cells from tertiary lymphoid organs within the human LN kidney and reported that 
11 out of 13 of them were secreting antibody to an auto-antigen, vimentin [309]. Our recent work 
[30] has described a significant up-regulation of this protein in human PTEC from diseased 
(including LN) patients, providing a possible link between PTEC having protective properties in 
the earlier stages of the disease process, by down-modulating local antibody production, yet 
contributing to the disease process at later time-points if such protective mechanisms are not 
successful.    
In order to identify mechanisms that are responsible for our observed immune modulation, 
we investigated molecules produced by PTEC within a resting and an IFN-γ induced 
inflammatory environment. These results are presented in our previous lab paper [45] and in 
Chapter 5 and demonstrate that IFN-γ activated PTEC (2 in Figure 8.1) express increased levels 
of MHC-II [45], sHLA-G, IDO and PD-L1 (3 in Figure 8.1), which may enable them to interact 
with immune cells in the context of non-professional AgPC. Based on results from chapters 5, 6 
and 7, we speculate that these molecules are up-regulated on PTEC during the early-phase of 
inflammation in the kidney disease process and participate in dampening this inflammation. 
This current PhD research is the first to investigate the role of sHLA-G, produced by IFN-γ 
activated PTEC, in regulating immune cell function in the context of the autologous human 
setting. Our in vitro studies demonstrate that sHLA-G produced by autologous PTEC can interact 
directly with MoDC and suppresses their surface expression of MHC-II, which is essential for 
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the activation of T and B cell responses in vivo (4 in Figure 8.1). In addition, as suggested by 
some of our transwell experimental results, sHLA-G may have an autocrine effect on PTEC (5 in 
Figure 8.1) and cause the up-regulation of un-identified immuno-regulatory molecule/s which 
may directly interact with MoDC (6 in Figure 8.1) and B cells (6 in Figure 8.1) to secrete 
elevated levels of anti-inflammatory cytokine IL-10 and suppress the number of antibody 
producing plasma cells respectively. The expression of receptors for sHLA-G, particularly 
ILT2/CD85j and ILT4/CD85d, has been demonstrated on MoDC [226], whilst ILT2/CD85j is 
also known to occur on B cells [310], enabling an interaction between these cells and sHLA-G. 
However, the expression of these receptors, or others (CD158d and CD160), enabling an 
autocrine interaction of PTEC with sHLA-G, still remains to be determined. Our lab anticipates 
investigating this further as more donors become available.  
The immuno-suppressive function of sHLA-G was initially identified via its role in 
protecting the foetus from the maternal immune system [80]. Subsequent studies have 
demonstrated a role for this molecule in the protection and maintenance of liver-kidney 
transplants [93, 94, 311]. Studies examining the functional role of sHLA-G within the human 
kidney have been confined almost exclusively to its role in transplantation. In general these 
studies have shown that the expression of sHLA-G by kidney tissue may aid in transplantation 
acceptance by down-regulating the activity of cells that are mainly involved in rejection, such as 
natural killer cells [99] and CD4
+
 T cells [100].  Furthermore, Qui et al [93] correlated high 
levels of sHLA-G in the plasma of kidney transplant patients with low levels of allo-reactive 
antibodies against HLA antigens expressed on the graft tissue. Therefore, it could be 
hypothesised that our observed results of lower MHC-II expression on DC and decreased 
antibody production by B cells, in the presence of autologous PTEC, may also be relevant, 
through a sHLA-G mechanism, to the successful maintenance of transplanted organs.  
PD-L1 is another potential mechanism through which PTEC regulate the responses of 
autologous immune cells within our in vitro setting, and possibly within the kidney interstitium 
itself. Based on the mechanistic data presented in chapters 4 and 5, the elevated PD-L1 on 
MoDC is driven by elevated PD-L1 expressed by autologous PTEC in response to IFN-γ 
activation (3 in Figure 8.1). Although this observation was intriguing, the intracellular signalling 
mechanism leading to elevated levels of PD-L1 on MoDC still remains to be determined. The 
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results presented in chapter 7 shows that PD-L1 also regulates B cell responses by partly down-
regulating the antibody secreting function of B cells.  
The biological significance of PD-L1 expression on PTEC is demonstrated to be beneficial 
during transplantation and various immune-mediated renal diseases. Starke et al showed a 
negative correlation between levels of allograft PD-L1 expression and kidney rejection in a 
human study [76]. Other studies using immuno-histological staining of renal biopsies have 
revealed elevated levels of PD-L1 expressed on PTEC during various immune mediated kidney 
diseases, such as LN, IgA nephropathy and interstitial nephritis, when compared with normal 
tissue [74]. The expression of PD-L1 during these clinical conditions has been considered 
beneficial based on various in vitro observations, which show that PTEC, by up-regulating PD-
L1 expression and functioning as non-professional AgPC, can inhibit T cell responses [75, 76]. 
The results obtained from our present study demonstrate that PTEC, by up-regulating PD-L1, 
also regulate other immune cells (MoDC and B cells). Therefore, based on these results, we 
propose that in the compromised inflamed interstitium, autologous PTEC up-regulate PD-L1, 
which is then able to interact with its ligand PD-1 expressed on DC, B cells and T cells, resulting 
in the dampening of adverse immune reactions.  
  The immuno-regulatory molecule IDO is also up-regulated on activated PTEC and its 
activity is an additional mechanism by which PTEC may down-regulate immune cell responses 
(7 in Figure 8.1). Results presented in chapter 5 demonstrate that IDO produced by activated 
autologous PTEC is partly responsible for the induction of elevated levels of PD-L1 and IL-10 
by MoDC (8 in Figure 8.1). We speculate that these immuno-suppressive MoDC fail to support 
continuing inflammation, and therefore, inhibit the damage caused to the kidney tissue by 
infiltrating pathogenic immune cells. The results presented in chapter 7 show that IDO also 
regulates B cell responses by partly down-regulating the antibody secreting function of PTEC-B 
cells. However, the transwell experiment results presented in chapters 5 and 7 demonstrate that 
autologous PTEC regulate MoDC IL-10 secretion and B cell antibody production by CD 
mechanisms. As IDO activity creates a micro-environment devoid of tryptophan (7 in Figure 
8.1), it would be expected that CI mechanisms would have been observed.  One explanation for 
this observed anomaly is that the tryptophan–depleted micro-environment may have an autocrine 
effect on PTEC (9 in Figure 8.1), resulting in the up-regulation of undefined immuno-regulatory 
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molecules. These molecules may then interact with MoDC and B cells through cell-to-cell 
contact dependent mechanisms, resulting in elevated levels of IL-10 secretion by MoDC (6 in 
Figure 8.1) and suppressed antibody production in B cells (6 in Figure 8.1). Our lab anticipates 
identifying these undefined regulatory molecules expressed on autologous PTEC as more donors 
become available. 
The expression of IDO on kidney PTEC has been shown to be beneficial under various 
pathological conditions. In a mouse model of crescentic GN, IDO expression was up-regulated 
on renal PTEC. Inhibition of IDO activity in this model by 1-MT elevated Th1 responses in the 
kidney interstitium and increased glomerular crescent formation. These findings underline the 
beneficial role of IDO during inflammatory renal diseases [136]. IDO is also shown to be 
beneficial in kidney transplantation. In an acute renal rejection rat model, a recombinant IDO 
gene was transfected into the donor kidney prior to transplantation. The successful expression of 
this IDO gene in the transplanted kidney resulted in the decreased expression of kidney injury 
molecule (KIM-1), elevated levels of Treg cells in the transplanted kidney interstitium and better 
graft acceptance and function [137]. Based on these studies and our in vitro results, we speculate 
that IDO expression in PTEC could be utilised as a target molecule to diagnose or treat various 
kidney pathological conditions. 
To translate our in vitro research work into clinical applicability, we propose that IFN-γ 
could be used as a key molecule as it stimulates the expression of regulatory molecules on PTEC 
which can subsequently modulate further inflammation. A recently published study identified a 
novel strategy to deliver IFN-γ to renal interstitial myofibroblasts in an unilateral ureteral 
obstruction mouse model for the treatment of renal fibrosis [312]. Based on our results, we 
propose that a similar strategy could be beneficial for patients identified with AKD and 
developing CKD where in situ administration of IFN-γ could up-regulate sHLA-G, PD-L1 or 
IDO on PTEC which would then be expected to dampen the on-going inflammation and control 
the damage caused to the kidney tissue.    
All of these results discussed above come with two major caveats, that is, the size and 
genetic variability of the human donors used within this study. Unlike in-bred mice or rats, the 
autologous donors for this research work come from a wide variety of ages and genetic 
backgrounds and consequently their cellular responses are – as would be expected – highly 
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variable. This inherent variability coupled with the relatively low numbers of donors available 
has resulted in a failure to reach significance in many of the experiments undertaken in this 
research project. However, despite this, there are strong trends in many of the experimental 
results supporting the conclusions drawn. In an ideal world, donor numbers should be increased 
by an order of magnitude so that 30-80 donors could be tested within each set of experimental 
parameters instead of the 3-8 donors that were used. Future directions for this project would 
include increasing the number of donors used in an effort to obtain significance. 
Based on the collective results, we hypothesise that the immuno-suppressive mechanisms 
of PTEC, mediated by sHLA-G, PD-L1, IDO or other undefined molecules, suppress the 
ongoing inflammation observed during kidney disease. We further speculate that if this 
inflammatory process is not successfully controlled by PTEC and the inflammation passes a 
certain threshold, progression of renal disease becomes irreversible, leading to CKD. Our recent 
scientific publications, on which I am a co-author, highlight changes in the molecular profiles of 
PTEC [30] and activation status of immune cells [313] isolated from diseased human kidneys. 
By comparing biopsy samples from CKD patients and control samples, we have reported 
alterations in the expression of genes and proteins by PTEC, which represent multiple 
pathological pathways that are associated with markers of the clinical phenotypes of CKD [30]. 
Analysis of these samples has also revealed the co-localisation of PTEC with elevated levels of 
activated mDC in the tubulointerstitium [313], mediated by PTEC-derived fractalkine [314]. 
These DC are a major source of TGF-β, which is one of the principle mediators for the 
development of renal fibrosis [315, 316]. Furthermore, elevated levels of these DC in the 
interstitium were associated with CKD and loss of kidney function [313]. Based on all our 
results, we propose that irrespective of the initial kidney disease etiology, during the early-stages 
of inflammation, PTEC down-regulate infiltrating immune cell responses in an effort to prevent 
uncontrolled damaging inflammation. However, if PTEC fail to maintain such an inflammatory 
equilibrium, uncontrolled inflammation may result in continuing tissue damage, where PTEC 
themselves participate in the disease process via necrosis, the release of DAMP and further 
activation of immune cells. The end result of such uncontrolled damage inevitably leads to the 
development of CKD and potentially ESKD. This PhD provides critical information of the 
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molecules participating in the PTEC immuno-suppressive mechanisms which can be used as 
diagnostic and therapeutic targets in renal medicine. 
 
 
134 
 
Chapter 9: References 
1. Chadban, S.J., et al., Prevalence of kidney damage in Australian adults: The AusDiab kidney 
study. J Am Soc Nephrol, 2003. 14(7 Suppl 2): p. S131-8. 
2. Atkins, R.C., et al., Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney 
Int Suppl, 2004(92): p. S22-4. 
3. Kidney Health Australia. Fast facts on CKD in Australia. 2014 24 September 2014; Available 
from: http://www.kidney.org.au/KidneyDisease/FastFactsonCKD/tabid/589/Default.aspx. 
4. Eric P. Widmaier, Hershel Raff, and K.T. Strang., The Kidney and Regulation of Water and 
Inorganic Ions, in Vander's Human Physiology: The Mechanisms of Body Function. 2006, 
McGraw-Hill: New York. 
5. Rogers, N.M., et al., Review article: Kidney dendritic cells: their role in homeostasis, 
inflammation and transplantation. Nephrology (Carlton), 2009. 14(7): p. 625-35. 
6. Anders, H.J. and M. Ryu, Renal microenvironments and macrophage phenotypes determine 
progression or resolution of renal inflammation and fibrosis. Kidney Int, 2011. 80(9): p. 915-25. 
7. Risdon, R.A., J.C. Sloper, and H.E. De Wardener, Relationship between renal function and 
histological changes found in renal-biopsy specimens from patients with persistent glomerular 
nephritis. Lancet, 1968. 2(7564): p. 363-6. 
8. Cameron, J.S., Clinicopathologic Correlations in Glomerular Disease, in Kidney Disease: 
Present status. 1970. p. 81-84. 
9. Hostetter, T.H., et al., Hyperfiltration in remnant nephrons: a potentially adverse response to 
renal ablation. Am J Physiol, 1981. 241(1): p. F85-93. 
10. Bertani, T., et al., Tubulo-interstitial lesions mediate renal damage in adriamycin 
glomerulopathy. Kidney Int, 1986. 30(4): p. 488-96. 
11. Remuzzi, G., A. Benigni, and A. Remuzzi, Mechanisms of progression and regression of renal 
lesions of chronic nephropathies and diabetes. J Clin Invest, 2006. 116(2): p. 288-96. 
12. Zoja, C., M. Abbate, and G. Remuzzi, Progression of renal injury toward interstitial 
inflammation and glomerular sclerosis is dependent on abnormal protein filtration. Nephrology 
Dialysis Transplantation, 2014: p. gfu261. 
13. Pang, W.W., et al., Human bone marrow hematopoietic stem cells are increased in frequency and 
myeloid-biased with age. Proc Natl Acad Sci U S A, 2011. 108(50): p. 20012-7. 
14. Ratts, R.B. and N.P. Weng, Homeostasis of lymphocytes and monocytes in frequent blood donors. 
Front Immunol, 2012. 3: p. 271. 
135 
 
15. Nyugen, J., et al., Impaired functions of peripheral blood monocyte subpopulations in aged 
humans. J Clin Immunol, 2010. 30(6): p. 806-13. 
16. Seidler, S., et al., Age-dependent alterations of monocyte subsets and monocyte-related 
chemokine pathways in healthy adults. BMC Immunol, 2010. 11: p. 30. 
17. Hearps, A.C., et al., Aging is associated with chronic innate immune activation and dysregulation 
of monocyte phenotype and function. Aging Cell, 2012. 11(5): p. 867-75. 
18. Agrawal, A., et al., Altered innate immune functioning of dendritic cells in elderly humans: a role 
of phosphoinositide 3-kinase-signaling pathway. J Immunol, 2007. 178(11): p. 6912-22. 
19. Sridharan, A., et al., Age-associated impaired plasmacytoid dendritic cell functions lead to 
decreased CD4 and CD8 T cell immunity. Age (Dordr), 2011. 33(3): p. 363-76. 
20. Panda, A., et al., Age-associated decrease in TLR function in primary human dendritic cells 
predicts influenza vaccine response. J Immunol, 2010. 184(5): p. 2518-27. 
21. Schlondorff, D.O., Overview of factors contributing to the pathophysiology of progressive renal 
disease. Kidney Int, 2008. 74(7): p. 860-6. 
22. Zoja, C., A. Benigni, and G. Remuzzi, Cellular responses to protein overload: key event in renal 
disease progression. Curr Opin Nephrol Hypertens, 2004. 13(1): p. 31-7. 
23. Lai, K.N., et al., Interaction between proximal tubular epithelial cells and infiltrating 
monocytes/T cells in the proteinuric state. Kidney Int, 2007. 71(6): p. 526-38. 
24. Wang, Y., et al., Induction of monocyte chemoattractant protein-1 in proximal tubule cells by 
urinary protein. J Am Soc Nephrol, 1997. 8(10): p. 1537-45. 
25. Zoja, C., et al., Protein overload stimulates RANTES production by proximal tubular cells 
depending on NF-kappa B activation. Kidney Int, 1998. 53(6): p. 1608-15. 
26. Tang, S., et al., Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in 
vitro and in vivo. J Clin Invest, 2003. 111(4): p. 515-27. 
27. Rot, A., et al., RANTES and macrophage inflammatory protein 1 alpha induce the migration and 
activation of normal human eosinophil granulocytes. The Journal of experimental medicine, 
1992. 176(6): p. 1489-1495. 
28. Alam, R., et al., RANTES is a chemotactic and activating factor for human eosinophils. The 
Journal of Immunology, 1993. 150(8): p. 3442-3448. 
29. Kuna, P., et al., RANTES induces nasal mucosal inflammation rich in eosinophils, basophils, and 
lymphocytes in vivo. American journal of respiratory and critical care medicine, 1998. 157(3): p. 
873-879. 
30. Wilkinson, R., et al., Laser Capture Microdissection and Multiplex-Tandem PCR Analysis of 
Proximal Tubular Epithelial Cell Signaling in Human Kidney Disease. PloS one, 2014. 9(1): p. 
e87345. 
136 
 
31. Naik, S.H., Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol, 
2008. 86(5): p. 439-52. 
32. Cresswell, P., Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol, 
1994. 12: p. 259-93. 
33. Hanau, D., et al., Fate of MHC class II molecules in human dendritic cells. Eur J Dermatol, 1999. 
9(1): p. 7-12. 
34. Goldberg, A.L., et al., The importance of the proteasome and subsequent proteolytic steps in the 
generation of antigenic peptides. Mol Immunol, 2002. 39(3-4): p. 147-64. 
35. Trombetta, E.S. and I. Mellman, Cell biology of antigen processing in vitro and in vivo. Annu 
Rev Immunol, 2005. 23: p. 975-1028. 
36. Lin, M.L., et al., The cell biology of cross-presentation and the role of dendritic cell subsets. 
Immunol Cell Biol, 2008. 86(4): p. 353-62. 
37. Valenzuela, J., C. Schmidt, and M. Mescher, The roles of IL-12 in providing a third signal for 
clonal expansion of naive CD8 T cells. J Immunol, 2002. 169(12): p. 6842-9. 
38. Tuting, T., et al., Autologous human monocyte-derived dendritic cells genetically modified to 
express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by 
cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol, 
1998. 160(3): p. 1139-47. 
39. Hart, D.N. and J.W. Fabre, Endogenously produced Ia antigens within cells of convoluted tubules 
of rat kidney. J Immunol, 1981. 126(6): p. 2109-13. 
40. Muller, C.A., et al., Expression of HLA-DQ, -DR, and -DP antigens in normal kidney and 
glomerulonephritis. Kidney Int, 1989. 35(1): p. 116-24. 
41. Rubin-Kelley, V. and A. Jevnikar, Antigen presentation by renal tubular epithelial cells. Journal 
of the American Society of Nephrology, 1991. 2(1): p. 13-26. 
42. Shoskes, D.A., N.A. Parfrey, and P.F. Halloran, Increased major histocompatibility complex 
antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation, 
1990. 49(1): p. 201-7. 
43. Wuthrich, R.P., et al., Enhanced MHC class II expression in renal proximal tubules precedes loss 
of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol, 1989. 134(1): p. 45-51. 
44. Hagerty, D.T. and P.M. Allen, Processing and presentation of self and foreign antigens by the 
renal proximal tubule. J Immunol, 1992. 148(8): p. 2324-30. 
45. Wilkinson, R., et al., Activated human renal tubular cells inhibit autologous immune responses. 
Nephrol Dial Transplant, 2010. 
137 
 
46. Starke, A., Wüthrich,R.P., Waeckerle-Men,Y., TGF-Beta Treatment Modulates PD-L1 and CD40 
Expression in Proximal Renal Tubular Epithelial Cells and Enhances CD8 +  Cytotoxic T-Cell 
Responses. Nephron Experimental Nephrology, 2007. 1: p. e22-29. 
47. Hathcock, K.S., et al., Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression 
and function. The Journal of experimental medicine, 1994. 180(2): p. 631-640. 
48. Azuma, M., et al., B70 antigen is a second ligand for CTLA-4 and CD28. Nature, 1993. 
366(6450): p. 76-9. 
49. Freeman, G.J., et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell 
proliferation. Science, 1993. 262(5135): p. 909-11. 
50. Stack, R.M., et al., IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 
and B7-2. J Immunol, 1994. 152(12): p. 5723-33. 
51. Barcy, S., et al., FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. 
Int Immunol, 1995. 7(2): p. 179-89. 
52. Buelens, C., et al., Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) 
expression on human peripheral blood dendritic cells. Eur J Immunol, 1995. 25(9): p. 2668-72. 
53. Willems, F., et al., Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression 
on human monocytes. Eur J Immunol, 1994. 24(4): p. 1007-9. 
54. Harding, F.A., et al., CD28-mediated signalling co-stimulates murine T cells and prevents 
induction of anergy in T-cell clones. Nature, 1992. 356(6370): p. 607-9. 
55. Logue, E.C. and W.C. Sha, CD28-B7 bidirectional signaling: a two-way street to activation. Nat 
Immunol, 2004. 5(11): p. 1103-5. 
56. Collins, A.V., et al., The interaction properties of costimulatory molecules revisited. Immunity, 
2002. 17(2): p. 201-10. 
57. Girard, T., et al., CD80 and CD86 IgC domains are important for quaternary structure, receptor 
binding and co-signaling function. Immunology letters, 2014. 161(1): p. 65-75. 
58. Wülfing, C., H.M. Tunbridge, and D.C. Wraith, New inhibitory signaling by CTLA-4. Nature 
immunology, 2014. 15(5): p. 408-409. 
59. Walker, L.S. and D.M. Sansom, The emerging role of CTLA4 as a cell-extrinsic regulator of T 
cell responses. Nat Rev Immunol, 2011. 11(12): p. 852-63. 
60. Tivol, E.A., et al., CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction 
in CTLA-4-deficient mice. J Immunol, 1997. 158(11): p. 5091-4. 
61. Finger, E.B. and J.A. Bluestone, When ligand becomes receptor--tolerance via B7 signaling on 
DCs. Nat Immunol, 2002. 3(11): p. 1056-7. 
138 
 
62. Niemann-Masanek, U., et al., B7-1 (CD80) and B7-2 (CD 86) expression in human tubular 
epithelial cells in vivo and in vitro. Nephron, 2002. 92(3): p. 542-56. 
63. Singer, G.G., et al., Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells. 
Kidney Int, 1993. 44(5): p. 1030-5. 
64. Yokoyama, H., et al., B7+-transfectant tubular epithelial cells induce T cell anergy, ignorance or 
proliferation. Kidney Int, 1994. 45(4): p. 1105-1112. 
65. De Haij, S., et al., Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-
H1. Kidney Int, 2005. 68(5): p. 2091-2102. 
66. Wahl, P., et al., Renal tubular epithelial expression of the costimulatory molecule B7RP-1 
(inducible costimulator ligand). J Am Soc Nephrol, 2002. 13(6): p. 1517-26. 
67. Yamazaki, T., et al., Expression of programmed death 1 ligands by murine T cells and APC. J 
Immunol, 2002. 169(10): p. 5538-45. 
68. Latchman, Y., et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat 
Immunol, 2001. 2(3): p. 261-8. 
69. Freeman, G.J., et al., Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family 
Member Leads to Negative Regulation of Lymphocyte Activation. The Journal of Experimental 
Medicine, 2000. 192(7): p. 1027-1034. 
70. Okazaki, T., et al., PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by 
recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc 
Natl Acad Sci U S A, 2001. 98(24): p. 13866-71. 
71. Cai, G., et al., PD-1 ligands, negative regulators for activation of naive, memory, and recently 
activated human CD4+ T cells. Cell Immunol, 2004. 230(2): p. 89-98. 
72. Dong, H., et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and 
interleukin-10 secretion. Nat Med, 1999. 5(12): p. 1365-9. 
73. Tamura, H., et al., B7-H1 costimulation preferentially enhances CD28-independent T-helper cell 
function. Blood, 2001. 97(6): p. 1809-16. 
74. Chen, Y., et al., Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp 
Nephrol, 2006. 102(3-4): p. e81-92. 
75. Ding, H., X. Wu, and W. Gao, PD-L1 is expressed by human renal tubular epithelial cells and 
suppresses T cell cytokine synthesis. Clinical Immunology, 2005. 115(2): p. 184-191. 
76. Starke, A., et al., Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. 
Kidney Int, 2010. 78(1): p. 38-47. 
77. Zhang, J., et al., Renal tubular epithelial expression of the coinhibitory molecule B7-DC 
(programmed death-1 ligand). J Nephrol, 2006. 19(4): p. 429-38. 
139 
 
78. Carosella, E.D., et al., HLA-G molecules: from maternal–fetal tolerance to tissue acceptance. 
Advances in immunology, 2003. 81: p. 199-252. 
79. Clark, G.F. and D.J. Schust, Manifestations of immune tolerance in the human female 
reproductive tract. Frontiers in immunology, 2012. 4: p. 26-26. 
80. Kovats, S., et al., A class I antigen, HLA-G, expressed in human trophoblasts. Science, 1990. 
248(4952): p. 220-223. 
81. El Chérif Ibrahim, M.M., et al., Heat shock and arsenite induce expression of the nonclassical 
class I histocompatibility HLA-G gene in tumor cell lines. Cell stress & chaperones, 2000. 5(3): p. 
207. 
82. Mouillot, G., et al., Hypoxia modulates HLA-G gene expression in tumor cells. Human 
immunology, 2007. 68(4): p. 277-285. 
83. López, A.S., et al., Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules 
indoleamine dioxygenase and HLA-G in macrophages. Immunology letters, 2008. 117(1): p. 91-
95. 
84. Lopez, A.S., et al., Regulatory role of tryptophan degradation pathway in HLA-G expression by 
human monocyte-derived dendritic cells. Mol Immunol, 2006. 43(14): p. 2151-60. 
85. Lefebvre, S., et al., Molecular mechanisms controlling constitutive and IFN-γ-inducible HLA-G 
expression in various cell types. Journal of reproductive immunology, 1999. 43(2): p. 213-224. 
86. Colonna, M., et al., A common inhibitory receptor for major histocompatibility complex class I 
molecules on human lymphoid and myelomonocytic cells. The Journal of experimental medicine, 
1997. 186(11): p. 1809-1818. 
87. Cosman, D., et al., A novel immunoglobulin superfamily receptor for cellular and viral MHC 
class I molecules. Immunity, 1997. 7(2): p. 273-282. 
88. Colonna, M., et al., Cutting edge: human myelomonocytic cells express an inhibitory receptor for 
classical and nonclassical MHC class I molecules. The Journal of Immunology, 1998. 160(7): p. 
3096-3100. 
89. Shiroishi, M., et al., Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete 
with CD8 for MHC class I binding and bind preferentially to HLA-G. Proceedings of the National 
Academy of Sciences, 2003. 100(15): p. 8856-8861. 
90. Ponte, M., et al., Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-
associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-
specific receptor. Proceedings of the National Academy of Sciences, 1999. 96(10): p. 5674-5679. 
91. Rajagopalan, S. and E.O. Long, A human histocompatibility leukocyte antigen (HLA)-G–specific 
receptor expressed on all natural killer cells. The Journal of experimental medicine, 1999. 
189(7): p. 1093-1100. 
140 
 
92. LeMaoult, J., et al., HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting 
cells, NK cells, and T cells. The FASEB journal, 2005. 19(6): p. 662-664. 
93. Qiu, J., et al., Soluble HLA‐G Expression and Renal Graft Acceptance. American journal of 
transplantation, 2006. 6(9): p. 2152-2156. 
94. Crispim, J., et al., Human leukocyte antigen-G expression after kidney transplantation is 
associated with a reduced incidence of rejection. Transplant immunology, 2008. 18(4): p. 361-
367. 
95. Lila, N., et al., Soluble human leukocyte antigen-G: a new strategy for monitoring acute and 
chronic rejections after heart transplantation. J Heart Lung Transplant, 2007. 26(4): p. 421-2. 
96. Naji, A., et al., CD3+ CD4low and CD3+ CD8low are induced by HLA-G: novel human 
peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood, 2007. 
110(12): p. 3936-3948. 
97. Créput, C., et al., Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is 
associated with allograft acceptance in liver-kidney transplantation. Journal of hepatology, 2003. 
39(4): p. 587-594. 
98. Rouas‐Freiss, N., et al., HLA‐G in Transplantation: A Relevant Molecule for Inhibition of Graft 
Rejection? American Journal of Transplantation, 2003. 3(1): p. 11-16. 
99. Contini, P., et al., Soluble HLA‐A,‐B,‐C and‐G molecules induce apoptosis in T and NK CD8+ 
cells and inhibit cytotoxic T cell activity through CD8 ligation. European journal of immunology, 
2003. 33(1): p. 125-134. 
100. Le Friec, G., et al., Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell 
proliferation without altering dendritic differentiation and maturation processes. Human 
immunology, 2003. 64(8): p. 752-761. 
101. Lila, N., et al., Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-
proliferative response: a CD4+ T cell regulatory mechanism. Proceedings of the National 
Academy of Sciences, 2001. 98(21): p. 12150-12155. 
102. Fournel, S., et al., Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated 
apoptosis in activated CD8+ cells by interacting with CD8. The Journal of Immunology, 2000. 
164(12): p. 6100-6104. 
103. Yamamoto, S. and O. Hayaishi, Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-
cleaving enzyme or enzymes. J Biol Chem, 1967. 242(22): p. 5260-6. 
104. Takikawa, O., et al., Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J 
Biol Chem, 1986. 261(8): p. 3648-53. 
105. Ohtaki, H., et al., Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates 
liver injury in HBV-specific CTL-induced fulminant hepatitis. Biochim Biophys Acta, 2014. 
141 
 
106. Kiank, C., et al., Psychological stress-induced, IDO1-dependent tryptophan catabolism: 
implications on immunosuppression in mice and humans. PLoS One, 2010. 5(7): p. e11825. 
107. Zhou, L., et al., Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. 
Eur J Gastroenterol Hepatol, 2012. 24(6): p. 695-701. 
108. Kwidzinski, E. and I. Bechmann, IDO expression in the brain: a double-edged sword. J Mol Med 
(Berl), 2007. 85(12): p. 1351-9. 
109. Ban, Y., et al., Indoleamine 2,3-dioxygenase levels at the normal and recurrent spontaneous 
abortion fetal-maternal interface. J Int Med Res, 2013. 41(4): p. 1135-49. 
110. Wang, X.F., et al., The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus 
on macrophage polarization of THP-1 cells. Cell Immunol, 2014. 289(1-2): p. 42-48. 
111. Takikawa, O., Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-
tryptophan metabolism. Biochem Biophys Res Commun, 2005. 338(1): p. 12-9. 
112. Fougeray, S., et al., Tryptophan depletion and the kinase GCN2 mediate IFN-gamma-induced 
autophagy. J Immunol, 2012. 189(6): p. 2954-64. 
113. Jalili, R.B., et al., Suppression of islet allogeneic immune response by indoleamine 2,3 
dioxygenase-expressing fibroblasts. J Cell Physiol, 2007. 213(1): p. 137-43. 
114. Lahdou, I., et al., Role of human corneal endothelial cells in T-cell-mediated alloimmune attack 
in vitro. Invest Ophthalmol Vis Sci, 2014. 55(3): p. 1213-21. 
115. Ryan, J.M., et al., Interferon-gamma does not break, but promotes the immunosuppressive 
capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 2007. 149(2): p. 353-63. 
116. Lob, S., et al., Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the 
wood for the trees? Nat Rev Cancer, 2009. 9(6): p. 445-52. 
117. Mellor, A.L. and D.H. Munn, IDO expression by dendritic cells: tolerance and tryptophan 
catabolism. Nat Rev Immunol, 2004. 4(10): p. 762-74. 
118. Tone, S., et al., Primary structure of human indoleamine 2,3-dioxygenase deduced from the 
nucleotide sequence of its cDNA. Nucleic Acids Res, 1990. 18(2): p. 367. 
119. Dai, W. and S.L. Gupta, Molecular cloning, sequencing and expression of human interferon-
gamma-inducible indoleamine 2,3-dioxygenase cDNA. Biochem Biophys Res Commun, 1990. 
168(1): p. 1-8. 
120. Fallarino, F., U. Grohmann, and P. Puccetti, Indoleamine 2,3-dioxygenase: from catalyst to 
signaling function. Eur J Immunol, 2012. 42(8): p. 1932-7. 
121. Robinson, C.M., K.A. Shirey, and J.M. Carlin, Synergistic transcriptional activation of 
indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine 
Res, 2003. 23(8): p. 413-21. 
142 
 
122. Currier, A.R., et al., Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-
induced antichlamydial indoleamine dioxygenase activity independently. J Interferon Cytokine 
Res, 2000. 20(4): p. 369-76. 
123. Babcock, T.A. and J.M. Carlin, Transcriptional activation of indoleamine dioxygenase by 
interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine, 
2000. 12(6): p. 588-94. 
124. Fujigaki, S., et al., Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated 
dominantly by an IFN-gamma-independent mechanism. Eur J Immunol, 2001. 31(8): p. 2313-8. 
125. Pfefferkorn, E.R., Interferon gamma blocks the growth of Toxoplasma gondii in human 
fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A, 1984. 
81(3): p. 908-12. 
126. Yoshida, R., et al., Induction of indoleamine 2,3-dioxygenase in mouse lung during virus 
infection. Proc Natl Acad Sci U S A, 1979. 76(8): p. 4084-6. 
127. Munn, D.H., et al., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 
1998. 281(5380): p. 1191-3. 
128. Cady, S.G. and M. Sono, 1-methyl-dl-tryptophan, β-(3-benzofuranyl)-dl-alanine (the oxygen 
analog of tryptophan), and β-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are 
competitive inhibitors for indoleamine 2,3-dioxygenase. Archives of Biochemistry and 
Biophysics, 1991. 291(2): p. 326-333. 
129. Mellor, A.L. and D.H. Munn, Tryptophan catabolism and T-cell tolerance: immunosuppression 
by starvation? Immunology today, 1999. 20(10): p. 469-473. 
130. Morita, T., et al., 3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in 
monocyte-derived cells stimulated by interferon-γ. Annals of clinical biochemistry, 2001. 38(3): 
p. 242-251. 
131. Terness, P., et al., Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2, 3-Dioxygenase–
expressing Dendritic Cells Mediation of Suppression by Tryptophan Metabolites. The Journal of 
experimental medicine, 2002. 196(4): p. 447-457. 
132. Fallarino, F., et al., T cell apoptosis by tryptophan catabolism. Cell death and differentiation, 
2002. 9(10): p. 1069-1077. 
133. Heyliger, S., E. Mazzio, and K. Soliman, The anti-inflammatory effects of quinolinic acid in the 
rat. Life sciences, 1999. 64(14): p. 1177-1187. 
134. Bao, Y.S., et al., Serum levels and activity of indoleamine2,3-dioxygenase and tryptophanyl-tRNA 
synthetase and their association with disease severity in patients with chronic kidney disease. 
Biomarkers, 2013. 18(5): p. 379-85. 
135. Schefold, J.C., et al., Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum 
levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between 
chronic inflammation and uraemic symptoms. Nephrol Dial Transplant, 2009. 24(6): p. 1901-8. 
143 
 
136. Hou, W., et al., Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism 
accelerates crescentic glomerulonephritis. Clin Exp Immunol, 2009. 156(2): p. 363-72. 
137. Vavrincova-Yaghi, D., et al., Gene therapy with adenovirus-delivered indoleamine 2,3-
dioxygenase improves renal function and morphology following allogeneic kidney 
transplantation in rat. J Gene Med, 2011. 13(7-8): p. 373-81. 
138. Mohib, K., et al., Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion 
injury. Am J Physiol Renal Physiol, 2008. 295(1): p. F226-34. 
139. Yuan, F., et al., Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for 
patients with renal cell carcinoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2012. 37(7): p. 
649-55. 
140. Arioka, Y., et al., Pre-administration of L-tryptophan improved ADR-induced early renal failure 
in mice. Life Sci, 2012. 91(3-4): p. 100-6. 
141. Jefford, M., et al., Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro 
from blood monocytes: differential regulation of function by specific classes of physiologic 
stimuli. Blood, 2003. 102(5): p. 1753-63. 
142. Soos, T., et al., CX3CR1+ interstitial dendritic cells form a contiguous network throughout the 
entire kidney. Kidney international, 2006. 70(3): p. 591-596. 
143. Guilliams, M., et al., From skin dendritic cells to a simplified classification of human and mouse 
dendritic cell subsets. European journal of immunology, 2010. 40(8): p. 2089-2094. 
144. Steinman, R.M. and J. Idoyaga, Features of the dendritic cell lineage. Immunological reviews, 
2010. 234(1): p. 5-17. 
145. Krüger, T., et al., Identification and functional characterization of dendritic cells in the healthy 
murine kidney and in experimental glomerulonephritis. Journal of the American Society of 
Nephrology, 2004. 15(3): p. 613-621. 
146. Segerer, S., et al., Compartment specific expression of dendritic cell markers in human 
glomerulonephritis. Kidney international, 2008. 74(1): p. 37-46. 
147. Hart, D.N., et al., Localization of HLA-ABC and DR antigens in human kidney. Transplantation, 
1981. 31(6): p. 428-33. 
148. Markovic-Lipkovski, J., et al., Association of glomerular and interstitial mononuclear leukocytes 
with different forms of glomerulonephritis. Nephrol Dial Transplant, 1990. 5(1): p. 10-7. 
149. Lukacs-Kornek, V., et al., The kidney-renal lymph node-system contributes to cross-tolerance 
against innocuous circulating antigen. The Journal of Immunology, 2008. 180(2): p. 706-715. 
150. Geissmann, F., et al., Development of monocytes, macrophages, and dendritic cells. Science, 
2010. 327(5966): p. 656-661. 
144 
 
151. Teteris, S.A., D.R. Engel, and C. Kurts, Homeostatic and pathogenic role of renal dendritic cells. 
Kidney international, 2011. 80(2): p. 139-145. 
152. Scholz, J., et al., Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic 
nephritis. Journal of the American Society of Nephrology, 2008. 19(3): p. 527-537. 
153. Rogers, N.M., et al., Review article: kidney dendritic cells: their role in homeostasis, 
inflammation and transplantation. Nephrology, 2009. 14(7): p. 625-635. 
154. Tipping, P.G. and S.R. Holdsworth, T cells in crescentic glomerulonephritis. Journal of the 
American Society of Nephrology, 2006. 17(5): p. 1253-1263. 
155. Tadagavadi, R.K. and W.B. Reeves, Endogenous IL-10 attenuates cisplatin nephrotoxicity: role 
of dendritic cells. The Journal of Immunology, 2010. 185(8): p. 4904-4911. 
156. Kim, M.-G., et al., Depletion of kidney CD11c+ F4/80+ cells impairs the recovery process in 
ischaemia/reperfusion-induced acute kidney injury. Nephrology Dialysis Transplantation, 2010. 
25(9): p. 2908-2921. 
157. Lassen, S., et al., Ischemia reperfusion induces IFN regulatory factor 4 in renal dendritic cells, 
which suppresses postischemic inflammation and prevents acute renal failure. The Journal of 
Immunology, 2010. 185(3): p. 1976-1983. 
158. Hochheiser, K., et al., Kidney dendritic cells become pathogenic during crescentic 
glomerulonephritis with proteinuria. Journal of the American Society of Nephrology, 2011. 
22(2): p. 306-316. 
159. Macconi, D., et al., Proteasomal processing of albumin by renal dendritic cells generates 
antigenic peptides. Journal of the American Society of Nephrology, 2009. 20(1): p. 123-130. 
160. Heymann, F., et al., Kidney dendritic cell activation is required for progression of renal disease 
in a mouse model of glomerular injury. The Journal of clinical investigation, 2009. 119(5): p. 
1286-1297. 
161. Teichmann, L.L., et al., Dendritic cells in lupus are not required for activation of T and B cells 
but promote their expansion, resulting in tissue damage. Immunity, 2010. 33(6): p. 967-978. 
162. Paul, W.E., Fundamental immunology. 6th ed. 2008, Philadelphia, USA: Lippinocott Williams 
and Wilkins. 
163. Balazs, M., et al., Blood dendritic cells interact with splenic marginal zone B cells to initiate T-
independent immune responses. Immunity, 2002. 17(3): p. 341-52. 
164. Griffin, D.O., N.E. Holodick, and T.L. Rothstein, Human B1 cells in umbilical cord and adult 
peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med, 2011. 
208(1): p. 67-80. 
165. McHeyzer-Williams, L.J. and M.G. McHeyzer-Williams, Antigen-specific memory B cell 
development. Annu Rev Immunol, 2005. 23: p. 487-513. 
145 
 
166. Smith, K.G., et al., The phenotype and fate of the antibody‐forming cells of the splenic foci. 
European journal of immunology, 1996. 26(2): p. 444-448. 
167. Slifka, M.K., et al., Humoral immunity due to long-lived plasma cells. Immunity, 1998. 8(3): p. 
363-372. 
168. Caraux, A., et al., Circulating human B and plasma cells. Age-associated changes in counts and 
detailed characterization of circulating normal CD138− and CD138+ plasma cells. 
haematologica, 2010. 95(6): p. 1016-1020. 
169. Sun, C.-Y., et al., The characteristics and significance of locally infiltrating B cells in lupus 
nephritis and their association with local BAFF expression. International journal of 
rheumatology, 2013. 2013. 
170. Hutloff, A., et al., Involvement of inducible costimulator in the exaggerated memory B cell and 
plasma cell generation in systemic lupus erythematosus. Arthritis & Rheumatism, 2004. 50(10): 
p. 3211-3220. 
171. Jang, H.R., et al., B Cells Limit Repair after Ischemic Acute Kidney Injury. J Am Soc Nephrol. 
21(4): p. 654-665. 
172. Heller, F., et al., The contribution of B cells to renal interstitial inflammation. The American 
journal of pathology, 2007. 170(2): p. 457-468. 
173. Steinmetz, O.M., et al., Analysis and classification of B-cell infiltrates in lupus and ANCA-
associated nephritis. Kidney Int, 2008. 74(4): p. 448-457. 
174. Cohen, C.D., et al., CD20-positive infiltrates in human membranous glomerulonephritis. Journal 
of nephrology, 2005. 18(3): p. 328. 
175. Segerer, S. and D. Schlöndorff, B cells and tertiary lymphoid organs in renal inflammation. 
Kidney international, 2007. 73(5): p. 533-537. 
176. Cheng, J., et al., Ectopic B-cell clusters that infiltrate transplanted human kidneys are clonal. 
Proceedings of the National Academy of Sciences, 2011. 108(14): p. 5560-5565. 
177. Pei, G., et al., Renal interstitial infiltration and tertiary lymphoid organ neogenesis in IgA 
nephropathy. Clin J Am Soc Nephrol, 2014. 9(2): p. 255-64. 
178. Lehnhardt, A., et al., Nodular B‐Cell Aggregates Associated with Treatment Refractory Renal 
Transplant Rejection Resolved by Rituximab. American journal of transplantation, 2006. 6(4): p. 
847-851. 
179. Curtsinger, J.M., D.C. Lins, and M.F. Mescher, Signal 3 determines tolerance versus full 
activation of naive CD8 T cells: dissociating proliferation and development of effector function. J 
Exp Med, 2003. 197(9): p. 1141-51. 
180. Macatonia, S.E., et al., Dendritic cells produce IL-12 and direct the development of Th1 cells 
from naive CD4+ T cells. J Immunol, 1995. 154(10): p. 5071-9. 
146 
 
181. Szabo, S.J., et al., A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell, 
2000. 100(6): p. 655-69. 
182. Leung, B.P., et al., Combined effects of IL-12 and IL-18 on the induction of collagen-induced 
arthritis. J Immunol, 2000. 164(12): p. 6495-502. 
183. Zheng, W. and R.A. Flavell, The transcription factor GATA-3 is necessary and sufficient for Th2 
cytokine gene expression in CD4 T cells. Cell, 1997. 89(4): p. 587-96. 
184. Mangan, P.R., et al., Transforming growth factor-beta induces development of the T(H)17 
lineage. Nature, 2006. 441(7090): p. 231-4. 
185. Acosta-Rodriguez, E.V., et al., Interleukins 1beta and 6 but not transforming growth factor-beta 
are essential for the differentiation of interleukin 17-producing human T helper cells. Nat 
Immunol, 2007. 8(9): p. 942-9. 
186. Langrish, C.L., et al., IL-23 drives a pathogenic T cell population that induces autoimmune 
inflammation. J Exp Med, 2005. 201(2): p. 233-40. 
187. Ivanov, II, et al., The orphan nuclear receptor RORgammat directs the differentiation program of 
proinflammatory IL-17+ T helper cells. Cell, 2006. 126(6): p. 1121-33. 
188. Murphy, K.M. and B. Stockinger, Effector T cell plasticity: flexibility in the face of changing 
circumstances. Nat Immunol, 2010. 11(8): p. 674-80. 
189. Zhou, L., M.M. Chong, and D.R. Littman, Plasticity of CD4+ T cell lineage differentiation. 
Immunity, 2009. 30(5): p. 646-55. 
190. Jonuleit, H., et al., Identification and functional characterization of human CD4(+)CD25(+) T 
cells with regulatory properties isolated from peripheral blood. J Exp Med, 2001. 193(11): p. 
1285-94. 
191. Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the 
transcription factor Foxp3. Science, 2003. 299(5609): p. 1057-61. 
192. Nakamura, K., A. Kitani, and W. Strober, Cell contact-dependent immunosuppression by 
CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor 
beta. J Exp Med, 2001. 194(5): p. 629-44. 
193. Sullivan, B.M., et al., Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl 
Acad Sci U S A, 2003. 100(26): p. 15818-23. 
194. Intlekofer, A.M., et al., Effector and memory CD8+ T cell fate coupled by T-bet and 
eomesodermin. Nat Immunol, 2005. 6(12): p. 1236-44. 
195. Calvani, N., et al., Up-regulation of IL-18 and predominance of a Th1 immune response is a 
hallmark of lupus nephritis. Clin Exp Immunol, 2004. 138(1): p. 171-8. 
196. van Es, L.A., et al., GMP-17-positive T-lymphocytes in renal tubules predict progression in early 
stages of IgA nephropathy. Kidney Int, 2008. 73(12): p. 1426-33. 
147 
 
197. Bolton, W.K., et al., T-cells and macrophages in rapidly progressive glomerulonephritis: 
clinicopathologic correlations. Kidney Int, 1987. 32(6): p. 869-76. 
198. Portilla, D. and M.D. Okusa, T cells and T-cell receptors in acute renal failure. Kidney Int, 2006. 
69(2): p. 208-10. 
199. Dong, X., et al., Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic 
and local injury to the kidney. Kidney Int, 2005. 68(3): p. 1096-108. 
200. Solez, K., L. Morel-Maroger, and J.D. Sraer, The morphology of "acute tubular necrosis" in man: 
analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore), 
1979. 58(5): p. 362-76. 
201. Rabb, H., et al., Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in 
mice. Am J Physiol Renal Physiol, 2000. 279(3): p. F525-31. 
202. Yokota, N., et al., Protective effect of T cell depletion in murine renal ischemia-reperfusion 
injury. Transplantation, 2002. 74(6): p. 759-63. 
203. Ascon, M., et al., Renal ischemia-reperfusion leads to long term infiltration of activated and 
effector-memory T lymphocytes. Kidney Int, 2009. 75(5): p. 526-35. 
204. Tipping, P.G. and S.R. Holdsworth, T cells in crescentic glomerulonephritis. J Am Soc Nephrol, 
2006. 17(5): p. 1253-63. 
205. Tipping, P.G., et al., Crescentic glomerulonephritis in CD4- and CD8-deficient mice. 
Requirement for CD4 but not CD8 cells. Am J Pathol, 1998. 152(6): p. 1541-8. 
206. Huang, X.R., S.R. Holdsworth, and P.G. Tipping, Evidence for delayed-type hypersensitivity 
mechanisms in glomerular crescent formation. Kidney Int, 1994. 46(1): p. 69-78. 
207. Kawasaki, K., et al., Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. 
Kidney Int, 1992. 41(6): p. 1517-26. 
208. Paust, H.-J., et al., The IL-23/Th17 axis contributes to renal injury in experimental 
glomerulonephritis. Journal of the American Society of Nephrology, 2009. 20(5): p. 969-979. 
209. Adrogue, H.E., et al., Coincident activation of Th2 T cells with onset of the disease and 
differential expression of GRO-gamma in peripheral blood leukocytes in minimal change disease. 
Am J Nephrol, 2007. 27(3): p. 253-61. 
210. Gandolfo, M.T., et al., Foxp3+ regulatory T cells participate in repair of ischemic acute kidney 
injury. Kidney Int, 2009. 76(7): p. 717-729. 
211. Afzali, B., et al., The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ 
transplantation and autoimmune disease. Clinical & Experimental Immunology, 2007. 148(1): p. 
32-46. 
212. Wolf, D., et al., CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement 
membrane glomerulonephritis in mice. J Am Soc Nephrol, 2005. 16(5): p. 1360-70. 
148 
 
213. Wang, Y.M., et al., Foxp3-transduced polyclonal regulatory T cells protect against chronic renal 
injury from adriamycin. J Am Soc Nephrol, 2006. 17(3): p. 697-706. 
214. Ferenbach, D. and J. Hughes, Macrophages and dendritic cells: what is the difference? Kidney 
Int, 2008. 74(1): p. 5-7. 
215. Segerer, S., et al., Compartment specific expression of dendritic cell markers in human 
glomerulonephritis. Kidney Int, 2008. 74(1): p. 37-46. 
216. Fiore, N., et al., Immature myeloid and plasmacytoid dendritic cells infiltrate renal 
tubulointerstitium in patients with lupus nephritis. Mol Immunol, 2008. 45(1): p. 259-65. 
217. Segerer, S., et al., Expression of the chemokine monocyte chemoattractant protein-1 and its 
receptor chemokine receptor 2 in human crescentic glomerulonephritis. J Am Soc Nephrol, 2000. 
11(12): p. 2231-42. 
218. Frank, J., et al., Human renal tubular cells as a cytokine source: PDGF-B, GM-CSF and IL-6 
mRNA expression in vitro. Exp Nephrol, 1993. 1(1): p. 26-35. 
219. Kronsteiner, B., et al., Human mesenchymal stem cells and renal tubular epithelial cells 
differentially influence monocyte-derived dendritic cell differentiation and maturation. Cellular 
Immunology, 2011. 267(1): p. 30-38. 
220. Wuthrich, R.P., et al., MHC class II, antigen presentation and tumor necrosis factor in renal 
tubular epithelial cells. Kidney Int, 1990. 37(2): p. 783-792. 
221. Schoop, R., et al., Suppressed T-cell activation by IFN-{gamma}-induced expression of PD-L1 on 
renal tubular epithelial cells. Nephrol. Dial. Transplant., 2004. 19(11): p. 2713-2720. 
222. Waeckerle-Men, Y., A. Starke, and R.P. Wuthrich, PD-L1 partially protects renal tubular 
epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant, 2007. 22(6): 
p. 1527-36. 
223. Waeckerle-Men, Y., et al., Limited Costimulatory Molecule Expression on Renal Tubular 
Epithelial Cells Impairs T Cell Activation. Kidney Blood Press Res, 2007. 30(6): p. 421-429. 
224. Egner, W., R. Andreesen, and D.N. Hart, Allostimulatory cells in fresh human blood: 
heterogeneity in antigen-presenting cell populations. Transplantation, 1993. 56(4): p. 945-50. 
225. Dzionek, A., et al., BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of 
dendritic cells in human peripheral blood. J Immunol, 2000. 165(11): p. 6037-46. 
226. MacDonald, K.P., et al., Characterization of human blood dendritic cell subsets. Blood, 2002. 
100(13): p. 4512-20. 
227. Jongbloed, S.L., et al., Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique 
myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med, 2010. 207(6): p. 1247-
60. 
149 
 
228. Radford, K.J., et al., CD11c+ blood dendritic cells induce antigen-specific cytotoxic T 
lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher 
levels of MHC class I expression. J Immunother, 2006. 29(6): p. 596-605. 
229. Ito, T., et al., Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible 
costimulator ligand. J Exp Med, 2007. 204(1): p. 105-15. 
230. Jego, G., et al., Plasmacytoid dendritic cells induce plasma cell differentiation through type I 
interferon and interleukin 6. Immunity, 2003. 19(2): p. 225-234. 
231. Hoeffel, G., et al., Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity, 
2007. 27(3): p. 481-92. 
232. Di Pucchio, T., et al., Direct proteasome-independent cross-presentation of viral antigen by 
plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol, 2008. 
9(5): p. 551-7. 
233. Haniffa, M., et al., Human Tissues Contain CD141< sup> hi</sup> Cross-Presenting Dendritic 
Cells with Functional Homology to Mouse CD103< sup>+</sup> Nonlymphoid Dendritic Cells. 
Immunity, 2012. 37(1): p. 60-73. 
234. Jongbloed, S.L., et al., Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique 
myeloid DC subset that cross-presents necrotic cell antigens. The Journal of experimental 
medicine, 2010. 207(6): p. 1247-1260. 
235. Lindstedt, M., K. Lundberg, and C.A. Borrebaeck, Gene family clustering identifies functionally 
associated subsets of human in vivo blood and tonsillar dendritic cells. J Immunol, 2005. 175(8): 
p. 4839-46. 
236. Robbins, S.H., et al., Novel insights into the relationships between dendritic cell subsets in human 
and mouse revealed by genome-wide expression profiling. Genome Biol, 2008. 9(1): p. R17. 
237. Woltman, A.M., et al., Quantification of dendritic cell subsets in human renal tissue under 
normal and pathological conditions. Kidney Int, 2007. 71(10): p. 1001-8. 
238. Cavassani, K.A., et al., TLR3 is an endogenous sensor of tissue necrosis during acute 
inflammatory events. The Journal of experimental medicine, 2008. 205(11): p. 2609-2621. 
239. Patole, P.S., et al., Viral double-stranded RNA aggravates lupus nephritis through Toll-like 
receptor 3 on glomerular mesangial cells and antigen-presenting cells. Journal of the American 
Society of Nephrology, 2005. 16(5): p. 1326-1338. 
240. Wilkinson, R., et al., Numerical and functional assessment of blood dendritic cells in prostate 
cancer patients. The Prostate, 2006. 66(2): p. 180-192. 
241. Wilkinson, R., et al., Numerical and functional assessment of blood dendritic cells in prostate 
cancer patients. Prostate, 2006. 66(2): p. 180-92. 
242. Kassianos, A.J., et al., Isolation of human blood DC subtypes. Methods Mol Biol, 2010. 595: p. 
45-54. 
150 
 
243. Lutz, M.B. and G. Schuler, Immature, semi-mature and fully mature dendritic cells: which 
signals induce tolerance or immunity? Trends in immunology, 2002. 23(9): p. 445-449. 
244. Blankenstein, T. and T. Schüler, Cross-priming versus cross-tolerance: are two signals enough? 
Trends in immunology, 2002. 23(4): p. 171-173. 
245. Akbari, O., R.H. DeKruyff, and D.T. Umetsu, Pulmonary dendritic cells producing IL-10 
mediate tolerance induced by respiratory exposure to antigen. Nat Immunol, 2001. 2(8): p. 725-
31. 
246. Vopenkova, K., et al., Complex evaluation of human monocyte-derived dendritic cells for cancer 
immunotherapy. J Cell Mol Med, 2012. 16(11): p. 2827-37. 
247. Holtl, L., et al., Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed 
autologous dendritic cells. Clin Cancer Res, 2002. 8(11): p. 3369-76. 
248. Azuma, T., et al., Dendritic cell immunotherapy for patients with metastatic renal cell 
carcinoma: University of Tokyo experience. Int J Urol, 2002. 9(6): p. 340-6. 
249. Sallusto, F. and A. Lanzavecchia, Efficient presentation of soluble antigen by cultured human 
dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of experimental 
medicine, 1994. 179(4): p. 1109-1118. 
250. Gieseler, R., et al., In-vitro differentiation of mature dendritic cells from human blood monocytes. 
Clinical and Developmental Immunology, 1998. 6(1-2): p. 25-39. 
251. Wilson, N.S., et al., Most lymphoid organ dendritic cell types are phenotypically and functionally 
immature. Blood, 2003. 102(6): p. 2187-2194. 
252. Geijtenbeek, T.B., et al., Identification of DC-SIGN, a novel dendritic cell–specific ICAM-3 
receptor that supports primary immune responses. cell, 2000. 100(5): p. 575-585. 
253. Buelens, C., et al., Interleukin‐10 prevents the generation of dendritic cells from human 
peripheral blood mononuclear cells cultured with interleukin‐4 and 
granulocyte/macrophage‐colony‐stimulating factor. European journal of immunology, 1997. 
27(3): p. 756-762. 
254. Karikó, K., et al., mRNA is an endogenous ligand for Toll-like receptor 3. Journal of Biological 
Chemistry, 2004. 279(13): p. 12542-12550. 
255. Rate, A., et al., Airway epithelial cells regulate the functional phenotype of locally differentiating 
dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J 
Immunol, 2009. 182(1): p. 72-83. 
256. Kronsteiner, B., et al., Human mesenchymal stem cells and renal tubular epithelial cells 
differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell 
Immunol, 2011. 267(1): p. 30-8. 
151 
 
257. Verkade, M.A., et al., Functional impairment of monocyte-derived dendritic cells in patients with 
severe chronic kidney disease. Nephrology Dialysis Transplantation, 2007. 22(1): p. 128-138. 
258. Tipping, P.G., et al., Immune modulation with interleukin-4 and interleukin-10 prevents crescent 
formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol, 1997. 
27(2): p. 530-7. 
259. Kitching, A.R., et al., Interleukin-10 inhibits experimental mesangial proliferative 
glomerulonephritis. Clin Exp Immunol, 2002. 128(1): p. 36-43. 
260. Tadagavadi, R.K. and W.B. Reeves, Endogenous IL-10 attenuates cisplatin nephrotoxicity: role 
of dendritic cells. J Immunol, 2010. 185(8): p. 4904-11. 
261. De Smedt, T., et al., Effect of interleukin-10 on dendritic cell maturation and function. Eur J 
Immunol, 1997. 27(5): p. 1229-35. 
262. Holdsworth, S.R., A.R. Kitching, and P.G. Tipping, Th1 and Th2 T helper cell subsets affect 
patterns of injury and outcomes in glomerulonephritis. Kidney Int, 1999. 55(4): p. 1198-216. 
263. Paust, H.J., et al., Regulatory T cells control the Th1 immune response in murine crescentic 
glomerulonephritis. Kidney Int, 2011. 80(2): p. 154-64. 
264. Bonelli, M., J.S. Smolen, and C. Scheinecker, Treg and lupus. Ann Rheum Dis, 2010. 69 Suppl 
1: p. i65-66. 
265. Carosella, E.D., et al., HLA-G: from biology to clinical benefits. Trends Immunol, 2008. 29(3): p. 
125-32. 
266. Carosella, E.D. and J. LeMaoult, HLA-G: a look back, a look forward. Cell Mol Life Sci, 2011. 
68(3): p. 337-40. 
267. Crispim, J.C., et al., Human leukocyte antigen-G expression after kidney transplantation is 
associated with a reduced incidence of rejection. Transpl Immunol, 2008. 18(4): p. 361-7. 
268. Rebmann, V., et al., Soluble total human leukocyte antigen class I and human leukocyte antigen-
G molecules in kidney and kidney/pancreas transplantation. Hum Immunol, 2009. 70(12): p. 995-
9. 
269. Von Bubnoff, D., et al., Identification of IDO-positive and IDO-negative human dendritic cells 
after activation by various proinflammatory stimuli. The Journal of Immunology, 2011. 186(12): 
p. 6701-6709. 
270. Jürgens, B., et al., Interferon-γ–triggered indoleamine 2, 3-dioxygenase competence in human 
monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood, 2009. 
114(15): p. 3235-3243. 
271. Harris, R.C. and E.G. Neilson, Toward a unified theory of renal progression. Annu Rev Med, 
2006. 57: p. 365-80. 
152 
 
272. Schlondorff, D.O., Overview of factors contributing to the pathophysiology of progressive renal 
disease. Kidney international, 2008. 74(7): p. 860-866. 
273. Wang, S., et al., Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple 
costimulatory function from PD-1 interaction. J Exp Med, 2003. 197(9): p. 1083-91. 
274. Sharpe, A.H. and G.J. Freeman, The B7-CD28 superfamily. Nat Rev Immunol, 2002. 2(2): p. 
116-26. 
275. Hua, Z. and B. Hou, TLR signaling in B-cell development and activation. Cell Mol Immunol, 
2013. 10(2): p. 103-6. 
276. Segerer, S. and D. Schlondorff, B cells and tertiary lymphoid organs in renal inflammation. 
Kidney Int, 2008. 73(5): p. 533-7. 
277. Mizoguchi, A., et al., Chronic intestinal inflammatory condition generates IL-10-producing 
regulatory B cell subset characterized by CD1d upregulation. Immunity, 2002. 16(2): p. 219-230. 
278. Fillatreau, S., et al., B cells regulate autoimmunity by provision of IL-10. Nature immunology, 
2002. 3(10): p. 944-950. 
279. Cherukuri, A., et al., Immunologic Human Renal Allograft Injury Associates with an Altered IL-
10/TNF-alpha Expression Ratio in Regulatory B Cells. J Am Soc Nephrol, 2014. 25(7): p. 1575-
85. 
280. Crotty, S., et al., Tracking human antigen-specific memory B cells: a sensitive and generalized 
ELISPOT system. J Immunol Methods, 2004. 286(1-2): p. 111-22. 
281. Farnes, P., et al., MITOGENIC ACTIVITY IN PHYTOLACCA AMERICANA (POKEWEED). 
Lancet, 1964. 2(7369): p. 1100-1. 
282. Bekeredjian-Ding, I., et al., Poke weed mitogen requires Toll-like receptor ligands for 
proliferative activity in human and murine B lymphocytes. PLoS One, 2012. 7(1): p. e29806. 
283. Bourke, E., et al., The toll-like receptor repertoire of human B lymphocytes: inducible and 
selective expression of TLR9 and TLR10 in normal and transformed cells. Blood, 2003. 102(3): p. 
956-63. 
284. Bernasconi, N.L., N. Onai, and A. Lanzavecchia, A role for Toll-like receptors in acquired 
immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression 
in memory B cells. Blood, 2003. 101(11): p. 4500-4. 
285. Hemmi, H., et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-
dependent signaling pathway. Nat Immunol, 2002. 3(2): p. 196-200. 
286. Jurk, M., et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral 
compound R-848. Nat Immunol, 2002. 3(6): p. 499. 
287. Bishop, G.A., et al., Molecular mechanisms of B lymphocyte activation by the immune response 
modifier R-848. J Immunol, 2000. 165(10): p. 5552-7. 
153 
 
288. Mingari, M.C., et al., Human interleukin-2 promotes proliferation of activated B cells via surface 
receptors similar to those of activated T cells. Nature, 1984. 312(5995): p. 641-3. 
289. Jahnmatz, M., et al., Optimization of a human IgG B-cell ELISpot assay for the analysis of 
vaccine-induced B-cell responses. J Immunol Methods, 2013. 391(1-2): p. 50-9. 
290. Hart, O.M., et al., TLR7/8-mediated activation of human NK cells results in accessory cell-
dependent IFN-gamma production. J Immunol, 2005. 175(3): p. 1636-42. 
291. Dorner, T. and P.E. Lipsky, Correlation of circulating CD27high plasma cells and disease 
activity in systemic lupus erythematosus. Lupus, 2004. 13(5): p. 283-9. 
292. Caraux, A., et al., Circulating human B and plasma cells. Age-associated changes in counts and 
detailed characterization of circulating normal CD138- and CD138+ plasma cells. 
Haematologica, 2010. 95(6): p. 1016-20. 
293. Zhong, X., et al., Suppression of expression and function of negative immune regulator PD-1 by 
certain pattern recognition and cytokine receptor signals associated with immune system danger. 
Int Immunol, 2004. 16(8): p. 1181-8. 
294. Lee, S.B. and R. Kalluri, Mechanistic connection between inflammation and fibrosis. Kidney Int 
Suppl, 2010(119): p. S22-6. 
295. Tapmeier, T.T., et al., Pivotal role of CD4+ T cells in renal fibrosis following ureteric 
obstruction. Kidney Int, 2010. 78(4): p. 351-62. 
296. Eddy, A.A., Experimental insights into the tubulointerstitial disease accompanying primary 
glomerular lesions. J Am Soc Nephrol, 1994. 5(6): p. 1273-87. 
297. Liu, Y., Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol, 2011. 7(12): p. 
684-696. 
298. Rodriguez-Iturbe, B., et al., Role of immunocompetent cells in nonimmune renal diseases. Kidney 
Int, 2001. 59(5): p. 1626-40. 
299. Mezzano, S.A., et al., Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in 
human membranous nephropathy. Kidney Int, 2000. 57(1): p. 147-58. 
300. Remuzzi, G., P. Ruggenenti, and A. Benigni, Understanding the nature of renal disease 
progression. Kidney Int, 1997. 51(1): p. 2-15. 
301. Zoja, C., et al., Protein overload stimulates RANTES production by proximal tubular cells 
depending on NF-[kgr]B activation. Kidney Int, 1998. 53(6): p. 1608-1615. 
302. John, R. and P.J. Nelson, Dendritic cells in the kidney. J Am Soc Nephrol, 2007. 18(10): p. 2628-
35. 
303. Paust, H.-J., et al., The IL-23/Th17 Axis Contributes to Renal Injury in Experimental 
Glomerulonephritis. J Am Soc Nephrol, 2009. 20(5): p. 969-979. 
154 
 
304. Penny, M.J., R.A. Boyd, and B.M. Hall, Permanent CD8(+) T cell depletion prevents proteinuria 
in active Heymann nephritis. J Exp Med, 1998. 188(10): p. 1775-84. 
305. Pinheiro, H.S., et al., Contribution of CD4+ T cells to the early mechanisms of ischemia- 
reperfusion injury in a mouse model of acute renal failure. Braz J Med Biol Res, 2007. 40(4): p. 
557-68. 
306. Summers, S.A., et al., Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc 
Nephrol, 2009. 20(12): p. 2518-24. 
307. Mu, W., et al., IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic 
renal disease. J Am Soc Nephrol, 2005. 16(12): p. 3651-60. 
308. Chang, A., et al., Renal Pathology: SC23-3 LUPUS TUBULOINTERSTITIAL AND VASCULAR 
DISEASE. Pathology, 2014. 46 Suppl 2: p. S40. 
309. Clark, M.R., et al., Vimentin is a dominant target of in situ humoral immunity in human lupus 
tubulointerstitial nephritis. Arthritis research & therapy, 2014. 16(Suppl 1): p. A18. 
310. Merlo, A., et al., Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate 
immunoglobulin and cytokine production by human B lymphocytes. Clinical and diagnostic 
laboratory immunology, 2005. 12(6): p. 705-712. 
311. Lila, N., et al., Implication of HLA-G molecule in heart-graft acceptance. The lancet, 2000. 
355(9221): p. 2138. 
312. Poosti, F., et al., Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy 
for the treatment of renal fibrosis. The FASEB Journal, 2014: p. fj. 14-258459. 
313. Kassianos, A.J., et al., Increased tubulointerstitial recruitment of human CD141hi CLEC9A+ and 
CD1c+ myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease. American 
Journal of Physiology-Renal Physiology, 2013. 305(10): p. F1391-F1401. 
314. Kassianos, A.J., et al., Fractalkine–CX3CR1-dependent recruitment and retention of human 
CD1c&plus; myeloid dendritic cells by in vitro–activated proximal tubular epithelial cells. 
Kidney international, 2015. 
315. Yamamoto, T., et al., Sustained expression of TGF-beta 1 underlies development of progressive 
kidney fibrosis. Kidney Int, 1994. 45(3): p. 916-27. 
316. Zhu, Y., H.K. Usui, and K. Sharma, Regulation of transforming growth factor beta in diabetic 
nephropathy: implications for treatment. Semin Nephrol, 2007. 27(2): p. 153-60. 
155 
 
Appendix-1 
Primary antibodies 
Antigen Conjugate  Mouse Isotype   Clone  Manufacturer  
     
CD3 APC IgG2a HIT3a BD Biosciences 
CD4 APC IgG1 L200 BD Biosciences 
CD20 APC IgG2b 2H2 BD Biosciences 
CD25 APC IgG1 M-A251 BD Biosciences 
CD27 APC IgG1 O323 Biolegend 
CD83  APC IgG1 HB15e BD Biosciences 
HLA-DR  APC IgG2a G46-6 BD Biosciences 
     
CD3 FITC IgG2a HIT3a BD Biosciences 
CD20 FITC IgG2b 2H2 BD Biosciences 
CD27 FITC IgG1 L128 BD Biosciences 
CD138 FITC IgG1 MI15 BD Biosciences 
CD209 FITC IgG2b DCN46 BD Biosciences 
     
CD3 Pacific orange IgG1 UCHT1 Life Technologies 
HLA-DR  Pacific orange IgG2b TÜ36 Life Technologies 
     
CD3 PE IgG2a HIT3a Biolegend 
CD4 PE IgG1 RPA-T4 BD Biosciences 
CD14 PE IgG2a M5E2 BD Biosciences 
CD20 PE IgG2b 2H2 Biolegend 
CD38 PE IgG1 HIT2 BD Biosciences 
CD69 PE IgG1 FN50 BD Biosciences 
CD83  PE IgG1 HB15e Biolegend 
HLA-DR  PE IgG2a G46-6 BD Biosciences 
HLA-G PE IgG2a 87G Biolegend 
     
CD80 PE-Cy7 IgG1 L307.4 BD Biosciences 
CD274 PE-Cy7 IgG1 MIH1 BD Biosciences 
     
CD19 PerCP IgG1 4G7 BD Biosciences 
CD69 PerCP IgG1 L78 BD Biosciences 
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CD3 PerCP-Cy5.5 IgG2a HIT3a Biolegend 
CD4 PerCP-Cy5.5 IgG1 RPA-T4 BD Biosciences 
CD14 PerCP-Cy5.5 IgG2a M5E2 BD Biosciences 
     
CD86 V450 IgG1 2331(FUN-1) BD Biosciences 
CD209 V450 IgG2b DCN46 BD Biosciences 
     
anti PD-L1 Unconjugated IgG2b 29E.2A3 Biolegend 
anti sHLA-G Unconjugated IgG2a 87G Biolegend 
anti CD3 Unconjugated IgE CLB-T3/4.E, 1XE Sanquin 
anti CD28 Unconjugated IgG1 CLB-CD28/1, 15E8 Sanquin 
anti IL-10 Unconjugated IgG2b 23738 R&D Systems 
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Appendix-2 
Commercial suppliers  
Autoimmune diagnostika Gm bH, Strassberg, Germany 
BD Biosciences, San Jose, USA 
Beckman Coulter, Gladesville, NSW, Australia 
Biolegend, Balcatta, WA, Australia 
BioTek, Mulgrave, VIC, Australia 
Biovendor, Alexandria, NSW, Australia 
Boeco Germany, Hamburg, Germany 
Carl Zeiss Inc, Oberkochen, Germany 
Corning, Lindfield, NSW, Australia 
GE Healthcare, Silverwater, NSW, Australia 
Labtech, Windsor, NSW, Australia 
Life Technologies, Mount Waverly, VIC, Australia 
Mabtech, Preston, VIC, Australia 
Miltenyi Biotec, Auburn, CA, USA 
Nalgene, Rochester, NY, USA 
Olympus Corporation, Japan 
Perkin Elmer, Wellesley, MA, USA 
Promega, Madison, WI, USA 
Qiagen, Doncaster, VIC, Australia 
R&D Systems, Minneapolis, MN, USA 
Roche Diagnostics, Mannheim, Germany 
SABiosciences, Frederick, MD, USA 
Sanquin, Amsterdam, The Netherlands 
Sigma-Aldrich, St Louis, MO, USA 
Stratagene, La Jolla, CA, USA 
Thermo-scientific, Noble Park, VIC, Australia 
 
